

**ALAN J. KIVITZ, MD, CPI
PRESIDENT & MEDICAL DIRECTOR
ALTOONA ARTHRITIS AND OSTEOPOROSIS CENTER
ALTOONA CENTER FOR CLINICAL RESEARCH**

175 Meadowbrook Lane, Duncansville, PA 16635
(814) 693-0300 Office; (814) 693-0400 FAX
WEB SITE: www.altoonaresearch.com

EDUCATION

- B.S., Cum Laude, Biology, Rensselaer Polytechnic Institute, Troy, New York, 1973
- M.D., Albany Medical College, Albany, New York, 1977

POST-GRADUATE TRAINING

- | | |
|-------------|---|
| 1977 - 1978 | Intern, Internal Medicine North Shore University Hospital (Cornell), Manhasset, New York Memorial Sloan-Kettering Cancer Center, New York, New York |
| 1978 - 1980 | Resident, Internal Medicine Memorial Sloan-Kettering Cancer Center, New York, New York North Shore University Hospital (Cornell), Manhasset, New York |
| 1980 | Assistant Chief Resident, Internal Medicine North Shore University Hospital (Cornell), Manhasset, New York |
| 1980 - 1982 | Fellow, Rheumatology, Albany Medical College, Albany, New York |

MEDICAL SCHOOL ACTIVITIES

- | | |
|-------------|--|
| 1978 - 1980 | Clinical Associate, Cornell University, Medical College, New York, N.Y. |
| 1980 - 1982 | Fellow, Albany Medical College, Albany, New York |
| 1982 - 1987 | Clinical Assistant Professor of Family & Community Medicine The Milton S. Hershey Medical Center of The Pennsylvania State University |

LICENSURE Pennsylvania MD# 026744-E

BOARDS AND CERTIFICATIONS

- | | |
|----------------|---|
| 1975 | National Board Exam, Part I |
| 1977 | National Board Exam, Part II |
| 1978 | National Board Exam, Part III |
| 1978 | New York State Licensure #135642 |
| 1982 | Pennsylvania Licensure #MD-026744-E |
| 1980 (Sept.) | Board Certified, American Board of Internal Medicine |
| 1982 (Nov.) | Board Certified, American Board of Internal Medicine, Subspecialty of Rheumatology |
| 2005 | Certified Clinical Investigator (DIA) |
| 2006 – Present | Certified Physician Investigator (ACRP) |

SOCIETIES AND MEMBERSHIPS

- American Medical Association
- Blair County Medical Society - Past President 1992
- Pennsylvania Medical Society
- Fellow, American College of Rheumatology
- International Society for Clinical Densitometry
- Drug Information Association

PAST WORK EXPERIENCE

1980 – 1982 Medical House Physician, Memorial Hospital, Albany, New York
1980 - 1981 Emergency Room Physician, St. Peters Hospital, Albany, New York

CURRENT POSITIONS

1982 - Present President and Founder of Altoona Arthritis and Osteoporosis Center & High Complexity Medical Lab Director for Adult and Pediatric Rheumatology Lab at 175 Meadowbrook Lane, Duncansville, PA 16635. Altoona Arthritis and Osteoporosis Center is a private single practice specialty group practice consisting of 4 board certified Rheumatologists, 5 Physician Assistants, and one Nurse Practitioner. The center offers in-house laboratory service, x-ray, DXA, and in-house MRI.

1991 - Present President and Founder and Medical Director, Altoona Center for Clinical Research at 175 Meadowbrook Lane, Duncansville, PA 16635

MEDICAL STAFF PRIVILEGES

- UPMC, Altoona, PA
- Encompass Health

INVITED SPEAKER AND PRESENTATIONS:

2003: Physician Moderator: Introduction of HUMIRA™ (adalimumab) an Innovative, Monoclonal Anti-TNF α Antibody in Pittsburgh, Pennsylvania at the Hyatt Regency Pittsburgh International Airport

2003: May - American College of Rheumatology: "Oxymorphone Extended Release Improves Pain and Quality of Life in Patients with Osteoarthritis: Results of a Dose-Ranging Study"

2003: June – The European League Against Rheumatism: "Oxymorphone Extended Release Improves Pain and Quality of Life in Patients with Osteoarthritis: Results of a Dose-Ranging Study"

2003: Update on TNF Inhibitor Therapy – University of Virginia, Charlottesville, VA

2016: Sanofi/Genzyme/Regeneron ACR Innovation Theater

2017: Elsevier Office of Continuing Medical Education (EOCME). Faculty member for the webcast

activity **Evolving Treatment Paradigms for Rheumatoid Arthritis: *Translating Comprehensive Patient Evaluations Into Personalized Therapy***

2017: PeerView Institute for Medical Education: Rheumatoid Arthritis Panel Discussion on “*Addressing Unmet Needs in Rheumatoid Arthritis Through Novel Treatment Options and Enhanced Physician-Patient Collaboration*”

2017: Pfizer India Speaker Circuit for Rheumatologists in Delhi, Kolkata, Bangalore, Hyderabad, and Chennai. Speaker on: ORAL Strategy study and put the results of this study into perspective with other clinical studies, Discuss how JAK inhibition fits into the RA treatment paradigm, Discuss the practicalities in using this new therapy, particularly with respect to screening, monitoring, use of concomitant therapies (once tofacitinib is added and continued) or any special circumstances, and Provide a platform to share expertise and clinical experiences with prominent leaders in rheumatology

2018: PRIME® Education, LLC **Course Director/Speaker** for our 1-hour expert panel video activity entitled “*Solving the Problem of Choice in Treatment Decisions for Patients with RA: Evidence-Based, Guideline-Directed, and Patient-Centered Strategies*”

2018: Speaker for Sanofi –titled “A Novel IL-6i treatment for RA-Clinical Practice” at three Israeli Rheumatology Centers in Petah Tikva and Tel Aviv. He also gave a presentation at the Israeli Annual Rheumatology Congress in Jerusalem titled “The Role of IL6 in the Pathogenesis of RA and Associated Co-Morbidities”. He took part in an advisory board discussion “Smart Cycling in RA Management” and a Q & A session with Israeli Rheumatologists.

2018: PANLAR 2018 Congress, Buenos Aires, Argentina
Presented Posters: “Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis: Primary Results through 52 Weeks from a Phase 3 Randomized Placebo-controlled Study (FUTURE 4) and “Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis 2-year Results from a Phase 3 Study”.

2018: Flexion Innovation Theater at ACR in Chicago

2018: <https://www.wearecentralpa.com/news/study-offers-pain-relief/1383324984>

2018: https://drive.google.com/file/d/13heow4DAI0V0ySqBdK187K-AZv_3nXp_/view?ts=5b2c161b

2019: <http://www.altoonamirror.com/news/local-business/2019/09/clinical-research-center-praised/>

2019: Taiwanese Speaker Series in Hong Kong, Taipei, and Shanghai to participate in the Pfizer Inflammation & Immunology Conference speaker series called “Signaling the Future: JAK Inhibition in Rheumatoid Arthritis Treatment”.

2019: OARSI Conference in Canada. Presented a Poster on “Safety and Systemic Exposure of Triamcinolone Acetonide Following Intra-Articular Injection of Triamcinolone Acetonide Extended-Release or Standard Triamcinolone in Patients with Hip Osteoarthritis”

2019: AbbVie Live National Broadcast on Rinvoq (upadacitinib) for Rheumatoid Arthritis

2019: Provider for Medscape CME “**When To Switch Treatments in Psoriatic Arthritis**”

2019: Conducted at ACR in Atlanta MOBILITY 5-year video abstract
<https://vimeo.com/inceptioncompany/review/374999042/f914462872>

2020: *Real-World Perspectives on Personalizing Therapy in Knee Osteoarthritis*

2021: Abstract Reviewer for American College of Rheumatology Annual Meeting

2021: *Guest speaker for* Support Group meeting for Sjogren’s Foundation.
Topic of discussion: **Clinical Trials**

2021: Advisor for Pfizer Tanezumab FDA Meeting

2021: ACR Activities: RRF Taskforce member

2022: Abstract Reviewer for American College of Rheumatology Annual Meeting

Advocacy:

June 17, 2021: Invited to participate in virtual fly organized by PA Rheumatology Society and CSRO with Congressman John Joyce to discuss issues of concern to Rheumatology

Consultant for Clinical Trials:

| | |
|--------------------------|---|
| Aventis Pharmaceuticals | Indication: Rheumatoid Arthritis |
| Novartis Pharmaceuticals | Indication: Osteoarthritis and Rheumatoid Arthritis |
| Grunenthal | Indication: Osteoarthritis |
| Eli Lilly | Indication: Rheumatoid Arthritis |
| Pfizer | Indication: Rheumatoid Arthritis |
| Eli Lilly | Indication: Walking Treadmill for OA |
| AbbVie | Indication: Rheumatoid Arthritis |
| AbbVie | Indication: Psoriatic Arthritis |
| Grunenthal | Indication: Osteoarthritis |

SPEAKER BUREAU, ADVISORY BOARD, CONSULTANT:

AbbVie, Bristol Myers Squibb, Amgen, Genentech, Novartis, Pfizer, Celgene, Horizon, Lilly, Iroko, GlaxoSmithKline, Genzyme/Regeneron/Sanofi, UCB, Flexion, Merck, and Janssen

AWARDS

Clinical Associate Professor of Lock Haven University of Pennsylvania

Sincere Interest in Education by Hollidaysburg Area Senior High School

COMMITTEES

Janssen AWARE Steering Committees

Regeneron/Sanofi Genzyme Steering Committees

ACR Activities: RRF Taskforce member

EDUCATION

- | | |
|------|---|
| 2016 | Medscape Rheumatology TV Broadcast: Panelist on an upcoming roundtable discussion on treatment selection when TNF inhibitors fail in patients with RA. |
| 2016 | Faculty member in a multi-pronged online CME activity titled Clinical Updates in Rheumatoid Arthritis: “ <i>New Strategies to Target Remission and Individualize Comprehensive Care</i> ”. Provided by Integritas Communications and Global Education Group |
| 2017 | Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education “Addressing Unmet Needs in Rheumatoid Arthritis Through Novel Treatment Options and Enhanced Physician-Patient Collaboration” |

ABSTRACTS AND PUBLICATIONS

Kivitz, AJ, Schnitzer, TJ, Greenwald, M, In Medicine, A, Matzura-Wolfe D, Polis, AB, Dixon, ME, Dobbins, TW, Geba, GP. "Rofecoxib Provides Superior Relief of Pain in Osteoarthritis (OA) Compared to Celecoxib" *Pain Med.* 2001, Sep;2(3):244

Murphy, T., Kivitz, A., Sands, E., "Management of Postmenopausal Osteoporosis", *JAOA* (supplement 6) 2003;103:S6-S11

Murphy, FT, Kivitz, AJ, Zumer, MJ, Marvasti, A, Flagg, SD, Kolasinski, SL
"The Clinical Utility of the High-Sensitivity Quantitative Determination of C-Reactive Protein (hs-CRP) by Latex Particle Enhanced Immunoturbidimetric Assay in Patients with Inflammatory Rheumatic Disease". *Arthritis Rheum* 2003;48;(9)Suppl.:S623

Kivitz, A., Ma, C., Ahdieh, H., "Oxymorphone Extended Release Improves Pain and Quality of Life in Patients with Osteoarthritis: Results of a Dose-Ranging Study". *Arthritis Rheum* 2003;48;(9)Suppl.,1221:S485

Kivitz, A., Bartholomew, L., Rynes, R., Kremer, J., McGoldrick, M., "Reversal of Acute Renal Failure in Lupus Nephritis by Plasmapheresis" (Unpublished)

Kivitz, A., Ehrich, E., Schnitzer, T., "MK-966: A Highly Selective Cox-2 Inhibitor, Was Effective in the Treatment of Osteoarthritis (OA) of the Knee and Hip in a 6-week Placebo Controlled Study." *American College of Rheumatology Poster Presentation, 1997.*

Bocanegra, T.S., Kivitz, A., Hurley, S.M., Talwalker, S., Ball, J.A., Kuss, M.E., Fakouhi, M.K., Dunnahoo, S., Dhadda, S., Grossman, E.H., and Skipper, M., "Treatment of osteoarthritis (OA) with diclofenac/misoprostol is associated with a lower incidence of gastroduodenal ulcers (GDU) compared to nabumetone and naproxen." *American College of Rheumatology Poster Presentation, 1998*

Weaver, A, Schnitzer, TJ, Polis, AB, Dixon, ME, Kivitz, A. and Gormley, GJ, "A Clinical Trial Comparing Rofecoxib to Celecoxib and Acetaminophen in the Treatment of Osteoarthritis (OA): Early Efficacy Results." Received by *Eular 2000* and presented in Nice, France.

Simon, L.S., Weaver, A.L., Graham, D.Y., Kivitz, A., Lipsky, P.E., Hubbard, R.C., Isakson, P.C., Verburg, K.M., Yu, S.S., Zhao, W.W., Geis, G.S., "Anti-Inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis". *JAMA* 1999;282:1921-1928.

M. Murphy, A. Kivitz, M. Palmer. "The Effects of Rofecoxib, A COX-2 Specific Inhibitor, vs Ibuprofen on Biochemical Indices of Bone Turnover in Patients with Osteoarthritis" (abstract)
In: *ASBMR 21st Annual Meeting, September 30-October 4, 1999. St. Louis, MO.*

Mulder, H, Kivitz, A, Walravens, M, Glowinski, J, Ritter-Hrncirik, C, /zovich, N, Bolognese, M. "Risedronate Increases Bone Mass and Reduces Vertebral Fractures in Postmenopausal Women." Received by *ECT 2000* and presented in Finland on May 6-May 10, 2000.

Kivitz, A.J., Agrawal, N.M., Caldwell, J., Weaver, A.L., Bocanegra, T.S., Ball, J., Dhadda, S., Hurley, S., Hancock, L. Comparison of the Upper Gastrointestinal Safety of Arthrotec® and Nabumetone in Osteoarthritis Patients at High Risk for Developing Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Ulcers.

Kivitz, A.J., Paulus, H.E., Olsen, N.J., Weisman, M.H., Matteson, E.L., Furst, D.E., Vollenhoven, R.V., Genovese, M.C., Anderson, J.D., Cohen, S.B., Wei, N., Meijerink, J.H., Jacobs, C.A., Mocci, S., Baughman, J.E., Kavanaugh, A.F., “Allele-and Antigen-Specific Treatment of Rheumatoid Arthritis: Final Results From A Double Blind Placebo Controlled Phase 1 Trial”. ACR 64th Scientific Meeting and ARHP 35th Annual Scientific Meeting, October 28 – November 2, 2000, Philadelphia, PA.

Kivitz, A.J., “Rofecoxib Provides Superior Relief of Pain in Osteoarthritis (OA) Compared to Celecoxib”. American Academy of Pain Medicine’s 17th Annual Meeting in Miami Beach, Florida on Feb. 14-18, 2001.

Burch, F., Tesser, J., Bell, L., Kivitz, A.J. “Baseline C5b-9 Level Correlates with CRP and ACR 20 Response to the Humanized Anti-C5 Antibody h5G1.1 in Patients with Rheumatoid Arthritis” Presented at ACR, 2001.

Kivitz, A.J., Schnitzer, T.J., Greenwald, M., Fleischmann, R.M., Matzura-Wolfe, D., Polis, A.B., Dixon, M.E., Dobbins, T.W., Geba, G.P., “Rofecoxib Provides Superior Relief of Symptoms of Osteoarthritis (OA) Compared to Celecoxib” Presented at EULAR, 2001.

Kivitz, A.J., Burch, F., Birbara, C., Rollins, S., Tesser, J. “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Humanized Anti-C5 Antibody h5G1.1 in Patients with Rheumatoid Arthritis” Presented at ACR, 2001.

Kivitz, A.J., Moskowitz, R.W., Woods, E., Hubbard, R.C., Verburg, K.M., Lefkowitz, J.B., Geis, G.S. “Comparative Efficacy and Safety of Celecoxib and Naproxen in the Treatment of Osteoarthritis of the Hip”. The Journal of International Medical Research 2001; 29: 467-479

Tesser, J, Kivitz, A.J., Fleischmann, R., Mojeik, C.F., Bombara, M., Burch, F., “Safety and Efficacy of the Humanized Anti-C5 Antibody h5G1.1 in Patients with Rheumatoid Arthritis” Presented at ACR, 2001.

Gottlieb, A.B., Mease, P.J., Kivitz, A.J., Burch, F.X., Siegel, E., Cohen, S.B., Burge, D.J., “Improvement in Disease Activity in Patients with Psoriatic Arthritis receiving Etanercept (Enbrel®): Results of a Phase 3 Multicenter Clinical Trial”. Annals of Rheumatic Diseases 2002;61(39)OP0100

Kivitz, A.J., Eisen, G., Zhao, W.W., Recker, D.P., Verburg, K.M., “The Cox-2 Specific Inhibitor Valdecoxib is as Effective as the Conventional NSAID Naproxen in Treating Symptomatic Osteoarthritis of the Knee and Demonstrates Reduced Gastrointestinal Ulceration”. Annals of Rheumatic Diseases 2002;61(120)THU0205

Guler, H.P., Caldwell, J.R., Fleischman, R.M., Cohen, S.B., Kivitz, A.J., Levy, R.M., Littlejohn, T., McIlwain, H., Offenberg, H., Papadopoulos, J., Stahl, N. “Weekly Treatment with IL-1 Trap is Well Tolerated and Improves ACR criteria in Patients with Active Rheumatoid Arthritis”. Annals of Rheumatic Diseases 2002;61(60)OP0090

Wanke, L.A., Gottlieb, A.B., Mease, P.J., Kivitz, A.J., Cohen, S.B., Burge, D.J. “Etanercept (Enbrel) Improves Health-Related Quality of Life in Psoriatic Arthritis Patients” Annals of Rheumatic Diseases 2002;61(300)SAT0168

Wellborne, F., Keystone, E.C., Kivitz, A., Greenwald, M., Teoh, L., Fischkoff, S., Chartash, E. “Adalimumab (D2E7), a Fully Human Anti-TNF, a Monoclonal Antibody, Improved Health-Related Quality of Life in Patients with Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy” Arthritis and Rheumatism 2002;393(339)1394

Alan Kivitz, William Bensen, William Makarowski, Terry Bevirt, William Riley, David Recker. “Valdecoxib Provides Similar Efficacy and Improved Upper GI Safety Compared with Naproxen in Elderly and Non-elderly Patients with Osteoarthritis (OA) or Rheumatoid Arthritis” Arthritis and Rheumatism 2002;230(338)338

Peter Ory, John T. Sharp, David Salomen, Joel Rubenstein, Philip J. Mease, Alan J. Kivitz, Daniel J. Burge, Wayne Tsuji. “Etanercept (ENBREL®) Inhibits Radiographic Progression in Patients with Psoriatic Arthritis” Arthritis

and Rheumatism 2002;(338)442

Arthur Kavanaugh, Mark Genovese, Jan Baughman, Alan Kivitz, Ken Bulpitt, Nancy Olsen, Michael Weisman, Eric Matteson, Daniel Furst, Ronald van Vollenhoven, James Anderson, Stanley Cohen, Nathan Wei, Jan Meijerink, Cindy Jacobs, Simonetta Mocci. "Allele and Antigen-Specific Treatment of Rheumatoid Arthritis: A Double Blind, Placebo Controlled Phase 1 Trial" J Clin Rheumatol 2003;449-454

Mease, P., Siegel, E., Ruderman, E., Kivitz, A., Burch, F., Cohen, S., Ritchlin, C., Tsuji, W., Burge, D. "Etanercept (Enbrel®) in Patients with Psoriatic Arthritis and Psoriasis Continued Observations" Presented at Annual European Congress of Rheumatology, Lisbon, Portugal, June 18-21 (Abstract) 2003

Kivitz, A., Ahdieh, H., Ma, C. "Oxymorphone Extended Release (ER) Improves Pain and Quality of Life in Patient with Osteoarthritis Results of a Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study" Accepted at Annual European Congress of Rheumatology, Lisbon, Portugal, June 18-21 (Abstract) 2003

M. Luggen, A. Kivitz, J. Schechtman, E. Boling, M. Totoritis, M. Ingram, J. Aldworth, M. Greenwald, J. Forstot. "Results of a Phase II, Double-Blind, Randomized Study of a Nondepleting Anti-CD4 Monoclonal Antibody (Clenoliximab) Given in Combination with Methotrexate (MTX) in Patients with Moderate to Severe Rheumatoid Arthritis (RA)" Presented at Annual European Congress of Rheumatology, Lisbon, Portugal, June 18-21 (Abstract)

A. Kivitz, S. Nayiager, T. Schimansky, A. Gimona, H. Thurston, C. Hawkey. "Gastrointestinal Safety and Tolerability of Lumiracoxib in Patients with Rheumatoid Arthritis" Accepted for publication. Aliment Pharmacol Ther 2004;19: 1189-1198

G. Scott, C. Rordorf, S. Milosavljev, W. Chase, R. Fleischmann, A. Kivitz. "Multiple-dose lumiracoxib shows rapid absorption and cyclooxygenase-2 (COX-2) selectivity without accumulation in patients with rheumatoid arthritis", to the 6th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT)" Presented in Ankara, Turkey, June 24-28, 2003

Goldstein, J.L., Kivitz, A.J., Verburg, K.M., Recker, D.P., Palmer, R.C., Kent, J.D. "A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects" Aliment Pharmacol Ther 2003;18:125-132

Kivitz, A.J., Greenwald, M.W., Cohen, S.B., Polis, A.B., Najarian, D.K., Dixon, M.E., Moidel, R.A., Green, J.A., Baraf, H., Petruschke, R.A., Matsumoto, A.K., Geba, G.P.,. "Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial". Journal of the American Geriatrics Society, 2004: Volume 52, Issue 5.

Davis, J.C., Van der Heijee, D.M., Braun, J., Dougados, M., Cush, J.J., Clegg, D.O., Kivitz, A.J., Inman, R.D., Solinger, A., Whitmore, J., Tsuji, W. "One Year Efficacy of Etanercept in Ankylosing Spondylitis" Arthritis and Rheumatism, 2004;50:1620, 611 (Abstract)

Schnitzer, T.J., Kivitz, A.J., Lipetz, R.S., Sanders, N., Hee, A. "A Phase II Study of the Efficacy and Safety of AZD3482, A CINOD, In Subjects with Osteoarthritis of the Knee" Annual European Congress of Rheumatology, 2004 (Abstract)

Pavelka, K., Nayiager, S., Kivitz, A., Patel, N., Yu, S., Sloan, V. "Efficacy and Tolerability of Lumiracoxib in the Treatment of Rheumatoid Arthritis: A 13-Week, Randomized, Double-Blind Study". Annual European Congress of Rheumatology, 2004 (Abstract)

Mease, P.J., Kivitz, A.J., Burch, F.X., Siegel, E.L., Cohen, S.B., Ory, P., Salonen, D., Rubenstein, J., Sharp, J.T., Tsuji, W. "Etanercept Treatment of Psoriatic Arthritis: Safety, Efficacy, and Effect on Disease Progression. Arthritis and Rheumatism, 2004;50: 2264-2272

Kivitz, A.J., McAdam, L.P., Miller, D., Chen, P.Y., van Adelsberg, J., Reicin, A.S. "Three Year Efficacy and Safety

of Rofecoxib and Naproxen for Rheumatoid Arthritis”, 2004 (Abstract)

Kivitz, A., Rodrigues, J., Hwang, E., Padula, S., Wood, C., Kovacs, B. “Efficacy and Safety of Three Doses of Meloxicam in the Treatment of Active Rheumatoid Arthritis: Results from a Twelve-Week, Placebo-controlled, Multinational Trial.” *Arthritis and Rheumatism*, 2004;50:332, 175 (Abstract)

Holten, J. van, Pavelka, K., Vencovsky, J., Stahl, H., Rozman, B., Genovese, M., Kivitz, A., Alvaro, J., Nuki, G., Furst, D., Herrero-Beaumont, G., McInnes, I., Musikic, P., Tak, P. A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase II Study of Subcutaneously Administered Interferon Beta 1a in the Treatment of Patients with Active Rheumatoid Arthritis.” *Arthritis and Rheumatism*, 2004;50:520, 238 (Abstract)

Kivitz, A., Rodrigues, Padula, S., Kovacs, B., Wood, C., Hall, D. “Effect of Flare Criteria on Ability to Assess Clinical Response to Meloxicam (7.5, 15, 22.5 mg per day) in Rheumatoid Arthritis Patients.” *Arthritis and Rheumatism*, 2004;50:978, 396 (Abstract)

Baumgartner, S., Paulus, H., Burch, F., Kivitz, A., Dunn, M., Kerr, D., Tsuji, W., Weisman, M. “A Study to Determine the Safety of Etanercept (ENBREL) in Patients with Rheumatoid Arthritis who have Concomitant Comorbid Conditions”. *Arthritis and Rheumatism*, 2004;50:1765, 660 (Abstract)

Battisti, W.P., Katz, N.P., Weaver, A.L., Matsumoto, A.K., Kivitz, A.J., Polis, A.B., Geba, G.P. “Pain Management in Osteoarthritis: A Focus on Onset of Efficacy – A Comparison of Rofecoxib, Celecoxib, Acetaminophen., and Nabumetone Across Four Clinical Trials.
The Journal of Pain, Vol 5, No 9 (November), 2004:pp511-520

Sowers, J.R., White, W.B., Pitt, B., Whelton, A., Simon, L., Winer, N., Kivitz, A., van Ingen, H., Brabant, T., Fort, J. “The Effects of Cyclooxygenase –2 Inhibitors and Nonsteroidal Anti-Inflammatory Therapy on 24-hour Blood Pressure in Patients with Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus” *Arch Intern Med*. 2005;165:161-168

Sietsema, W., Kivitz, A., Reuter, S., D’Souza, S.. “Metrics and Trends in Rheumatoid Arthritis Clinical Trials: An Eight-Year Perspective”. Abstract presented at EULAR 2005, Vienna, Austria
Annals of the Rheumatic Diseases, Vol 64, Supplement III

Meese, P., Szechinski, J., Greenwald, M., Leirisalo-Repo, M., Kivitz, A., Barile-Fabris, L., Kalsi, J., Eames, J.: “Improvements in Patient Reported Outcomes Over 24 Weeks for Rituximab with Methotrexate in Rheumatoid Arthritis Patients in Phase IIb Trial (DANCER)”
Arthritis & Rheumatism, Vol. 52, Number 9 (Supplement); 280:138-139

Chevalier, X., Goupille, P., Beaulieu, A., Burch, F., Conrozier, T., Loeuille, D., Kivitz, A., Silver, D., Kiefer, P., Zhou, L., Bevirt, T., Appleton, B.: “Results from a Double Blind, Placebo-Controlled, Multicenter Trial of a Single Intra-Articular Injection of Anakinra (Kineret®) in Patients with Osteoarthritis of the Knee”.
Arthritis & Rheumatism, Vol. 52, Number 9 (Supplement); 1339:507

Kivitz, A., Fairfax, M., Sheldon, E., Oleka, N., Galer, B., Gammaitoni, A.: “A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% with Celecoxib 200 mg in Patients with Pain from Osteoarthritis of the Knee”.
Arthritis & Rheumatism, Vol. 52, Number 9 (Supplement); 1340:507

Shannon, M., Kivitz, A., Landau, C., Sessler, N., Yichaun, X., Ripa, S.: “Buprenorphine Transdermal System in Chronic Pain Due to Osteoarthritis”. Presented at the American Academy of Physical Medicine and Rehabilitation on October 27-30 in Philadelphia, PA.

Davis, J., van der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D., Inman, R., Kivitz, A., Zhou, L., Solinger, A., Tsuji, W.: “Sustained Durability and Tolerability of Etanercept in Ankylosing Spondylitis for 96 Weeks”
Ann Rheum Dis 2005;64:1557-1562

Schnitzer, Thomas J., Kivitz, Alan J., Lipetz, Robert S., Sanders, Nick, Hee, Angela. "Comparison of the COX-Inhibiting Nitric Oxide Donator AZD3582 and Rofecoxib in Treating the Signs and Symptoms of Osteoarthritis of the Knee.

Arthritis & Rheumatism 2005;53:827-837

Williams, Gary W., Kivitz, Alan J., Brown, Mark T., Verburg, Kenneth M. "A Comparison of Valdecoxib and Naproxen in the Treatment of Rheumatoid Arthritis Symptoms"

Clinical Therapeutics, Volume 28, Number 2, 2006

Emkey, Ronald, Koltun, William, Beusterien, Kathleen, Seidman, Larry, Kivitz, Alan, Devas, Vipul, Masanauskaite, Daiva. "Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)"

Current Medical Research and Opinion; Vol. 21, No 12, 2005, 1895-1903

McClung, Michael R., Lewiecki, E. Michael, Cohen, Stanley B., Bolognese, Michael A., Woodson, Grattan C., Moffett, Alfred H., Peacock, Munro, Miller, Paul D., Lederman, Samuel N., Chesnut, Charles H., Lain, Douglas, Kivitz, Alan J., Holloway, Donna L., Zhang, Charlie, Peterson, Mark C., Bekker, Pirow J. "Denosumab in Postmenopausal Women with Low Bone Mineral Density"

The New England Journal of Medicine; Volume 354, No 8:821-831. February 23, 2006

R. Emkey, MD,¹ A. Kivitz, MD,² W. Koltun, MD,³ R. B. Leslie, PharmD, RPh⁴

Once-Monthly Ibandronate and Once-Weekly Alendronate: Preference Results from the BALTO I and II Studies
The 14th Annual Congress on Women's Health, Hilton Head Island, SC: June 3-6, 2006

Van der Heijde, D., Kivitz, A., Schiff, M., Sieper, J., Dijkmans, B., Braun, J., Dougados, M., Reveille, J., Wong, R., Kupper, H., Davis, J. "Long-Term Adalimumab Treatment Reduces Signs and Symptoms in Ankylosing Spondylitis (AS) Patients" – 1 Year Results from the ATLAS Trial

Presented at EULAR 2006

Van der Heijde, D., Kivitz, A., Schiff, M., Sieper, J., Dijkmans, B., Braun, J., Dougados, M., Reveille, J., Wong, R., Kupper, H., Davis, J. "Efficacy and Safety of Adalimumab in Patients With Ankylosing Spondylitis" Arthritis and Rheumatism, Vol. 54, No. 7, July 2006, pp 2136-2146

J. Davis, MP Luo, H. Zeidler, A. Matsumoto, B. Dijkmans, C. Salvarani, E. Veys, R. Wong, D van der Heijde. "Adalimumab Reduces Pain and Fatigue in Ankylosing Spondylitis (AS) Patients" Results from the ATLAS Trial
Presented at EULAR 2006

J. Peng, P. Noertersheuser, S. Paulson, D van der Heijde, M. Schiff, A. Kivitz, J. Sieper, J. Braun, R. Westhovens, R. Wong, H. Kupper, J. Davis. "Pharmacokinetics of Adalimumab in Patients with Active Ankylosing Spondylitis", The ATLAS Trial

Presented at EULAR 2006

Davis, J., Kivitz, A., Schiff, M., Sieper, J., Dijkmans, B., Braun, J., Dougados, M., Reveille, J., Wong, R., Kupper, H., Van der Heijde, D.: "Major Clinical Response and Partial Remission in Ankylosing Spondylitis Subjects Treated with Adalimumab": The ATLAS Trial.

Arthritis & Rheumatism, Vol. 52, Number 9 (Supplement); 483:208

Van der Heijde, D., Kivitz, A., Schiff, M., Sieper, J., Dijkmans, B., Braun, J., Dougados, M., Reveille, J., Wong, R., Kupper, H., Davis, J.: "Adalimumab Therapy Results in Significant Reduction of Signs and Symptoms in Subjects with Ankylosing Spondylitis": The ATLAS Trial.

Arthritis & Rheumatism, Vol. 52, Number 9 (Supplement); 691:281

Kaine, J., Luo, A., Kivitz, A., Birbara, C.: "Effect of Adalimumab (Humira®) on Response to Influenza Virus and Pneumococcal Vaccines in Patients with Rheumatoid Arthritis (RA)"

Presented at Eular 2006

Grossbard, E., Baluom, M., Kivitz, A.: "A Phase I Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic Study of R788/406 and Methotrexate in Sixteen Patients with Rheumatoid Arthritis"
Arthritis & Rheumatism, Volume 54, Number 9 (Supplement) 939:408

Van der Heijde, D., Kivitz, A., Schiff, H., Sieper, J., AC Dijkmans, B., Wordsworth, P., Wong, R., Kupper, H., Davis, J.: "Treatment with Adalimumab Reduces Signs and Symptoms and Induces Partial Remission in Patients with Ankylosing Spondylitis (AS): 1-Year Results from ATLAS"
Arthritis & Rheumatism, Volume 54, Number 9 (Supplement) 2017:792

Mease, P., Wei, N., Fudman, E., Kivitz, A., Hobbs, K., Anklesaria, P., Heald, A.: "A Phase ½ Clinical Study of Intra-Articular Administration of a Recombinant Adeno-Associated Vector Containing a TNF-α Antagonist Gene in Inflammatory Arthritis"
Arthritis & Rheumatism, Volume 54, Number 9 (Supplement) 925:403

Kaine, J., Kivitz, A., Birbara, C., Luo, A.: "Abilities to Develop Protective Antibodies to Pneumococcal and Influenza Vaccine are Maintained in Rheumatoid Arthritis (RA) Patients Treated with Adalimumab (Humira®)"
Arthritis & Rheumatism, Volume 54, Number 9 (Supplement) 1235:515

Burge, D., Shu, C., Martin, T., Littlejohn, T. W., Wallace, D.J., Talborn, J., Palmer, W. R., Kivitz, A.: "TRU-015, a Small Modular Immunopharmaceutical (SMIP™) Drug Candidate Directed Against CD20, Demonstrates Clinical Improvement in Subjects with Rheumatoid Arthritis"
Arthritis & Rheumatism, Volume 54, Number 9 (Supplement) 463:230

Goldbach-Mansky, R. T., Wilson, M., Alli, S., Pham, T. H., Kivitz, A., Silverfield, J., Kempf, P., Olsen, N., Fleischmann, R., Tao, S., Lipsky, P.: "A Multi-Center, Double-Blind, Randomized Study in Patients with Active Rheumatoid Arthritis (RA) Comparing An Extract From a Chinese Vine, Tripterygium Wilfordii Hook F (TWHF) to Sulfasalazine"
Arthritis & Rheumatism, Volume 54, Number 9 (Supplement) 484:238

Koffeman, E., Amox, D., Genovese, M., Kavanaugh, A., Schiff, M., Santana, E., Dennehey, C., Posever, J., Belardi, F., Molitor, J., Bathon, J., Matteson, E., Kivitz, A., Berry, C., Keogh, E., Puga Yung, G., Tremoulet, A., Zieseniss, P., Gosch, C., Friend, S., Martinex, A., Le, T., Samodal, S., Cutter, G., Albani, S.
"Clinical and Immunological Effects of Epitope-Specific Therapy in Rheumatoid Arthritis (RA): Synergistic Effect of dnaJP1 with Hydroxychloroquine (HCQ)"
Arthritis & Rheumatism, Volume 54, Number 9 (Supplement) 499:244

Kivitz, A., Fairfax, M., Sheldon, E., Barlas, S., Gammaitoni, A., Gould, E., "A Randomized, Open-Label Study Comparing the Efficacy and Safety of Lidocaine Patch 5% with Celecoxib 200 mg/d in Patients With Pain from Osteoarthritis of the Knee"
Presented at the AAPM&R Meeting in Hawaii 2006

Kivitz, A., Cohen, S., Dowd, J., Edwards, W., Thakker, S., Wellborne, F., Renz, C., Segurado, O.,
"Clinical Assessment of Pain, Tolerability, and Preference of an Autoinjection Pen Versus a Prefilled Syringe, for Patient Self-Administration of the Fully Human, Monoclonal Antibody Adalimumab: The TOUCH Trial"
Clinical Therapeutics, Volume 28, Number 10, 2006:1619

Kivitz, A., Ma, C., Ahdieh, H., Galer, B. "A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging , phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee"
Clinical Therapeutics, 2006, March; 28(3):352-64

Davis, J., Van der Heijde, D., Braun, J., Dougados, M., Cush, J., Clegg, D., Inman, R., Kivitz, A., Zhou, L., Solinger, A., Tsuji, W. "Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks"
Ann Rheum Dis. 2005 Nov ;64 (11):1557-62

Sowers, J., White, W., Pitt, B., Whelton, A., Simon, L., Winer, N., Kivitz, A., Van Ingen, H., Brabant, T., Fort, J. "The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus"
Arch Intern Med. 2005 Jan. 24;165(2):161-8

Kivitz, A., Eisen, G., Zhao, W., Bevirt, T., Recker, D. "Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis"
J Fam Pract. 2002 Jun ;51 (6):530-7 12100776

Kivitz, A., Segurado, O. "HUMIRA® Pen: a novel autoinjection device for subcutaneous injection of the fully human monoclonal antibody adalimumab"
2007 Future Drugs Ltd: ISSN 1743-4440, page 109

Murphy, F., Kivitz, A., Zumer, M., Marvasti, A., Flagg, S., Kolasinski, S. "The Clinical Utility of the High Sensitivity Quantitative Determination of C-Reactive Protein (hs-CRP) by Latex Particle Enhanced Immunoturbidimetric Assay in Patients with Inflammatory Rheumatic Disease".
Arthritis & Rheumatism, Vol. 48:S623 Presented at ACR Annual Scientific Meeting, Orlando 2003

Weisman, M., Paulus, H., Burch, F., Kivitz, A., Fierer, J., Dunn, M., Kerr, D., Tsuji, W., Baumgartner, S. "A Placebo-Controlled, Randomized, Double-Blinded Study Evaluating the Safety of Etanercept in Patients with Rheumatoid Arthritis and Concomitant Comorbid Diseases"
Rheumatology (Oxford) April 29, 2007:17470434

Mease, P., Kivitz, A., Burch, F., Siegel, E., Cohen, S., Ory, P., Salonen, D., Rubenstein, J., Sharp, J., Dunn, M., Tsuji "Continued Inhibition of Radiographic Progression in Patients with Psoriatic Arthritis Following 2 Years of Treatment with Etanercept"
J Rheumatol Feb. 1, 2006: 16463435

Genovese, M.C., Mease, P.J., Thomson, G.T.D., Kivitz, A.J., Perdok, R.J., Weinberg, M.A. "Adalimumab Efficacy in Patients with Psoriatic Arthritis Who Failed Prior DMARD Therapy"
Presented at EULAR 2007

Fleischmann, R., Kivitz, A.J., Franklin, C., Pavlik-Gaylord, S., Sridharan, S., Kirsch, T.M., "A Randomized, Double-Blind, Placebo-Controlled, Sequential-Dose Study of the Safety of Aprepitant (TMI-005), a Novel Oral Dual Inhibitor of TNF-Alpha-Converting Enzyme/Metalloproteinase, in Patients with Rheumatoid Arthritis on a Background of Methotrexate"
Presented at EULAR 2007

Hoffman, H.M., Amar, N.J., Cartwright, R.C., Kivitz, A.J., Belomestnov, P., Mellis, S.J., Weinstein, S.P. "Durability of Response to Riloncept (IL-1 Trap) in a Phase 3 Study of Patients with Cryopyrin-Associated Periodic Syndromes (CAPS): Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS)" Abstract at the American Academy of Allergy Asthma and Immunology, Annual Meeting March 14-18, 2008.

S. Cohen, S. Proudman, A. Kivitz, F. Burch, JP Donahue, L. Ni, B. Appleton "Results from a Randomized Controlled Trial of AMG 108 (a fully Human monoclonal antibody to IR-1R type 1) in Patients with Osteoarthritis of the Knee"
Arthritis and Rheumatism, Volume 56, Number 9, 1684, page S660

Thomas Schnitzer, Alan Kivitz, Bruce Rankin, Chester Fisher, Richard Fishman, Howard Marker, Hayet Frayssinet, Brigitte Duquesroix. "Efficacy and Safety of Naproxinod Compared to Placebo and Naproxen in Patients with Osteoarthritis of the Knee: Results from a 13-Week Randomized Double-Blind Trial"
Arthritis and Rheumatism, Volume 56, Number 9, 1678, page S658

Hal Hoffman, Fred Wolfe, Arthur Kavanaugh, Alan Kivitz, Imogene Grimes, Steve Weinstein, Scott Mellis. "Sustained Efficacy of Rilonacept IL-1 Trap in Patients with Cryopyrin-Associated Periodic Syndromes (CAPS) Arthritis and Rheumatism, Volume 56, Number 9, 1291, page S518

D. van der Heijde, M.H. Schiff, J. Sieper, A. Kivitz, B. AC Dijkmans, P.J. Mease, H. Kupper, R. Wong, S. Ballal, J. Davis. "Long-Term Spinal Mobility in Ankylosing Spondylitis (AS) Patients Treated with Adalimumab: 104-Week Results from ATLAS". Arthritis and Rheumatism, Volume 56, Number 9, 1160, page S471

Desiree van der Heijde, Michael H. Schiff, Joachim Sieper, Alan Kivitz, Ben AC Dijkmans, Philip J. Mease, Hartmut Kupper, Robert L. Wong, John C. Davis. "2-Year Safety and Efficacy Results From the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis (ATLAS)". Arthritis and Rheumatism, Volume 56, Number 9, 581, page S252

D. van der Heijde, M.P. Luo, A. Kivitz, M.H. Schiff, J. Sieper, B. AC Dijkmans, J. Braun, M. Dourados, P. Wordsworth, R. Wong, H. Kupper, J. Davis. "Ankylosing Spondylitis (AS) Patients on Adalimumab Show Sustained Improvement in Health-Related Quality of Life (HRQOL): 104-Week Results from ATLAS". Arthritis and Rheumatism, Volume 56, Number 9, 1494, page S590

Philip Mease, Nathan Wei, Edward Fudman, Alan Kivitz, Pervin Anklesaria, Alison Heald. "Local Treatment for Inflammatory Arthritis: A Phase ½ Clinical Study of Intra-Articular Administration of a Recombinant Adeno-Associated Vector Containing a TNF-α Antagonist Gene". Arthritis and Rheumatism, Volume 56, Number 9, 2084, page S793

Alan J. Kivitz, MD, Luis R. Espinoza, MD, Yvonne R. Sherrer, MD, Maria Liu-Dumaw, MS, Christine R. West, PhD. "A Comparison of the Efficacy and Safety of Celecoxib 200 mg and Celecoxib 400 mg Once Daily in Treating the Signs and Symptoms of Psoriatic Arthritis". Seminars in Arthritis and Rheumatism, Vol 37, No 3, Page 164

A. Kivitz, TM Keaveny, HK Genant, T. Fuerst, MB Enslin, G. Dasic, R. Davies, EM Lewiecki. "Once-monthly oral ibandronate effect on hip bone quality and strength assessed by volumetric quantitative computed tomography and finite element analysis in postmenopausal women with osteoporosis". Presented at ISCD, 14th Annual Meeting, March 12-15 in San Francisco

Alison Heald, Philip Mease, Nathan Wei, Edward Fudman, Alan Kivitz, Joy Schechtman, Robert Trapp, Kathryn Hobbs, Pervin Anklesaria, "Safety, Local Tolerability and Clinical Response After Intra-Articular Administration of a Recombinant Adeno-Associated Vector Containing a TNF Antagonist Gene in Inflammatory Arthritis". Presented at EULAR 2008 in Paris

Thasia Woodworth, A. Sebba, A. Calvo, S. Li, M. Lowenstein, V. Basijokiene, M. Saavedra-Salinas, T. Reitblat, R. Faraawi, A. Kivitz, R. Blackburn, G. Jones, "Tocilizumab Monotherapy Improves Quality of Life Compared with Methotrexate Monotherapy in Patients with Rheumatoid Arthritis: The Ambition Study". Presented at EULAR 2008 in Paris

Desiree van der Heijde, M. Schiff, B. Dijkmans, J. Sieper, A. Kivitz, R. Westhovens, P. Wordsworth, R. Wong, H. Kupper, S. Ballal, J. Davis for the ATLAS Group. "Three-Year Safety and Efficacy Results from the Adalimumab (Humira®) Trial Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis (ATLAS)". Presented at EULAR 2008 in Paris

Thomas Schnitzer, Richard Fishman, Chester Fisher, Bruce Rankin, Alan Kivitz, Howard Marker, Hayet Frayssinet, Brigitte Duquesroix, "Comparison of Naproxen to Naproxen and Placebo: Results of a 13-Week Phase 3 Pivotal Trial in Patients with Osteoarthritis of the Knee with Particular Focus on Blood Pressure Effects". Presented at EULAR 2008 in Paris

Steven Weinstein, Arthur Kavanaugh, Frederick Wolfe, Hal Hoffman, Alan Kivitz, Imogene Grimes, Scott Mellis, “Rilonacept (IL-1 Trap): Durability of Response in Patients with Cryopyrin-Associated Periodic Syndrome (CAPS)”
Presented at EULAR 2008 in Paris

Jorge Sanchez-Guerrero, Hilda E. Fragoso-Loyo, C. Michael Neuwelt, Daniel L. Wallace, Ellen M. Ginzler, Yvonne R.S. Sherrer, Harris H. McIlwain, Pamela G. Freeman, Cynthia Aranow, Michelle A. Petri, Atul A. Deodhar, Ellen Blanton, Susan Manzi, Arthur Kavanaugh, Jeffrey R. Lisse, Rosalind Ramsey-Goldman, James D. McKay, Alan J. Kivitz, Philip J. Mease, Anne E. Winkler, Leslie E. Kahl, Albert H. Lee, Richard A. Furie, C. Vibeke Strand, Lillian Lou, Mumtaz Ahmed, Betty Quarles, Kenneth E. Schwart. “Effects of Prasterone on Bone Mineral Density in Women with Active Systemic Lupus Erythematosus Receiving Chronic Glucocorticoid Therapy”.
The Journal of Rheumatology. Page 1567 – 1575

A. Kivitz, T.M. Keaveny, H. K. Genant, K. Engelke, T. Fuerst, D. Kopperdahl, M. Fries, G. Dasic, L.A. Fitzpatrick, E.M. Lewiecki. “QCT and FEA Assessment of Proximal Femur Bone Quality and Strength in Women with Postmenopausal Osteoporosis Receiving Once-Monthly Oral Ibandronate for 12 Months”
Presented at ASBMR 30th Annual Meeting, Sept. 2008

E.M. Lewiecki, H.K. Genant, K. Engelke, F. Fuerst, M. Fries, M. Enslin, L.A. Fitzpatrick, A. Kivitz
“Hip Structural Analysis Based on DXA Data in Women with Postmenopausal Osteoporosis Receiving Once-Monthly Oral Ibandronate for 12 months” Presented at ASBMR 30th Annual Meeting, Sept. 2008

D. Padhi, A. Kivitz, T.J. Weber, K. Lyles, E. Lee, B. Cooke, H. Deng, E. Posvar. “An Assessment of Serum Calcium and Bone Resorption Markers in Patients Transitioned from Alendronate to Denosumab”
Presented at ASBMR 30th Annual Meeting, Sept. 2008

D. Burge, S. Bookbinder, A. Kivitz, R. Fleischmann, C. Shu, J. Bannink. “Pharmacokinetic and Pharmacodynamic Properties of TRU-015, a CD20-Directed Small Modular Immunopharmaceutical Protein Therapeutic, In Patients with Rheumatoid Arthritis: A Phase I, Open-Label, Dose-Escalation Clinical Study”
Clinical Therapeutics, Volume 30, Number 10, 1806

X. Chevalier, P. Goupille, A.D. Beaulieu, F. X. Burch, W.G. Burch, W.G. Bensen. T. Conrozier, D. Loeuille, A. J. Kivitz, D. Silver, B.E. Appleton. „Intraarticular Injection of Anakinra in Osteoarthritis of the Knee: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study“
Arthritis and Rheumatism (Arthritis Care & Research) Vol. 61, No 3, March 15, 2009 pp 344-352

Xiaoping Zhang, Christophe Schmitt, Susan Grange, Kimio Terao, Kazuhiro Miya, Alan Kivitz, Mark Marino.
“Disease-Drug Interaction Studies of Tocilizumab with Cytochrome P450 Substrates in Vitro and in Vivo”
Poster presented at 2009 ASCPT Annual Meeting March 18-21, 2009 in National Harbor, MD

Raphaella Goldbach-Mansky, Mildred Wilson, Roy Fleischmann, Nancy Olsen, Joel Silverfield, Phillip Kempf, Alan Kivitz, Yvonne Sherrer, Frank Pucino, Gyorgy Csako, Rene Costello, Tuyet Hang Pham, Christopher Snyder, Sesiree van der Heijde, Xuelian Tao, Robert Wesley, Peter Lipsky, “Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis”
Annals of Internal Medicine, Volume 151, Number 4, August 18, 2009

Athena S. Papas, Phillip C. Fox, Alan Kivitz, Steven Carsons, Anne L. Stevens, Brian Bray, William R. Thelin, Richard Boucher, M. Ross Johnson. “Oral Rinse Formulation of P552-02 is not Orally Bioavailable in Subjects with Primary Sjogrens Syndrome”

Eva C. Koffeman, Mark Genovese, Diane Amox, Elissa Keogh, Ernesto Santana, Eric L. Matteson, Arthur Kavanaugh, Jerry A. Molitor, Michael H. Schiff, James O. Posever, Joan M. Bathon, Alan J. Kivitz, Rodrigo Samodal, Francies Belardi, Carolyn Dennehey, Theo van den Broek, Femke van Wijk, Xiao Zhang, Peter Ziesenis, Tho Le, Berent A. Prakken, Gary C. Cutter, and Salvatore Albani.
“Epitope-Specific Immunotherapy of Rheumatoid Arthritis: Clinical Responsiveness Occurs With Immune

Deviation and Relies on the Expression of a Cluster of Molecules Associated With T-Cell Tolerance in a Double-Blind, Placebo-Controlled, Pilot Phase II Trial”
Arthritis and Rheumatism, Vol. 60, No 11 Nov. 2009, pp 3207-3216

Naoto Yokogawa, Jonathan S. Dunham, Lytia Fisher, Sue Mellberg, Frederick B. Vivino, Walter Chase, A. Kivitz, Michael Murphy. “A Double-Blind, Placebo-Controlled, Crossover Study Using a Latin Square Design to Evaluate the Safety, Tolerability, and Efficacy of NGX267 Oral Capsules in Patients with Xerostomia Associated with Sjogren’s Syndrome”.

Presented at ACR/ARHP Annual Scientific Meeting 2009 & Arthritis and Rheumatism Volume 60, Number 10

Xavier Mariette, Alan Kivitz, John D. Isaacs, William Stohl, Paul P. Tak, Richard E. Jones, Angelika Jahreis, Gillian K. Armstrong, Tim M. Shaw. “Effectiveness of Rituximab (RTX) plus Methotrexate (MTX) in Patients (pts) with Early Active Rheumatoid Arthritis (RA) and Disease Characteristics Associated with Poor Outcomes”.

Presented at ACR/ARHP Annual Scientific Meeting 2009 & Arthritis and Rheumatism Volume 60, Number 10

Elena Peeva, CR Beals, JA Bolognese, A. Kivitz, L. Taber, A. Harman, H. Chung, Steven S. Smugar, and Roland W. Moskowitz. “A Walking Model of Osteoarthritis (OA) Knee Pain: A Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Analgesic Effects of Naproxen, and Tramadol/Acetaminophen in Patients with OA of the Knee”.

Presented at ACR/ARHP Annual Scientific Meeting 2009 & Arthritis and Rheumatism Volume 60, Number 10

P. Mease, M. Genovese, C. Ritchlin, J. Wollenhaupt, Paul P. Tak, A. Kivitz, G. Gladstein, O. Bahary, S. Kelly, J. Teng, J.-C. Becker, and D. Gladman. “Abatacept in Psoriatic Arthritis – Results of a Phase II Study”

Presented at ACR/ARHP Annual Scientific Meeting 2009 & Arthritis and Rheumatism Volume 60, Number 10

P. Nash, S. Nayiager, M. Genovese, A. Kivitz, K. Oelke, C. Ludivico, W. Palmer, C. Rodriguez, I. Dalaet, S. Overfiend, A. Elegbe, and M. Corbo. “Immunogenicity Is Not Increased with Subcutaneous Administration of Abatacept with and without Methotrexate in Patients with Rheumatoid Arthritis: Results from a Phase III Study”

Presented at ACR/ARHP Annual Scientific Meeting 2009 & Arthritis and Rheumatism Volume 60, Number 10

Loren A. Laine, Michael Schiff, Mark Genovese, Alan Kivitz, George Tidmarsh, Michael E. Weinblatt. “Does High-Dose Famotidine Reduce Gastric and Duodenal Ulcers in NSAID Users? Two Double-Blind Six-Month Trials of Single-Tablet Combination Ibuprofen-Famotidine vs. Ibuprofen Alone (Reduce-1 and 2)”

Gastroenterology Journal, May 2009, Volume 136, Number 5, Suppl 1

Nicolino Ruperto, Daniel Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Perez, Clovis Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose Melo-Gomes, Claudia Saad-Magalhaes, J. Chavez, Christina Huemer, Alan Kivitz, Francisco Blanco, Ivan Foeldvari, Michael Hofer, Gerd Horneff, Hans-Iko Huppertz, Chantal Job Deslandre, Anna Loy, Kirsten Minden, Marilyn Punaro, Alejandro Flores Nunez, Leonard Sigal, Alan Kivitz, Marleen Nys, Alberto Martini, Edward Giannini. “Long-Term safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis” Wiley InterScience. Arthritis and Rheumatism, Vol. 62, No. 6, June 2010, pp 1792-1802

T.J. Schnitzer, A. Kivitz, H. Frayssinet, B. Duquesriox. “Efficacy and Safety of Naproxinod in the Treatment of Patients with Osteoarthritis of the Knee: a 13-week prospective, randomized, multicenter study”

Raphaela Goldbach-Mansky, Mildred Wilson, Roy Fleischmann, Nancy Olsen, Joel Silverfield, Phillip Kempf, Alan Kivitz, Yvonne Sherrer, Frank Pucino, Gyorgy Csako, Rene Costello, Tuyet Hang Pham, Christopher Snyder, Desiree van der Heijde, Xuelian Tao, Robert Wesley, Peter Lipsky. “**Comparison of *Tripterygium wilfordii* Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis: A Randomized Trial**”

← Intern Med August 18, 2009 vol. 151 no. 4 I-36

E. Peeva, CR Beals, JA Bolognese, AJ Kivitz, L. Taber, A Harman, SS Smugar, RW Moskowitz. “A Walking Model to Assess the Onset of Analgesia in Osteoarthritis Knee Pain”

Xiaoping Zhang,¹ Christoph Schmitt,² Barbara Kuhn,² Ludger Banken,² Alan Kivitz,³ and Susan

Grange² “Tocilizumab Reverses the Downregulating Effect of Inflammation on Metabolizing Cytochrome P450 3A4 Enzymes: A Disease-Drug Interaction Study Between Inflammation, Simvastatin, and Tocilizumab”

Paul Tiseo¹, Alan J Kivitz, MD², John E Ervin, MD³, Scott J Mellis, MD, PhD⁴, Haobo Ren¹, Damir Skific¹, Richard Wu¹, Peter Powchik¹ [710] **REGN475/SAR164877, a Nerve Growth Factor Inhibitor, in Osteoarthritis Patients with Moderate to Severe Knee Pain: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study. Presented at ACR 2010 in Atlanta, GA**

Michael E Weinblatt, MD¹, Mark C Genovese, MD², Alan J Kivitz, MD³, Alfonso E Bello, MD, MHS⁴, Amy Grahn⁵, Jeffrey W Sherman, MD, FACP⁵, Michael H Schiff, MD⁶ [945] **Efficacy, Safety and Tolerability of HZT-501, Including Users of Low-Dose Aspirin, a Single-Tablet Combination of Ibuprofen-Famotidine: Results of Two Phase 3 Trials. Presented at ACR 2010 in Atlanta, GA**

Tony Fiorino, MD, PhD¹, Alan J Kivitz, MD², Patricia Pardo, MD³, Rocelle Flores⁴, Zhihua Zhang, MD, PhD⁴, John S Bomalaski, MD⁵ “A Single Cohort, Dose Escalation Phase 1 Study of Intravenous Infusion of Pegsiticase (Formerly Uricase-PEG 20), a Drug for Managing Hyperuricemia in Refractory Gout. Presented at ACR 2010 in Atlanta, GA

Michael H Schiff, MD¹, Mark C Genovese, MD², Alan J Kivitz, MD³, Alfonso E Bello, MD, MHS⁴, Jeffrey W Sherman, MD, FACP⁵, Amy Grahn⁵, Michael E Weinblatt, MD⁶ [946] **Long Term Safety of an NSAID with Built-in Gastroprotection for Treatment of Pain and Inflammation Related to OA and RA: Results from a One Year Safety Trial of a Single-Tablet Combination of Ibuprofen-Famotidine vs. Ibuprofen Alone. Presented at ACR 2010 in Atlanta, GA**

Alan Kivitz, MD¹, Ernest A Kopecky, PhD, MBA², Yusong Chen, PhD³, Steve Xiang, PhD³, Matthew Wieman, MD³, Errol M Gould, PhD³ [944] **Efficacy and Safety of the Lidocaine Patch 5% (Lidoderm®) When Used as Adjunct Treatment in Patients with Osteoarthritis of the Knee. Presented at ACR 2010 in Atlanta, GA**

P. Mease, M. Genovese, C. Ritchlin, J. Wollenhaupt, Paul P. Tak, A. Kivitz, G. Gladstein, O. Bahary, S. Kelly, J. Teng, J.-C. Becker, and D. Gladman. “Abatacept in the Treatment of Psoriatic Arthritis” Results of a Six-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. *Arthritis and Rheumatism*. Vol. 63, No. 4, April 2011. pp 939-948

Stanley B Cohen, Susanna Proudman, Alan J Kivitz, Francis X Burch, John P Donohue, Deborah Burstein, Yu-Nien Sun, Christopher Banfield, Michael S Vincent, Liyun Ni and Debra J Zack.

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoarthritis of the knee Published electronically in *Arthritis Research & Therapy*, Center for

Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller P, Bolognese MA, Bone HG, Ljunggren O, Abrahamsen B, Yang Y-C, Grauer A, Libanati C, Hall JW, Boonen S. “A Phase 3 Study of the Efficacy and Safety of Denosumab in Men with Low Bone Mineral Density: Design of the ADAMO Trial”

Loren Laine, MD, Alan J. Kivitz, MD, Alfonso E. Bello, MD, Amy Y Grahn, MS, Michael H. Schiff, MD, Ali S. Taha, MD. “Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. *Am J of Gastroenterology* publication on Dec. 20, 2011; doi: 10.1038/ajg.2011.443

A. Kivitz, Joseph Gimbel, Candace Bramson, Mary Ann Nemeth, David Keller, Mark T. Brown, Christine R. West, Kenneth M. Verburg. "A Study of Tanezumab in Adults with Chronic Low Back Pain". Presented at ACR in Chicago 2011

A. Kivitz, Joy Schechtman, Michele Texter, Andreas Fichtner, Elliot Chartash. "Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients with Rheumatoid Arthritis Receiving Certolizumab Pegol. "Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients with Rheumatoid Arthritis Receiving Certolizumab Pegol" Presented at ACR in Chicago 2011

Robert Terkeltaub, H. Ralph Schumacher, A. Kivitz, Steven P. Weinstein, Richard Wu, Rebecca Gall, Robert Evans. "Rilonacept Efficacy for Gout Flare Prevention in Patients with Tophi and/or Polyarticular Disease who Initiate Uric Acid-Lowering Therapy. "Rilonacept Efficacy for Gout Flare Prevention in Patients with Tophi and/or Polyarticular Disease Who Initiate Uric Acid-Lowering Therapy". Presented at ACR Chicago 2011

R. Alten, A. So, A. Kivitz, T. Bardin, M. Bloch, A. Gimona, A. Widmer, G. Kammer, N. Schlesinger, H.R. Schumacher. "Efficacy of Canakinumab on Re-Treatment in Gouty Arthritis Patients with Limited Treatment Option: 24-Week Results from β -RELIEVED and β -RELIEVED-II Studies". Presented at ACR Chicago 2011

E. Orwoll, CS Teglbjaerg, BL Langdahl, R. Chapurlat, E. Czerwinski, DL Kendler, JY Reginster, A Kivitz, EM Lewiecki, P Miller, MA Bolognese, HG Bone, O Ljunggren, B Abrahamsen, Y-C Yang, A Grauer, C Libanati, JW Hall, S Boonen. "A Phase 3 Study of the Efficacy and Safety of Denosumab in Men with Low Bone Mineral Density: Design of the ADAMO Trial". The American Society for Bone and Mineral Research. San Diego, CA Sept. 16-20, 2011

"Cumulative Longer-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 years of Follow-up"
Abstract Accepted at ACR/Washington, DC, November 9-14, 2012

"Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis: 24 Week Results of a Phase 3 Double Blind Randomized Placebo-Controlled Study" Abstract Accepted at ACR/Washington, DC, November 9-14, 2012

"A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, In Patients with Rheumatoid Arthritis"
Abstract Accepted at ACR/Washington, DC, November 9-14, 2012

"Preliminary Results From a Controlled Trial (VISARA) to Evaluate the Humoural Immune Response to Vaccines in RA Patients Treatment with Tocilizumab (TCZ)"
Accepted abstract at EULAR 2012

"Sarilumab for the Treatment of Moderate-To-Severe- Rheumatoid Arthritis; Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study"
Accepted abstract at EULAR 2012

"The Effects of Multiple Doses of Sclerostin Antibody AMG785 in Healthy Men and Postmenopausal Women with Low Bone Mass"
Accepted abstract at EULAR 2012

J.L. Goldstein, S. Lakhanpal, S. Cohen, A. Bello, J. Ball, A. Grahn, A. Kivitz. "Decreased NSAID Associated Treatment Emergent Dyspepsia and Increased Patient Satisfaction Associated with Ibuprofen/Famotidine Combination Tablet: SODA Results from a 12 month trial.

Helena Marzo-Ortega, Alan Kivitz, Ricardo Blanco, Martin Cohen, Evie-Maria Delicha, Susanne Rohrer, Hanno Richards

“Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE”

BNJ Journal, Volume 3, Issue 2

2012: American College of Rheumatology, November 2012, Washington, DC

November 12, 2012: Speaker for Participation and Recruitment

November 12, 2012: Moderator for Abstract on Small Molecules, Biologics, and Gene Therapy

November 13, 2012: Poster Presentation on **Methods:** A randomized, double-blind, placebo (PBO) and active controlled 4-week Phase 2 study was conducted to evaluate the efficacy and safety of ARRY-797 vs PBO in patients with moderate to severe pain despite ongoing treatment with NSAIDs. Oxycodone extended release (Oxy ER) was used as an active control. 157 patients were randomized 1:1:1 to receive ARRY-797 (400 mg q12h), Oxy ER (10 mg q12h, Week 1; 20 mg q12h, Weeks 2 – 4) or PBO while maintaining use of NSAIDs.

November 13, 2012: Late Breaking Abstract: Poster Presentation on “A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional DMARDs in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA)”

Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4). Alvin F. Wells, Christopher J. Edwards, Adewale O. Adebajo, Alan J. Kivitz, Paul Bird, Kamal Shah, ChiaChi Hu, Randall M. Stevens, Jacob A. Aelion. 2013: American College of Rheumatology, October 2013, San Diego, CA

Poster Presentation: Predictors of Disease Course in Rheumatoid Arthritis – Treatment Approaches. “Nearly Pain Free Self-Administration of Methotrexate Using An Investigational Auto-Injector: Results of a Phase 2 Clinical Trial in Rheumatoid Arthritis with Mild to Severe Functional Limitations” 2013: American College of Rheumatology, October 2013, San Diego, CA

Poster Presentation: Rheumatoid Arthritis Treatment – Small Molecules, Biologics and Gene Therapy. “The Safety and Efficacy of Tocilizumab Subcutaneous in Combination with Traditional DMARDs in Patient with Moderate to Severe Rheumatoid Arthritis up to 48 Weeks (BREVACTA) 2013: American College of Rheumatology, October 2013, San Diego, CA

Roy M Fleischmann, Alan Kivitz, Ronald F van Vollenhoven, James W Shaw, Stefan Florentinus, Mahinda Karunaratne, Hartmut Kupper, Maxime Dougados, Gerd-Rudiger Burmester
NO DIFFERENCES IN PATIENT-REPORTED OUTCOMES BY METHOTREXATE DOSE AMONG EARLY RHEUMATOID ARTHRITIS PATIENTS TREATED CONCOMITANTLY WITH ADALIMUMAB: RESULTS FROM THE CONCERTO TRIAL Presented at EULAR, Spain, June 2013

Jochen Sieper, Alan Kivitz, Astrid van Tubergen, Atul Deodhar, Geoffroy Coteur, Franz Woltering, Robert Landewé
RAPID IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS: 24-WEEK RESULTS OF RAPID-AXSPA STUDY Presented at EULAR, Spain, June 2013

Gerd Burmester, Alan Kivitz, Hartmut Kupper, Udayasankar Arulmani, Stefan Florentinus, Sandra Goss, Suchitrita Rathmann, Roy Fleischmann
EFFICACY, PHARMACOKINETICS, AND SAFETY OF DIFFERENT DOSES OF METHOTREXATE IN COMBINATION WITH ADALIMUMAB: RESULTS FROM THE CONCERTO TRIAL Presented at EULAR, Spain, June 2013

Gerd Burmester, Alan J Kivitz, Ronald F van Vollenhoven, Stefan Florentinus, Piyalal M Karunaratne, Hartmut Kupper, Maxime Dougados, Roy M Fleischmann
METHOTREXATE DOSE HAS MINIMAL EFFECTS ON METHOTREXATE-RELATED TOXICITY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS TREATED IN COMBINATION WITH ADALIMUMAB – RESULTS OF CONCERTO TRIAL Presented at EULAR, Spain, June 2013

Thierry Dervieux, Michael E. Weinblatt, Alan Kivitz, Joel M. Kremer, “Methotrexate polyglutamation in relation to infliximab pharmacokinetics in rheumatoid arthritis” *Ann Rheum Dis* 2013; 72:908-910

Peter Nash, Sauithree Nayer, Mark C. Genovese, Alan J. Kivitz, Kurt Oelke, Charles Ludivico, William Palmer, Cristian Rodriguez, Ingrid Delaet, Ayanbola Elegbe, Michael Corbo, “Immunogenicity, Safety, and Efficacy of Abatacept Administered With or Without Background Methotrexate in Patients with Rheumatoid Arthritis: Results from a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study” *Arthritis and Care Research*, Vol. 65, No 5, May 2013 pp718-728

Alan J. Kivitz, Joseph S. Gimbel, Candace Bramson, Mary Anne Nemeth, David S. Keller, Mark T. Brown, Christine R. West, Kenneth M. Verburg. Published by Elsevier “Efficacy and Safety of Tanezumab versus Naproxen in the Treatment of Chronic Low Back Pain” Featured on www.MDLinx.com and International Association for the Study of Pain.

Desmond Padhi, Mark Allison, Alan J. Kivitz, Maria J. Gutierrez, Brian Stouch, Christine Wang, Graham Jang. “Multiple Doses of Sclerostin Antibody Romosozumab in Healthy Men and Postmenopausal Women with Low Bone Mass: A Randomized, Double-Blind, Placebo-Controlled Study. Featured in Wiley Online Library in Nov. 2013

David Bar-Or, Kristin M. Salottolo, Holli Loose, Matthew J. Phillips, Brian McGrath, Nathan Wei, James L. Borders, John E. Ervin, Alan Kivitz, Mark Hermann, Tammi Shlotzhauer, Melvin Churchill, Donald Slappey, Vaughan Clift. “A Randomized Clinical Trial to Evaluate Two Doses of an Intra-Articular Injection of LMWF-5A in Adults with Pain Due to Osteoarthritis of the Knee”. Published Feb. 3, 2014 in PLOS ONE.

Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up, planned for the ACR Pediatric Rheumatology Symposium 2014 (PRYSM).

Presented at EULAR June 2014: LACK OF EFFICACY OF CCR1 ANTAGONIST BMS-817399 IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS: RESULTS OF 12-WEEK PROOF-OF-CONCEPT STUDY

Alan Kivitz, Paulo Maciag, Parul Gulati, Shuyan Du, Sean E Connolly, Paul Davies, Xiaohui Li, Tamara Repsher, Helen G Haggerty, Marco Londei

Presented at EULAR June 2014: CANAKINUMAB PRE-FILLED SYRINGE VS TRIAMCINOLONE ACETONIDE IN THE TREATMENT OF ACUTE GOUTY ARTHRITIS ATTACKS: RESULTS FROM A POST-HOC ANALYSIS IN DIFFICULT-TO-TREAT PATIENTS P Sunkureddi, E Toth, JP Brown, A Kivitz, A Stancati, D Richard, K Lheritier, R Möricke

Presented at EULAR 2014: EFFICACY AND SAFETY OF CANAKINUMAB PRE-FILLED SYRINGE IN ACUTE GOUTY ARTHRITIS PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE ≥ 3 P Sunkureddi, E Toth, JP Brown, A Kivitz, A Stancati, D Richard, K Lheritier, R Möricke

Presented at EULAR 2014: Craig Wiesenhutter, Alan Kivitz, Jeffrey Kaine, John Lavery, Lydie Hazan, Edward Bernton

A PHASE I STUDY OF STAPHYLOCOCCAL PROTEIN A IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ON METHOTREXATE

Presented at EULAR 2014: APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENTS IN ENTHESTITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PALACE 4 PHASE 3, RANDOMIZED, CONTROLLED TRIAL Christopher Edwards, Alvin Wells, Adewale Adebajo, Alan Kivitz, Paul Bird, Kamal Shah, ChiaChi Hu, Randall M. Stevens, Jacob Aelion

Presented at EULAR 2014: LONG-TERM SAFETY AND TOLERABILITY OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL Adewale Adebajo, Alvin Wells, Christopher Edwards, Alan Kivitz, Paul Bird, Kamal Shah, ChiaChi Hu, Randall Stevens, Jacob Aelion

Presented at EULAR 2014: RANDOMIZATION TO PATIENT-REPORTED RAPID3 VERSUS PHYSICIAN-BASED CDAI TOOLS FOR PREDICTION OF TREATMENT RESPONSE AND ASSESSMENT OF PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING CERTOLIZUMAB PEGOL: RESULTS FROM THE PREDICT STUDY Jeffrey R. Curtis, Melvin Churchill, Alan Kivitz, Ahmed Samad, Laura Gauer, Geoffroy Coteur, Lee Gervitz, Willem Koetse, Jeffrey Melin, Yusuf Yazici

Presented at EULAR 2014: EVALUATION OF THE EFFECT OF TOFACITINIB ON MEASURED GLOMERULAR FILTRATION RATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS J Kremer, AJ Kivitz, JA Simon-Campos, EL Nasanov, H Tony, B Vlahos, C Hammond, J Bukowski, H Li, S Schulman, S Raber, A Zuckerman, JD Isaacs

Presented at EULAR 2014: EVALUATION OF THE EFFECT OF TOFACITINIB ON MEASURED GLOMERULAR FILTRATION RATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS J Kremer, AJ Kivitz, JA Simon-Campos, EL Nasanov, H Tony, B Vlahos, C Hammond, J Bukowski, H Li, S Schulman, S Raber, A Zuckerman, JD Isaacs

Presented at EULAR 2014: PALACE 4, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, FOR TREATMENT OF PSORIATIC ARTHRITIS: LONG-TERM (52-WEEK) IMPROVEMENTS IN PHYSICAL FUNCTION Alvin Wells, Christopher Edwards, Adewale O. Adebajo, Alan J. Kivitz, Paul Bird, Kamal Shah, ChiaChi Hu, Randall M. Stevens, Jacob A. Aelion

Presented at EULAR 2014: EFFECTS OF SARILUMAB PLUS MTX ON CLINICAL, RADIOGRAPHIC, AND FUNCTIONAL ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY Mark Genovese, Roy M. Fleischmann, Alan J. Kivitz, Maria Rell-Bakalarska, Renata Martincova, Stefano Fiore, Patricia Rohane, Hubert van Hoogstraten, Chunpeng Fan, Janet van Adelsberg, Steven Weinstein, Neil Graham, Neil Stahl, George Yancopoulos, Thomas W. Huizinga, Desiree van der Heijde

2014: American College of Rheumatology, November 2014, Boston, MA: A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy

2014: American College of Rheumatology, November 2014, Boston, MA: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate

2014: American College of Rheumatology, November 2014, Boston, MA: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

2014: American College of Rheumatology, November 2014, Boston, MA: A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-

Reported Outcomes

2014: American College of Rheumatology, November 2014, Boston, MA: A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-Week) Improvements in Physical Function

2014: American College of Rheumatology, November 2014, Boston, MA: An Exploratory 4-Week Study of a P2X3 Antagonist AF-219 in the Treatment of Patients with Osteoarthritis (OA) of the Knee

2014: American College of Rheumatology, November 2014, Boston, MA: Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naïve Patients: Results from a Phase 3, Randomized, Controlled Trial

2014: American College of Rheumatology, November 2014, Boston, MA: Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

2014: American College of Rheumatology, November 2014, Boston, MA: Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12-Week Data

2014: American College of Rheumatology, November 2014, Boston, MA: Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis

2014: American College of Rheumatology, November 2014, Boston, MA: Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data

2014: American College of Rheumatology, November 2014, Boston, MA: Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study

2014: American College of Rheumatology, November 2014, Boston, MA: Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)

2014: American College of Rheumatology, November 2014, Boston, MA: Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study

2014: American College of Rheumatology, November 2014, Boston, MA: The Efficacy and Safety of Tocilizumab Subcutaneous Q2W and Following Escalation from Q2W to QW Therapy in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis at 96 Weeks

Assessing Usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patient with rheumatoid arthritis. Jaime A. Pachon, Alan J. Kivitz, Kay-Uwe Heuer, Uwe Pichlmeier

Sage Open Medicine 2014

Subcutaneous Tocilizumab Versus Placebo in Combination with Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Alan Kivitz, Ewa Olech, Michael Borofsky, Beatriz M. Zazueta, Federico Navarro-Sarabia, Sebastiao C. Radominski, Joan T. Merrill, Lucy Rowell, Clare Nasmyth-Miller, Min Bao, Stephen Wright, Janet E. Pope.

Arthritis Care and Research, Vol. 66, No 11, November 2014

Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-

blind, placebo-controlled exploratory study in osteoarthritis of the knee. Paul J. Tiseo, Alan J. Kivitz, John E. Ervin, Haobo Ren, Scott J. Mellis
IASP PAIN 155 (2014) 1245-1252

SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE AND ANTI-TNF-IR PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF A PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2)

Authors: A. Kavanaugh¹, I.B. McInnes², S. Hall³, H. Chinoy⁴, A. Kivitz⁵, S. Kandala⁶, M. Patekar⁶, S. Mpfu⁷
Year: June 2015 at EULAR
Session Info: Psoriatic arthritis

IMMUNOGENICITY, SAFETY AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WHO MISSED DOSES

Authors: G.R. Burmester¹, M. Bao², W. Reiss³, T. Wallace⁴, S. Lacey⁵, A. Kivitz⁶
Year: June 2015 at EULAR
Session Info: Rheumatoid arthritis - other biologic treatment

A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY OF SUMMACTA AND BREVACTA TO EVALUATE SAFETY AND EFFICACY OF TOCILIZUMAB SC IN PATIENTS WITH MODERATE TO SEVERE RA

Authors: A. Kivitz¹, E. Olech², M. Borofsky³, J. Devenport⁴, J. Pei⁴, T. Wallace⁴, M. Michalska⁴
Year: June 2015 at EULAR
Session Info: Rheumatoid arthritis - other biologic treatment

LONG-TERM (104-WEEK) EFFICACY AND SAFETY OF APREMILAST MONOTHERAPY IN DMARD-NAVE PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL AND OPEN-LABEL EXTENSION (PALACE 4)

Authors: A. Wells¹, C. Edwards², A. Adebajo³, A. Kivitz⁴, P. Bird⁵, K. Shah⁶, C. Hu⁶, J. Aelion⁷
Year: June 2015 at EULAR
Session Info: Psoriatic arthritis

LONG-TERM SAFETY AND MAINTENANCE OF EFFICACY OF CANAKINUMAB LIQUID FORMULATION IN ACUTE GOUTY ARTHRITIS PATIENTS: RESULTS FROM A 36 WEEK EXTENSION STUDY

Authors: R. Möricke¹, P. Sunkureddi², E. Toth³, J.P. Brown⁴, U. Machein⁵, K. Lheritier⁵, G. Junge⁵, A. Kivitz⁶
Year: June 2015 at EULAR
Session Info: Bone diseases other than osteoporosis, metabolic diseases and crystal diseases

Safety, Efficacy and Biomarker Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Interim, Exploratory Analysis of Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

Yusuf Yazici¹, Timothy E. McAlindon², Roy Fleischmann³, Allan Gibofsky⁴, Nancy E. Lane⁵, Alan J. Kivitz⁶, Nebojsa Skrepnik⁷, Eddie Armas⁸, Christopher J. Swearingen¹, Anita DiFrancesco¹, Jevanesh R. S. Tambiah¹, John Hood¹ and Marc C. Hochberg⁹. ¹Samumed, San Diego, CA, ²Tufts Medical Center, Boston, MA, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Weill Cornell Medical College and Hospital for Special Surgery, New York, NY, ⁵UC Davis Medical Center, Sacramento, CA, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Tucson Orthopaedic Institute, Tucson, AZ, ⁸Well Pharma Medical Research, Miami, FL, ⁹University of Maryland School of Medicine, Baltimore, MD, USA, Baltimore, MD

Accepted at ACR in San Francisco 2015

Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Long-Term Safety and Efficacy Results from a 36-Week Extension Study

Prashanth Sunkureddi¹, Rüdiger Moericke², Edith Tóth³, Jacques P Brown⁴, Uwe Machein⁵, Karine Lheritier⁵, Guido Junge⁵ and Alan J Kivitz⁶. ¹Clear Lake Rheumatology, Nassau Bay, TX, ²Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ³Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ⁴Centre Hospitalier de l'Université Laval (CHUL), Quebec City, QC, Canada, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Altoona Center for Clinical Research, Duncansville, PA

Accepted at ACR in San Francisco 2015

Efficacy and Safety of Sarilumab Plus MTX in Subgroups of Patients with Rheumatoid Arthritis in a Phase 3 Study

Arthur Kavanaugh¹, Alan J. Kivitz², P Miranda³, Stefano Fiore⁴, Jonathan Fay⁵, Chunpeng Fan⁶, Janet van Adelsberg⁷ and T. W. J. Huizinga⁸ ¹University of California San Diego, La Jolla, CA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Centro De Estudios Reumatológicos, Santiago, Chile, ⁴Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Biostatistics, Sanofi, Bridgewater, NJ, ⁷Clinical Science, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Accepted at ACR in San Francisco 2015

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis in Anti-TNF-Naive Patients and Those Previously Exposed to Anti-TNF Therapy: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Dosing

Arthur Kavanaugh¹, Jain B. McInnes², Philip J. Mease³, Stephan Hall⁴, Hector Chinoy⁵, Alan J. Kivitz⁶, Manmath Patekar⁷, Zailong Wang⁸ and Shephard Mpofo⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Immunology, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁴Monash University, Melbourne, Australia, ⁵University of Manchester, Manchester, United Kingdom, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland

Accepted at ACR in San Francisco 2015

A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population

Alan J. Kivitz¹, Boulos Haraoui², Jeffrey Kaine³, Vanessa Castellano⁴, Eustratios Bananis⁴, Carol A Connell⁵, Elaine Hoffman⁵ and Liza Takiya⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Sarasota Arthritis Research Center, Sarasota, FL, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY

Accepted at ACR in San Francisco 2015

Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months

Vibeke Strand¹, Arthur Kavanaugh², Alan J. Kivitz³, Désirée van der Heijde⁴, Elaine Hoffmann⁵, Ermeg Akylbekova⁶, Arif Soonasra⁷, Mark Snyder⁷, Koshika Soma⁵, Eustratios Bananis⁷ and Josef S. Smolen⁸, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²University of California, San Diego School of Medicine, LaJolla, CA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Quintiles, Atlanta, GA, ⁷Pfizer Inc, Collegeville, PA, ⁸Medical University of Vienna, Vienna, Austria

Accepted at ACR in San Francisco 2015

Safety, Tolerability, and Pharmacodynamics of ABT-122, a Dual TNF- and IL-17-Targeted Dual Variable Domain (DVD)-IgTM in Subjects with Rheumatoid Arthritis

Roy Fleischmann¹, Frank Wagner², Alan J. Kivitz³, Heikki T. Mansikka⁴, Nasser Khan⁴, Jia Liu⁴, Jacob Gagnon⁴, Feng Hong⁵, Melanie Ruzek⁴ and Robert J. Padley⁴, ¹University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ²Charité Research Organisation GmbH, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc., Worcester, MA

Accepted at ACR in San Francisco 2015

Daniel J. Lovell, Nicolino Ruperto, Richard Mouy, Eliana Paz, Nadina Rubio-Perez, Clovis A. Silva, Carlos A. Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose A. Melo-Gomes, Gláudia Saad-Magalhaes, J. Chavez-Corrales, Christian Huemer, Alan Kivitz, Francisco J. Blanco, Ivan Foeldvari, Michael Hofer, Hans-Iko Huppertz, Chantal Job Deslandre, Kirsten Minden, Marilyn Punaro, Alan J. Block, Edward H. Giannini, and Alberto Martini. "Long-Term Safety, Efficacy, and Quality of Life in Patients with Juvenile Idiopathic Arthritis Treated with Intravenous Abatacept for Up to Seven Years" *Arthritis and Rheumatology*, Vol. 67, No. 10, October 2015. pp2759-2770

Roy D. Altmas, Vibeke Strand, Marc C. Hochberg, Allan Gibofsky, Joseph A. Markenson, William E. Hopkins, Byron Cryer, Alan Kivitz, Jennifer Nezzar, Olaolu Imasogie, Clarence L. Young. "Low-Dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study"

Postgraduate Medicine, Volume 127, Issue 5, 2015

Roy M. Fleischmann, Nemanja S. Damjanov, Alan J. Kivitz, Anna Legedza, Thomas Hooch, and Nils Kinnman. "A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients with Active Rheumatoid Arthritis"

Arthritis and Rheumatology, Vol. 67, No. 2, February 2015, pp 334-343

J. Sieper, R. Landewe, M. Rudwaleit, D. van der Heijde, M. Dougados, P.J. Mease, J. Braun, A. Deodhar, A. Kivitz, J. Walsh, B. Hoepken, T. Nurminen, and W.P. Maksymowych. "Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients with Axial Spondyloarthritis" Arthritis & Rheumatology, Vol. 67, No. 3, March 2015. pp 668-677

Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Maria Rell-Bakalarska, Renata Martincova, Stefano Fiore, Patricia Rohane, Hubert van Hoogstraten, Anju Garg, Chunpeng Fan, Janet van Adelsberg, Steven Weinstein, Neil Graham, Neil Stahl, George Yancopoulos, Tom W. J. Huizinga, Desiree van der Heijde. "Sarilumab plus Methotrexate in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III study"

Arthritis & Rheumatology journal website. March, 2015

John S. Sundy, H. Ralph Schumacher, Alan Kivitz, Steven P. Weinstein, Richard Wu, Shirletta King-Davis, and Robert R. Evans. "Rilonacept for Gout Flare Prevention in Patients Receiving Uric Acid-Lowering Therapy: Results of RESURGE, a Phase III, International Safety Study"

The Journal of Rheumatology. July/August 2014

Daniel J. Lovell, Nicolino Ruperto, Richard Mouy, Eliana Paz, Nadina Rubio-Perez, Clovis A. Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose A. Melo-Gomes, Claudia Saad-Magalhaes, J. Chavez-Corrales, Christian Huemer, Alan Kivitz, Francisco J. Blanco, Ivan Foeldvari, Michael Hofer, Hans-Iko Huppertz, Chantal Job Deslandre, Kirsten Minden, Marilyn Punaro, Alan J. Block, Edward H. Giannini, and Alberto Martini. "Long-term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated with Intravenous Abatacept for Up to Seven Years".

Arthritis and Rheumatology, Vol. 67, No. 10, October 2015 pp 2759-2770

Jeffrey R. Curtin, Melvin Churchill, Alan Kivitz, Ahmed Samad, Laura Gauer, Leon Gervitz, Willem Koetse, Jeffrey Melin, and Yusuf Yazici. "A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol".

Arthritis and Rheumatology, Vol. 67, No. 12, December 2015, pp 3104-3112

Bernard Schachtel, Mark Marino, Jeffrey D. Lazar, Hessam Aazami, Michael Burnette, Richard M. Glover, Alan J. Kivitz, Timothy M. Koehler, Karen Lewis, Mary Beth Lorton, Harris McIlwain, Mohammad Munir, David Oliver, Stephen J. Poland, Donato R. Ricci, Emily Schachtel, Ronald Surowitz, Leonid Tseytlin

Poster on the CLCT - 006 OA study: A Phase 3 multi-center actual-use study on the Safety and effectiveness of CL-108 for the treatment of moderate-to-severe pain associated with flares of osteoarthritis Safety and effectiveness of CL-108 for the treatment of moderate-to-severe pain associated with flares of osteoarthritis of the knee or hip

American Academy of Pain Medicine 2016 Feb 18–21, 2016; Palm Springs, CA

Wenhui Zhang, Robert M. Kernstock, Erik E. Karrer, Stanley B. Cohen, Vishala L. Chindalore, Alan J. Kivitz, Paul C. Blahunka, Leticia Delgado-Herrera, Bernhardt G. Zeiher, Nancy L. Samberg, and Jay P. Garg. "A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy".

American College of Clinical Pharmacology 2016.

A. Kivitz, R. Blanco, M. Maradiaga, J. Sieper, H. Tahir, M. Andersson, A. Readie, B. Porter
"Secukinumab Reduces Signs and Symptoms of Active Ankylosing Spondylitis: Results from a 16-Week, Randomized, Placebo-Controlled Phase 3 Trial"

L. Bessette, M. Khraishi, A.J. Kivitz, A. Kaliyaperumal, R. Grantab, M. Poulin-Costello, D. Collier.

"Single-Arm Study of Etanercept (ETN) in Adult Patients with Moderate to Severe Rheumatoid Arthritis (RA) who Failed Adalimumab (ADA) Treatment"

Tong Zhu, James Keirns, Corrie Howieson, Atsunori Kaibara, Ronald Goldwater, Alan J. Kivitz, Vishala Chindalore, Stanley Cohen, Vicki Santos, Bolanle Akinlade, Robert Kernstock, Leticia Delgado-Herrera, Paul C. Blahunka, Erik E. Karrer, Jay P. Garg, Nancy Samberg, and Bernhardt G. Zeiher. "Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T. Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients" Published by Wiley Periodicals in American College of Clinical Pharmacology 2016

Alan Kivitz, Ewa Olech, Michael Borofsky, Jenny Devenport, Jinglan Pei, Thomas Wallace, Margaret Michalska
“A Multicentre, Open-Label, Long-Term Extension Study in Patients with Moderate to Severe RA from the SUMMACTA and BREVACTA studies: Evaluation of the Safety and Efficacy of Tocilizumab SC”

B A. Sullivan, W Tsuji, A Kivitz, J Peng, G E Arnold, M J Boedigheimer, K Chiu, C L Green, A Kaliyaperumal C Wang, J Ferbas, J B Chung. “Inducible T-Cell Co-Stimulator Ligand (ICOSL) Blockade Leads to Selective Inhibition of Anti-KLH IgG responses in Subjects with Systemic Lupus Erythematosus”. Lupus, Science & Medicine Published on April 8, 2016

“Safety, Clinical, and Imaging Outcomes of a Novel, Intra-Articular, Injectable, Wnt Inhibitor (SM04690) in the Treatment of Osteoarthritis of the Knee: Exploratory Analysis of Results From a 24 Week, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study”.

E.B. Lee, N. Daskalakis, C. Xu, A. Paccaly, B. Miller, R. Fleischmann, I. Bodrug, A. Kivitz. “Disease Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis”
Eular in London June 2016

V. Strand, P. Mahajan, C. Chen, H. van Hoogstraten, E. K. Mangan, O. Hagino, N. Graham, G. da R.C. Pinheiro, A. Kivitz
“BENEFIT OF SARILUMAB WITH CSDMARDS ON PATIENT PRODUCTIVITY IN WORK, HOUSEHOLD WORK AND FAMILY, SOCIAL, LEISURE ACTIVITIES IN TNF-IR RA PATIENTS”
Eular In London June 2016

R. M. Fleischmann, F. Wagner, A. J. Kivitz, H. T. Mansikka, N. Khan, J. Liu, F. Hong, M. Ruzek, R. J. Padley “SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF ABT-122, A DUAL TNF- AND IL-17-TARGETED DUAL VARIABLE DOMAIN (DVD)-IG™ IN PATIENTS WITH RHEUMATOID ARTHRITIS”
Eular In London June 2016

A. Kivitz, L. Hazan, K. Hoffman, B. A. Wallin “MORAB-022, AN ANTI-GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR (GM-CSF) MONOCLONAL ANTIBODY (MAB): RESULTS OF THE FIRST STUDY IN PATIENTS WITH MILD-TO-MODERATE RHEUMATOID ARTHRITIS (RA)”
Eular In London June 2016

J. Doedens, W. Jones, K. Hill, M. Mason, P. Linsley, P. Mease, M. Dall'era, C. Aranow, R. Martin, S. Cohen, R. Fleischmann, A. Kivitz, D. Burge, D. Chaussabel, K. Elkon, J. Posada, C. Gabel “IMMUNE COMPLEX BOUND U1 AND Y1 RNA CORRELATES WITH INTERFERON-STIMULATED GENE EXPRESSION AND DISEASE ACTIVITY: AN OBSERVATIONAL STUDY OF SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS”
Eular In London June 2016

G. Burmester, P. Hrycaj, C. Pacheco-Tena, H. van Hoogstraten, E. K. Mangan, Y. Lin, D. Bauer, J. Fay, J. Parrino, A. Kivitz
“CLINICAL REMISSION OUTCOMES WITH SARILUMAB PLUS CSDMARDS IN ACTIVE, MODERATE-TO-SEVERE RA PATIENTS WITH INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS”
Eular In London June 2016

P. Emery, H. van Hoogstraten, E. K. Mangan, J. van Adelsberg, C. Fan, A. Kivitz, G. da R.C. Pinheiro, T. Huizinga
“CLINICAL RESPONSES OF SARILUMAB BASED ON RHEUMATOID FACTOR AND ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS”
Eular In London June 2016

R. Fleischmann, E. K. Mangan, J. van Adelsberg, J. Fay, H. van Hoogstraten, D. Bauer, D. Thompson, A. Kivitz,
“G. R. Burmester ONSET OF ACTION OF SARILUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS IN 2 PHASE 3 STUDIES”
Eular In London June 2016

H. Marzo-Ortega, C. W. Legerton, J. Sieper, A. Kivitz, R. Blanco, M. Cohen, J. Zuazo, A. Readie, B. Porter, H. Richards.
“SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)”
Eular In London June 2016

Y. Yazici¹, T. E. McAlindon, R. M. Fleischmann, A. Gibofsky, N. E. Lane, A. J. Kivitz, S. Majumdar, V. Strand, C. J. Swearingen, A. DiFrancesco, J. Tambiah, J. Hood, M. C. Hochberg. “SAFETY, CLINICAL AND IMAGING OUTCOMES OF A NOVEL, INTRA-ARTICULAR, INJECTABLE, WNT INHIBITOR (SM04690) IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE: EXPLORATORY ANALYSIS OF RESULTS FROM A 24 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY”
Eular In London June 2016

L. Bessette, M. Khraishi, A. J. Kivitz, A. Kaliyaperumal, R. Grantab, M. Poulin-Costello, D. Collie. “SINGLE-ARM STUDY OF ETANERCEPT (ETN) IN ADULT PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) WHO FAILED ADALIMUMAB (ADA) TREATMENT
Eular in London June 2016

V. Strand¹, A. Kavanaugh, A. Kivitz, D. van der Heijde, K. Kwok, E. Akyzbekova, A. Soonasra, M. Snyder, C. Connell, E. Bananis, J. Smolen “LONG-TERM RADIOGRAPHIC AND PATIENT-REPORTED OUTCOMES BASED ON CLINICAL DISEASE ACTIVITY INDEX RESPONSES WITH TOFACITINIB AT 6 MONTHS”
Eular in London June 2016

A. Kivitz, B. Haraoui, J. Kaine, V. Castellano, E. Bananis, C. A. Connell, H. Fan, L. Takiya
“SAFETY ANALYSIS OF TOFACITINIB 5 MG TWICE DAILY ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BACKGROUND CONVENTIONAL SYNTHETIC DMARDS IN A PHASE 3 RHEUMATOID ARTHRITIS POPULATION”
Eular in London June 2016

A. F. Wells, C. J. Edwards, A. J. Kivitz, P. Bird, D. Nguyen, K. Shah, L. Teng, J. A. Aelion “APREMILAST MONOTHERAPY AS THE FIRST SYSTEMIC TREATMENT IN DMARD-NAÏVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 3-YEAR TREATMENT RESULTS”
Eular in London June 2016

Kara Bickham, Alan J. Kivitz, Anish Mehta, Nancy Frontera, Sandhya Shah, Paul Stryszak, Zoran Popmihajlov, Paul M. Peloso. “Evaluation of two doses of etoricoxib, a COX2 selective nonsteroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial”

Abdallah, Hisham, Hsu, Joy, Lu, Peng, Fettner, Scott, Zhang, Xiaoping, Douglass, Wendy, Bao, Min, Rowell, Lucy; Roche. Burmester, Gerd. Kivitz, Alan; “Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From Two Randomized Controlled Trials: SUMMACTA and BREVACTA”
The Journal of Clinical Pharmacology

John R. Doedens, Wendell D. Jones, Kay Hill, Michael J. Mason, Vivian H. Gersuk, Philip J. Mease, Maria Dall’Era, Cynthia Aranow, Richard W. Martin, Stanley B. Cohen, Roy M. Fleischmann, Alan J. Kivitz, Daniel J. Burge, Damien Chaussabel, Keith B. Elkon, James A. Posada. “Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus”
The Journal of Immunology

Sunny Cho, Bernard Schachtel, Jeffrey D. Lazar, Hessam Aazami, Richard M. Glover, Alan J. Kivitz, Timothy M. Koehler, Mary Beth Lorton, Mohammad Munir, David Oliver, Stephen J. Poland, Donato R. Ricci, Emily Schachtel, Ronald Surowitz, Leonid Zeitlin, “**Patients treating flares of osteoarthritis with CL-108 experienced improvement in activities of daily living under actual conditions of use**” Poster for World Congress on Pain and encore abstract for AAMP 2016

Alan Kivitz, Thomas Wallace, Ewa Olech, Michael Borofsky, Jenny Devenport, Jinglan Pei, Margaret Michalska. “Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study”

Alexandra Zanin-Zhorov, Jonathan M. Weiss, Alissa Trzeciak, Wei Chen, Jingya Zhang, Melanie S. Nyuydzefe, Carmen Arencibia, Seetharam Polimera, Judilyn Fuentes-Duculan, Kathleen M Bonifacio, Norma Kunjravia, Inna

Cueto, Jennifer Soung, Roy M. Fleischman⁴, Alan Kivitz, Mark Lebwohl, Margarita Nunez, Johnnie Woodson, Shondra L. Smith, Robert F. West, Mark Berger, James G. Krueger, Samuel D. Waksal, and John Ryan. “Selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10” **Will be a Brief Communication report to Nature Medicine 2016**

J. Sieper, A. Kivitz, A. van Tubergen, A. Deodhar, K. Harris, T. Nurminen, R. Landewé “Certolizumab Pegol is Associated with Long-Term Improvements in Patient-Reported Outcomes in Axial Spondyloarthritis Patients, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 4-Year Outcomes from The Rapid-axSpA Study”
Presented at ISPOR 19 Annual European Congress 2016 | Vienna, Austria

“The Apremilast monotherapy used as the first systemic treatment-naïve patients of DMARDs with active psoriatic arthritis: results of treatment in 3 years”

Accepted as an E-Poster Rheumatology Conference in France 2016

Patient-Reported Outcomes for Etanercept Therapy in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment

ACR in Washington, DC November 2016

Differing Contribution of Methotrexate Polyglutamation to Infliximab and Adalimumab Exposure As Compared to Etanercept

ACR in Washington, DC November 2016

ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study

ACR in Washington, DC November 2016

Quality of Life Outcomes Following Therapy with Chs-0214 and Etanercept (Enbrel): Randomized, Double-Blind Study in Subjects with Rheumatoid Arthritis

ACR in Washington, DC November 2016

Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

ACR in Washington, DC November 2016

A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo As Co-Therapy with Methotrexate in Active Rheumatoid Arthritis (RA)

ACR in Washington, DC November 2016

Magnitude and Duration of Early Response with Tofacitinib: Post-Hoc Analysis of Two Phase 3, Placebo-Controlled Studies

ACR in Washington, DC November 2016

Apremilast Monotherapy As the First Systemic Treatment in DMARD-Naive Patients with Active Psoriatic Arthritis: 3-Year Treatment Results

ACR in Washington, DC November 2016

Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis

ACR in Washington, DC November 2016

Efficacy and Safety of Fasinumab for Osteoarthritic Pain in Patients with Moderate to Severe Osteoarthritis of the Knees or Hips

ACR in Washington, DC November 2016

Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference

ACR in Washington, DC November 2016

Bernard Schachtel, Jeffrey D. Lazar, Hessam Aazami, Richard M Glover, Alan J Kivitz, Timothy M Koehler, Mary Beth Lorton, Mohammad Munir, David Oliver, Stephen J Poland, Donato R Ricci, Emily Schachtel, Sunny Cho, Leonid Zeitlin, Ronald Surowitz. **"Patients treating flares of osteoarthritis with CL-108 experienced improvements in activities of daily living under actual conditions of use"**

33rd American Academy of Pain Medicine annual meeting, March 2017

"Selective oral ROCK2 inhibitor reduces clinical scores in patients with psoriasis vulgaris and normalizes skin pathology via concurrent regulation of IL-17 and IL-10"

Cutting Edge section of The Journal of Immunology

H. Marzo-Ortega, J. Sieper, A. Kivitz, R. Blanco, M. Cohen. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-year Results from a Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (MEASURE 2)"

A Kivitz, R. Blanco, M. Maradiaga, J. Sieper, H. Tahir, M. Andersson, A. Readie, B. Porter. "Secukinumab Reduces Signs and Symptoms of Active Ankylosing Spondylitis: Results from a 16 week, Randomized, Placebo-Controlled Phase 3 Trial."

A.J. Kivitz, S.R. Gutierrez-Urena, J. Poiley, M.C. Genovese, R. Kristy, K. Shay, X. Wang, J.P. Garg, and A. Zubrzycka-Sienkiewicz. "Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate"

Arthritis & Rheumatology, Vol. 69, No 4, April 2017, pp 709-719

X. Baraliakos, A.J. Kivitz, A. Deodhar, J. Braun, J.C. Wei, E.M. Delicha, Z. Talloczy, B. Porter. "Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results From A Phase 3 Extension Trial (Measure 1)"

EULAR 2017

Virginia Kraus, Phillip Conaghan, Hessam Aazami, Purvi Mehra, Alan Kivitz, Joelle Lufkin. "Synovial and Systemic Pharmacokinetics of Triamcinolone Acetonide Following Intra-articular Injection of an Extended-Release Microsphere-Based Formulation (FX006) or Standard Crystalline Suspension in Patients with Osteoarthritis of the Knee"

OARSI 2017 World Congress on Osteoarthritis, April 27-30 Las Vegas, NV, USA

Steven J. Russell, Robert Sala, Philip G. Conaghan, George Hubib, Quang Vo, Rickey Manning, Alan Kivitz, Yvonne Davis, Joelle Lufkin, James R. Johnson, Scott Kelley, Neil Bodick.

"In Type 2 Diabetes Mellitus Patients with Knee Osteoarthritis, Intra-articular Injection of FX006 (Extended Release Triamcinolone) Is Associated with Reduced Blood Glucose Elevation vs. Standard Triamcinolone: A Randomized, Blinded, Parallel-Group Study (Flexion)"

Roy Fleischmann, Eduardo Mysler, Stephen Hall, Alan J. Kivitz, Robert J. Moots, Zhen Luo, Ryan DeMasi, Koshika Soma, Richard Zhang, Liza Takiya, Svitlana Tatulych, Christopher Mojcik, Sriram Krishnaswami, Sujatha Menon, Josef S. Smolen. "Efficacy and Safety of tofacitinib Monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomized controlled trial"

The Lancet 2017

Helena Marzo-Ortega, Clarence W Legerton, Joachim Sieper, Alan J Kivitz, Ricardo Blanco, martin Cohen, Evie Maria Delicha, Susanne Rohrer, Hanno Richards. "SECUKINUMAB 150MG PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS WITH HIGH RETENTION RATE: 3-YEAR RESULTS FROM PHASE III TRIAL, MEASURE 2"

Eular June 2017

Xenofon Baraliakos, Alan J Kivitz, Atul Deodhar, Jürgen Braun, James CC Wei, Evie M Delicha, Zsolt Talloczy, Brian Porter "SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 3 EXTENSION TRIAL (MEASURE 1)" Eular June 2017

Peter Nash, Laura C Coates, Alan J Kivitz, Philip J Mease, Dafna D Gladman, Jose A Covarrubias-Cobos, Dona Fleishaker, Cunshan Wang, Elizabeth Kudlacz, Sujatha Menon, Thijs Hendrikx, Keith S Kanik. "SAFETY AND EFFICACY OF TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, UP TO 24 MONTHS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: INTERIM DATA FROM OPAL BALANCE, AN OPEN-LABEL, LONG-TERM EXTENSION STUDY"
Eular 2017

Terry Ann Mcnearney, Claire Smith, Roger Brown, Angelo Camporeale, Mark Deeg, David Montieth, Emily c Collins, Thomas J Schnitzer, Alan J Kivitz, Jayne Talbot, Yan Jin.
"PLASMA CGRP CONCENTRATIONS WERE NOT ASSOCIATED WITH PATIENT OA SYMPTOMS OR RESPONSE TO GALCANEZUMAB, A MONOCLONAL ANTIBODY AGAINST CGRP"
Eular 2017

Daniel Aletaha, Alan Kivitz, Guillermo Valenzuela, John Tesser, Steven Hays, Huihua Li, Carol A Connell, Eustratios Bananis, Arif Soonasra, Josef S Smolen. "MAGNITUDE AND DURATION OF EARLY RESPONSE WITH TOFACITINIB: POST-HOC ANALYSIS OF TWO PHASE 3, PLACEBO-CONTROLLED STUDIES"
Eular 2017

Stanley Cohen, Jose Luis Pablos, Hui Wang, Gerhard Anton Müller, Alan Kivitz, Alan Matsumoto, Eswar Krishnan
"ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY"
Eular 2017

James O'Dell, Alan Kivitz, Tsutomu Takeuchi, Yoshiya Tanaka, Ingrid Louw, Tamara Tiabut, Satoshi Nakashima, Jennifer Hodge, Hong Tang, Barbara Finck. "SWITCHING FROM ETANERCEPT TO CHS-0214: A ONE YEAR, RANDOMIZED, DOUBLE-BLIND STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS"
Eular 2017

James O'Dell, Alan Kivitz, Kim Papp, Craig Leonardi, Kathy Jensen, Hong Tang, Barbara Finck.
"RANDOMIZED, DOUBLE-BLIND, GLOBAL CLINICAL TRIAL TO EVALUATE EQUIVALENCE OF CHS-1420 TO ADALIMUMAB IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS"
Eular 2017

David Chernoff, Rebecca J. Bolce, Ching Chang Hwang, Xingbin Wang, Alan Kivitz, Jeffrey R. Curtis. "DAILY AND DIURNAL VARIATION AND DETERMINATION OF THE MINIMALLY IMPORTANT DIFFERENCE IN RHEUMATOID ARTHRITIS PATIENTS WITH MODERATE TO HIGH MULTI-BIOMARKER DISEASE ACTIVITY SCORES"
Eular 2017

Roy Fleischmann, Eduardo Mysler, Stephen Hall, Alan Kivitz, Robert Moots, Zhen Luo, Svitlana Tatulych, Ryan DeMasi, Koshika Soma, Richard Zhang, Liza Takiya, Chris Mojciak, Sriram Krishnaswami, Sujatha Menon, Josef Smolen. "TOFACITINIB WITH AND WITHOUT METHOTREXATE VERSUS ADALIMUMAB WITH METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: RESULTS FROM ORAL STRATEGY, A PHASE 3B/4 RANDOMISED TRIAL"
Eular 2017

Mark C. Genovese, Maria Greenwald, Christine Coddington, Anna Zubrzycka-Sienkiewicz, Alan J. Kivitz, Annie Wang, Kathyjo Shay, Xuegong Wang, Jay P. Garg, Mario H. Cardiel. "Peficitinib, A JAK Inhibitor, in Combination with Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis"
Arthritis & Rheumatology. Vol. 69, No.5 May 2017. pp 932-942

Y. Yazici, T.E. McAlindon, R. Fleischmann, A. Gibofsky, N.E. Lane, A.J. Kivitz, N. Skrepnik, E. Armas, C.J. Swearingen, A. DiFrancesco, R.S. Tambiah, J. Hood, M.C. Hochberg. "A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study"
[Osteoarthritis and Cartilage \(2017\)](#)

Desiree van der Heijde, Maxime Dougados, Robert Landewe, Joachim Seiper, Walter P. Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jurgen Braun, Philip J. Mease, Alan J. Kivitz, Jessica Walsh, Owen Davies, Lars

Bauer, Bengt Hoepken, Luke Peterson, and Atul Deodhar. "Sustained efficacy, Safety and Patient-Reported Outcomes of Certolizumab pegol in axial spondyloarthritis: 4 year outcomes from RAPID-axSpA. March 2017

Prof Roy Fleischmann, [Eduardo Mysler](#), [Stephen Hall](#), Alan J Kivitz, Robert J Moots, Zhen Luo, Ryan DeMasi, Koshika Soma, Richard Zhang, Liza Takiya, Svitlana Tatulych, Christopher Mojcik, Sriram Krishnaswami, Sujatha Menon, Josef S Smolen "Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial" **The Lancet in June 2017**

Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Stephen Hall, Hector Chinoy, Alan J. Kivitz, Zailong Wang, and Shephard Mpfu. "Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study *Journal of Rheumatology*

H. Marzo-Ortega, J. Sieper, A. Kivitz, R. Blanco, M. Cohen. R. Martin. A. Readie, H.B. Richards, B. Porter. "Secukinumab and Sustained Improvement in Signs and Symptoms of Patients with Active Ankylosing Spondylitis Through Two Years: Results from a Phase III Study. *Arthritis Care and Research*, Vol. 69, No. 7, July 2017 pp 1020-1029

Philip J Mease, Herbert Kellner, Akimichi Morita, Alan J. Kivitz, Kim A. Papp, Stella Aslanyan, Beate Berner, Kun Chen, Ann Eldred, and Frank Behrens. "Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis" *Arthritis & Rheumatology Journal 2017*

Roy M. Fleischmann, Frank Wagner, Alan J. Kivitz, Heikki T. Mansikka, Nasser Khan, Ahmed A. Othman, Amit Khatri, Feng Hong, Ping Jiang, Melanie Ruzek, Robert Padley. "Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis" *Arthritis & Rheumatology November 2017*

• **ABSTRACT NUMBER: 2796 • 2017 ACR/ARHP Annual Meeting**

A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis

Josef S. Smolen¹, Stanley B Cohen², Morton Scheinberg³, Tamas Shisha⁴, Dmitrij Kollins⁴, Peijuan Zhu⁵, Liyi Cen⁴, Alan J. [Kivitz](#)⁶, Andra Rodica Balanescu⁷, Juan J. Gomez-Reino⁸ and Hans-Peter Tony⁹, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Metroplex Clinical Research Centre, Dallas, TX, ³Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, ⁴Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, ⁵Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Research Center of Rheumatic Diseases, "Sf. Maria" Hospital, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ⁸BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, ⁹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany

Background/Purpose: Rituximab (RTX) is a mAb indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy...

• **ABSTRACT NUMBER: 615 • 2017 ACR/ARHP Annual Meeting**

Efficacy of Tofacitinib By Background Methotrexate Dose in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Pooled Data from 2 Phase 3 Trials

Alan J. [Kivitz](#)¹, Oliver FitzGerald², Peter Nash³, Shirley Pang⁴, Valderilio F Azevedo⁵, Elizabeth Kudlacz⁶, Cunshan Wang⁶, Daniela Graham⁶ and Liza Takiya⁷, ¹Department of Rheumatology, Altoona Center for Clinical

Research, Duncansville, PA, ²Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴St. Jude Medical Center, Fullerton, CA, ⁵Universidade Federal do Paraná, Curitiba, Brazil, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Colledgeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for psoriatic arthritis (PsA). The efficacy of tofacitinib has been evaluated in 2 Phase 3...

• **ABSTRACT NUMBER: 2951 • 2017 ACR/ARHP Annual Meeting**

Responsiveness of the Patient Reported Outcomes Measurement Information System to Golimumab Intravenous and Infliximab Treatment in a Real World Clinical Trial in Rheumatoid Arthritis Patients

Jeffrey R. Curtis¹, Douglas Conaway², Joy Schechtman³, Aaron Broadwell⁴, Alan J. Kivitz⁵, Vance Bray⁶, Shelly Kafka⁷, Dennis Parenti⁷, Shawn Black⁷, Stephen Xu⁸, Wayne Langholff⁸ and Clifton O. Bingham III⁹,

¹Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL,

²Rheumatology/Medicine, Carolina Health Specialists, Myrtle Beach, SC, ³Sun Valley Arthritis Center LTD, Peoria, AZ, ⁴Rheumatology Osteoporosis Specialists, Shreveport, LA, ⁵Altoona Arthritis & Osteoporosis Center, Altoona, PA, ⁶Denver Arthritis Clinic, Denver, CO, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Rheumatology, Johns Hopkins University, Baltimore, MD

Background/Purpose: The Patient (Pt) Reported Outcomes Measurement Information System (PROMIS [P]) questionnaires developed by the NIH have been validated and are a feasible assessment tool...

• **ABSTRACT NUMBER: 620 • 2017 ACR/ARHP Annual Meeting**

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Peter Nash¹, Laura C Coates², Alan J. Kivitz³, Philip J Mease⁴, Dafna D Gladman⁵, Jose A Covarrubias-Cobos⁶, Dona Fleishaker⁷, Cunshan Wang⁷, Elizabeth Kudlacz⁷, Sujatha Menon⁷, Thijs Hendriks⁸ and Keith S Kanik⁷,

¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶Unidad Reumatologica Las Americas S.C.P, Yucatán, Mexico, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Colledgeville, PA

• **ABSTRACT NUMBER: 1141 • 2017 ACR/ARHP Annual Meeting**

Initial Results of a Clinical Study to Determine Whether a Tolerizing Regimen of Pegloticase Can Increase the Frequency of Subjects Having Sustained Lowering of Serum Urate

Kenneth Saag¹, Mitchell Feinman², Alan J. Kivitz³, Herbert S. B. Baraf⁴, Roy Fleischmann⁵, Arthur Kavanaugh⁶ and Peter E. Lipsky⁷,

¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²ACME Research, LLC, Orangeburg, SC, ³Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁴Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁶Medicine, University of California, San Diego, La Jolla, CA, ⁷AMPEL BioSolutions, LLC, Charlottesville, VA

• **ABSTRACT NUMBER: 1539 • 2017 ACR/ARHP Annual Meeting**

High Retention Rate and Sustained Responses with Secukinumab 150mg in Patients with Active Ankylosing Spondylitis: 3-Year Results from a Phase 3 Study

Alan J. Kivitz¹, Helena Marzo-Ortega², Clarence Legerton³, Joachim Sieper⁴, Ricardo Blanco⁵, Martin Cohen⁶, Evie Maria Delicha⁷, Susanne Rohrer⁷ and Hanno Richards⁷,

¹Altoona Center for Clinical Research, Duncansville, PA, ²NIHR LBRC, LTHT and LIRMM, UoL, Leeds, United Kingdom, ³Low Country Rheumatology, Articularis Healthcare, Charleston, SC, ⁴University Clinic Benjamin Franklin, Berlin, Germany, ⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶McGill University, Montreal, QC, Canada, ⁷Novartis Pharma AG, Basel, Switzerland

- ABSTRACT NUMBER: 1686 • 2017 ACR/ARHP Annual Meeting**

Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) – a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge

Dinesh Khanna¹, Lorele Mendez², Rajaie Namas³, Mary Ellen Csuka⁴, Paul Caldron⁵, Jerry A. Molitor⁶, Alan J. Kivitz⁷, Philip Waller⁸, Lee Shapiro⁹, Sabeen Najam¹⁰, Amber Khan¹¹, Virginia D. Steen¹², Aneureka Chadha¹³ and James R Seibold¹⁴, ¹University of Michigan, Ann Arbor, MI, ²Medical Research Center of Miami, Miami, FL, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ⁴Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁵Arizona Arthritis & Rheumatology Research PLLC, Phoenix, AZ, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Accurate Clinical Research Inc, Houston, TX, ⁹Rheumatology, Albany Medical College, Albany, NY, ¹⁰Accurate Clinical Management LLC, Baytown, TX, ¹¹Accurate Clinical Management LLC, Houston, TX, ¹²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ¹³Austin Regional Clinic, Austin, TX, ¹⁴Scleroderma Research Consultants LLC, Litchfield, CT
- ABSTRACT NUMBER: 1784 • 2017 ACR/ARHP Annual Meeting**

The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjögren’s Syndrome: A Phase IIa Double-Blind, Placebo-Controlled Randomized Trial

Benjamin Fisher¹, Margit Zeher², Wan-Fai Ng³, Michele Bombardieri⁴, Maximilian Posch⁵, Athena S Papas⁶, Arwa M Farag⁶, Thomas Daikeler⁷, Bettina Bannert⁸, Alan J. Kivitz⁹, Steven E. Carsons¹⁰, David A. Isenberg¹¹, Francesca Barone¹², Simon Bowman¹³, Pascal Espie¹⁴, Grazyna Wieczorek¹⁴, Pierre Moulin¹⁴, David Floch¹⁴, Cyrielle Dupuy¹⁴, Xiaohui Ren¹⁴, Petra Faerber¹⁴, Andrew M Wright¹⁵, Hans Ulrich Hockey¹⁵, Michael Rotte¹⁴, James S. Rush¹⁵ and Peter Gergely¹⁴, ¹Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ²Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary., Debrecen, Hungary, ³Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ⁵Charité Research Organisation GmbH, Berlin, Germany, ⁶Tufts University, Boston, MA, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸University Hospital Basel, Basel, Switzerland, ⁹Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ¹⁰NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ¹¹Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ¹²Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom, ¹³Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, Novartis
- ABSTRACT NUMBER: 1828 • 2017 ACR/ARHP Annual Meeting**

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study

Karel Pavelka¹, Alan J. Kivitz², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Alan Slade⁷, Yi Wang⁷, Susanne Rohrer⁸ and Brian Porter⁷, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Altoona Center for Clinical Research, Duncansville, PA, ³MEDICAL PLUS s.r.o., Uherske Hradiste, Czech Republic, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland
- ABSTRACT NUMBER: 2091 • 2017 ACR/ARHP Annual Meeting**

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies

Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA

- ABSTRACT NUMBER: 2492 • 2017 ACR/ARHP Annual Meeting**

The Long-Term Safety and Durability of Response of Chs-0214, a Proposed Biosimilar to Etanercept: An Open-Label Safety Extension Study

Ingrid Louw¹, Alan J. Kivitz², Tsutomu Takeuchi³, Yoshiya Tanaka⁴, Satoshi Nakashima⁵, Jennifer Hodge⁶, Hong Tang⁶, Paula O'Connor⁶ and Barbara Finck⁶, ¹Panorama Medical Centre, Cape Town, South Africa, ²Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ³Keio University School of Medicine, Tokyo, Japan, ⁴School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Daiichi Sankyo, Tokyo, Japan, ⁶Coherus BioSciences, Inc., Redwood City, CA
- ABSTRACT NUMBER: 2795 • 2017 ACR/ARHP Annual Meeting**

Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re-Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study

Hans-Peter Tony¹, Hendrik Schulze-Koops², Klaus Krüger³, Stanley B Cohen⁴, Alan J. Kivitz⁵, Slawomir Jeka⁶, Edit Verecke⁷, Liyi Cen⁸ and Dmitrij Kollins⁸, ¹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius München, München, Germany, ⁴Metroplex Clinical Research Centre, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁷National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany
- ABSTRACT NUMBER: 601 • 2017 ACR/ARHP Annual Meeting**

Long-Term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects with Active Psoriatic Arthritis

Alvin F. Wells¹, Christopher J. Edwards², Alan J. Kivitz³, Paul Bird⁴, Dianne Nguyen⁵, Maria Paris⁵, Lichen Teng⁵ and Jacob A. Aelion⁶, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University Of New South Wales, Sydney, Australia, ⁵Celgene Corporation, Summit, NJ, ⁶West Tennessee Research Institute, Jackson, TN

S Sam Lim,¹ Alan J Kivitz,² Doug McKinnell,³ M Edward Pierson,⁴ Faye S O'Brien⁴ “Simulating clinical trial visits yields patient insights into study design and recruitment”
Dove Press, October 30, 2017

Alan Kivitz, Ewa Olech, Michael A. Borofsky, Beatriz Zazueta, Federico Navarro-Sarabia, Sebastiao C. Radominski, Joan T. Merrill, Cesar Pacheco-Tena, Jinglan Pei, Clare Nasmyth-Miller, and Janet E. Pope. “Two-Year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis”
The Journal of Rheumatology Dec. 19, 2017

Alvin F. Wells; Christopher J. Edwards; Alan J. Kivitz; Paul Bird; Dianne Nguyen; Maria Paris; Lichen Teng; Jacob A. Aelion “Long-term (4-Year) Efficacy and Safety of Apremilast Monotherapy in DMARD-Naive Subjects With Active Psoriatic Arthritis”
RWCS 2018

Nathaniel P. Katz, Philip G. Conaghan, Alan Kivitz, Dennis C. Turk, James R. Johnson, Scott Kelley, Neil Bodick, “Assay sensitivity of average daily pain (ADP) and Western Ontario and McMaster Osteoarthritis Index A-pain (WOMAC-A) in a phase 3 trial of intra-articular TA-ER for osteoarthritis knee pain”

[Secukinumab Improves Symptoms, Inhibits Radiographic Progression in Psoriatic Arthritis](#) [Early Response in Psoriatic Arthritis Treatment Predicts Long-Term Outcomes](#) [Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis](#)

[Alan J. Kivitz MD^a](#), [Stanley Cohen MD^b](#), [Edward Keystone MD, FRCPC^c](#), [Ronald F. van Vollenhoven MD PhD^d](#), [Boulos Haraoui MD^e](#), [Jeffrey Kaine MD^f](#), [Haiyun Fan MS^g](#), [Carol A. Connell RN, PhD^h](#), [Eustratios Bananis PhDⁱ](#), [Liza Takiya PharmD^g](#), [Roy Fleischmann MD^b](#) “A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population” <https://doi.org/10.1016/j.semarthrit.2018.07.006>
Rheumatology RHE-18-0397.R1: Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study

Philip G. Conaghan, MBBS, PhD, FRACP, FRCP, Steven J. Russell, MD, PhD, Robert Sala, George Habib, MD, Quang Vo, MD, Rickey Manning, MD, Alan Kivitz, MD, Yvonne Davis, MD, Joelle Lufkin, MPH, James R. Johnson, PhD, Scott Kelley, MD. “Triamcinolone Acetonide Extended-Release (TA-ER) Is Associated With Reduced Blood Glucose Elevation vs Standard Triamcinolone in Type 2 Diabetes Mellitus Patients with Knee Osteoarthritis: A Randomized, Blinded, Parallel-Group Study” Conaghan OARSI 2018 TA-ER glucose (encore) poster

P Nash, LC Coates, AJ Kivitz, PJ Mease, DD Gladman, JA Covarrubias-Cobos, D Fleishaker, C Wang, E Kudlacz, S Menon, T Hendrikx, KS Kanik. “Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the second interim analysis of OPAL Balance, an open-label, long-term extension study” presented at PANLAR 2018

Vibeke Strand, Margaret Michalska, Christine Birchwood, Jinglan Pei, Katie Tuckwell, Rebecca Finch, Alan J Kivitz, Josef S Smolen, Gerd R Burmester “Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis” published in final form on RMD <https://rmdopen.bmj.com/content/4/1/e000602>

Gerd R Burmester, Joel M Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Ahmed A Othman, Aileen L Pangan, Heidi S Camp “Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial”
Published **Online** June 13, 2018 [http://dx.doi.org/10.1016/S0140-6736\(18\)31115-2](http://dx.doi.org/10.1016/S0140-6736(18)31115-2)

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Rheumatology and Therapy, (), 1-16 Aug. 21, 2018

David Chernoff¹, P. Scott Eastman, Ching Chang Hwang, Darl D. Flake II, Xingbin Wang, Alan Kivitz, Jeffrey R. Curtis “Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores”
Clinical Rheumatology

Steven J. Russell, Robert Sala, Philip G. Conaghan, George Habib, Quang Vo, Rickey Manning, Alan Kivitz, Yvonne Davis, Joelle Lufkin, James R. Johnson, Scott Kelley and Neil Bodick. “**Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study**”
Oxford University Press doi:10.1093/rheumatology/key265 September 2018

Benjamin A. Fisher¹, Grazyna Wieczorek², Margit Zeher³, Wan-Fai Ng⁴, Michele Bombardieri⁵, Maximilian Posch⁶, Athena S Pappas⁷, Arwa M Farag⁷, Thomas Daikeler⁸, Bettina Bannert⁸, Alan J. Kivitz⁹, Steven E. Carsons¹⁰, David A. Isenberg¹¹, Francesca Barone¹, Simon J. Bowman¹, Pascal Espie², Sabina Pfister², David Floch², Cyrielle Dupuy², Xiaohui Ren², Petra Faerber^{2#}, Andrew M. Wright¹², Hans-Ulrich Hocke^{12,13}, Michael Rotte², Julie Doucet², Alexandre Avrameas², Marie-Anne Valentin², Sebastian Hoersch², Laura Demandt^{2#}, Gautier Robert², Celine

Cojean², James S. Rush^{2*} and Peter Gergely^{2*} “**Blockade of CD40-CD154 interactions provides therapeutic benefit in patients with primary Sjögren’s syndrome**”

CGRP Blockade by Galcanezumab Was Not Associated with Reductions in Signs and Symptoms of Knee Osteoarthritis in a Randomized Clinical Trial

Elsevier 2018

Alan J. Kivitz, Peter Nash, Hasan Tahir, Andrea Everding, Heřman Mann, Andrzej Kaszuba, Pascale Pellet, Albert Widmer, Luminita Pricop, Ken Abrams. “Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study” [Rheumatology and Therapy](#) September 2019, Volume 6, [Issue 3](#), pp 393–407|

Mark C. Genovese . Maria W. Greenwald . Sergio R. Gutierrez-Uren~a, Mario H. Cardiel . Jeffrey E. Poiley . Anna Zubrzycka-Sienkiewicz, Christine E. Codding . Annie Wang . Weizhong He . Rebecca Amos, Raul Vinueza . Xuegong Wang . Jay P. Garg Alan J. Kivitz. “Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study” *Rheumatol Ther* <https://doi.org/10.1007/s40744-019-00167-6>

2018: ACR IN CHICAGO

Oct. 22: Poster Presentation

Flexion Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis

Oct. 22: Poster Presentation

Novartis Spondyloarthritis Including Psoriatic Arthritis – Clinical III: Treatment of Axial SpA

Oct. 23: Poster Presentation

Gilead Poster Presentation GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis

2018 ABSTRACTS AT ACR IN CHICAGO

Long-Term Evaluation of Secukinumab in Ankylosing Spondylitis: 5 Year Efficacy and Safety Results from a Phase 3 Trial

[Xenofon Baraliakos](#)¹, [Jürgen Braun](#)², [Atul A. Deodhar](#)³, [Denis Poddubnyy](#)⁴, [Alan J. Kivitz](#)⁵, [Hasan Tahir](#)⁶, [Filip van Den Bosch](#)⁷, [Evie Maria Delicha](#)⁸, [Zsolt Talloczy](#)⁹ and [Anke Fierlinger](#)⁹, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, and Ruhr University Bochum, Herne, Germany, Herne, Germany, ³Oregon Health & Science University, Portland, Portland, OR, ⁴Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Whipps Cross University Hospital, Barts Health NHS Trust, London, United Kingdom, ⁷Rheumatology, Universitair Ziekenhuis, Ghent, Belgium, Gent, Belgium, ⁸Novartis Pharma AG, Basel, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States, East Hanover, NJ

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis: Long-Term (4-Year) Data from a Phase 3 Study

[Iain B. McInnes](#)¹, [Alan J. Kivitz](#)², [Peter Nash](#)³, [Proton Rahman](#)⁴, [Juergen Rech](#)⁵, [Bruce Kirkham](#)⁶, [Sandra V. Navarra](#)⁷, [Kevin Ding](#)⁸, [Emma Ilsley](#)⁹ and [Luminita Pricop](#)¹⁰, ¹University of Glasgow, Glasgow, United Kingdom, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Queensland, Brisbane, Australia, ⁴Memorial University, St John's, NF, Canada,

⁵University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷University of Santo Tomas Hospital, Manila, Philippines, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ

Determination of the Minimally Important Difference for Interpreting the RA Multi-Biomarker Disease Activity Test Score: Impact of Diurnal and Daily Biomarker Variation on Scores Adjusted for Age, Sex and Adiposity

David Chernoff¹, P. Scott Eastman², Darl D. Flake IP³, Alan J. Kivitz⁴ and Jeffrey R. Curtis⁵, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Senior Director, New Product Development, Crescendo Bioscience Inc., South San Francisco, CA, ³Myriad Genetics Inc., Salt Lake City, UT, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵University of Alabama at Birmingham, Birmingham, AL

GS-9876, a Novel, Highly Selective, SYK Inhibitor in Patients with Active Rheumatoid Arthritis: Safety, Tolerability and Efficacy Results of a Phase 2 Study

Alan J. Kivitz¹, Daksha P Mehta², Franziska Matzkies³, Afsaneh Mozaffarian³, Rebecca Kunder³, Julie Di Paolo⁴, Neelufar Mozaffarian³, Sean Hsueh³, JiYun Kim⁵, Wendy Jiang³, Lin Liu³, John S. Sundry⁶ and Mark C. Genovese⁷, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Center for Arthritis and Osteoporosis, Elizabethtown, KY, ³Gilead Sciences, Inc., Foster City, CA, ⁴Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA, ⁵Biomarkers, Gilead Sciences, Inc., Foster City, CA, ⁶Clinical Research, Inflammation and Respiratory, Gilead Sciences, Inc., Foster City, CA, ⁷Stanford University Medical Center, Palo Alto, CA

A Randomized, Double-Blind Phase III Study Comparing the Efficacy, Safety and Immunogenicity of PF-06438179/GP1111 (Ixifi™), an Infliximab Biosimilar, and Infliximab Reference Product (Remicade®) in Patients with Moderate to Severe Active RA: Results from Week 54 to Week 78

Stanley Cohen¹, Alan J. Kivitz², Michael Tee³, Carol Cronenberger⁴, Min Zhang⁵, Sarah Hackley⁶, Karl Schumacher⁷ and Muhammad I. Rehman⁸, ¹Metroplex Clinical Research Center, LLC, Dallas, TX, ²Altoona Center for Clinical Research, Duncansville, PA, ³Department of Medicine, Medical Center Manila and University of the Philippines, Manila, Philippines, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, La Jolla, CA, ⁶Pfizer Ltd, Sandwich, United Kingdom, ⁷Global Clinical Development, Biopharmaceuticals, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ⁸Pfizer Inc, Andover, MA

Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial

Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTH and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland pharmaceuticals, Sandoz Biopharmaceuticals, Holzkirchen, Germany, ⁸Pfizer Inc, Andover, MA

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study

Peter Nash¹, Laura C. Coates², Alan J. Kivitz³, Philip J. Mease⁴, Dafna D Gladman⁵, Jose A Covarrubias-Cobos⁶, Dona Fleishaker⁷, Cunshan Wang⁷, Elizabeth Kudlacz⁷, Sujatha Menon⁷, Lara Fallon⁸, Thijs Hendrikx⁹ and Keith S Kanik⁷, ¹University of Queensland, Brisbane, Australia, ²University of Oxford, Oxford, United Kingdom, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Unidad Reumatologica Las Americas S.C.P, Mérida, Yucatan, Mexico, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Canada, Montreal, QC, Canada, ⁹Pfizer Inc, Collegeville, PA

Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making

Peter C. Taylor¹, Neil Betteridge², T Michelle Brown³, John Woolcott⁴, Alan J. Kivitz⁵, Cristiano A F Zerbini⁶, Diane Whalley⁷, Oyebimpe Olayinka-Amao³, Connie Chen⁸, Palle Dahl⁹, Dario Ponce de Leon¹⁰, David Gruben¹¹ and Lara Fallon¹², ¹University of Oxford, Oxford, United Kingdom, ²Neil Betteridge Associates, London, United Kingdom, ³RTI Health Solutions, Research

Triangle Park, NC, ⁴Pfizer Inc, Collegetown, PA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Centro Paulista de Investigação Clínica, São Paulo, Brazil, ⁷RTI Health Solutions, Manchester, United Kingdom, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Ballerup, Denmark, ¹⁰Pfizer Inc, Lima, Peru, ¹¹Pfizer Inc, Groton, CT, ¹²Pfizer Canada, Montreal, QC, Canada

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Measurement of Dissolution of Urate Deposits Associated with Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin By Dual Energy Computed Tomography

Rehan Azeem¹, Earl Sands¹, Lloyd Johnston², Wesley DeHaan Ph.D.³, Alan J. Kivitz³, Takashi Kei Kishimoto², Justin Park¹ and Savvas Nicolaou⁴, ¹Selecta Biosciences, Inc, Watertown, MA, ²Selecta Biosciences, Watertown, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Radiology, University of British Columbia, Vancouver, BC, Canada

Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing

Earl Sands¹, Alan J. Kivitz², Wesley DeHaan Ph.D.¹, Lloyd Johnston¹ and Takashi Kei Kishimoto¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA

Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study

Alan J. Kivitz¹, Karel Pavelka², Eva Dokoupilova³, Ricardo Blanco⁴, Marco Maradiaga⁵, Hasan Tahir⁶, Yi Wang⁷, Brian Porter⁸, Anna Stefanska⁹, Susanne Rohrer¹⁰ and Hanno Richards¹⁰, ¹Altoona Center for Clinical Research, Duncansville, PA, ²1st Faculty of Medicine, Charles University, Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic, ³University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, MEDICAL PLUS s.r.o., Uherske Hradiste, Czech Republic, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁶Rheumatology, Barts Health NHS Trust, London, United Kingdom, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ, ⁹Novartis Ireland Limited, Dublin, Ireland, ¹⁰Novartis Pharma AG, Basel, Switzerland

Systemic Exposure of Triamcinolone Acetonide Following Bilateral Injection of Extended-Release Triamcinolone Acetonide and Standard Triamcinolone in Patients with Bilateral Knee Osteoarthritis

Alan J. Kivitz¹, Louis Kwong², Tammi Shlotzhauer³, Joelle Lufkin⁴, Teresa Curto⁵ and Scott Kelley⁴, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Department of Orthopaedic Surgery, Harbor-UCLA Medical Center, Torrance, CA, ³Rochester Clinical Research, Inc., Rochester, NY, ⁴Flexion Therapeutics, Inc., Burlington, MA, ⁵Cytel Inc., Waltham, MA

Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy

Jeffrey Kaine¹, Alan J. Kivitz², Eduardo Mysler³, Noriko Iikuni⁴, Haiyun Fan⁵, Annette Diehl⁵, Jerome Paulissen⁶ and Christopher W Murray⁵, ¹Sarasota Arthritis Research Center, Sarasota, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegetown, PA, ⁶Syneos Health, Raleigh, NC

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegadricase) with Svp-Rapamycin Enables Sustained Reduction of Acute Gout Flares

Rehan Azeem¹, Alan J. Kivitz², Earl Sands¹, Wesley DeHaan Ph.D.³, Lloyd Johnston³ and Takashi Kei Kishimoto³, ¹Selecta Biosciences, Inc, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Watertown, MA

United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab

Aaron Broadwell¹, Vance Bray², Douglas Conaway³, Joy Schechtman⁴, Alan J. Kivitz⁵, Dennis Parenti⁶, Shawn Black⁶, Stephen Xu⁷, Wayne Langholff⁷ and Shelly Kafka⁶, ¹Rheumatology Osteoporosis Specialists, Shreveport, LA, ²Denver Arthritis Clinic, Denver, CO, ³Carolina Health Specialists, Myrtle Beach, SC, ⁴Sun Valley Arthritis Center, Peoria, AZ, ⁵Altoona Arthritis & Osteoporosis Center, Altoona, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Janssen Research & Development, LLC, Spring House, PA

Michael J. Langworthy, Philip G. Conaghan, Joseph J. Ruane, Alan J. Kivitz, Joelle Lufkin, Amy Cinar, Scott D. Kelley. "Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis"
Published in Springer Link February 25, 2019

Article ID: ACR23771

Article DOI: 10.1002/acr.23771

Internal Article ID: 16044776

Article: Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch from Reference Rituximab in Patients with Active Rheumatoid Arthritis

Journal: Arthritis Care & Research

Alan J. Kivitz, Philip G. Conaghan, Amy Cinar, Joelle Lufkin, Scott D. Kelley
"Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials"
Published in Springer Link May 7, 2019

9 ABSTRACTS PRESENTED AT 2019 EULAR MADRID, SPAIN:

FIRST-IN-HUMAN STUDY OF NOVEL IMPLANTED VAGUS NERVE STIMULATION DEVICE TO TREAT RHEUMATOID ARTHRITIS,

Mark C. Genovese, Norman Gaylis, David Sikes, Alan Kivitz, Diane M Horowitz, Charles Peterfy, Yaakov Levine, David Chernoff

A NOVEL, HIGHLY SELECTIVE, SYK INHIBITOR IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY RESULTS OF A PHASE 2 STUDY,

Alan Kivitz, Daksha Mehta, Franziska Matzkies, Afsaneh Mozaffarian, Rebecca Kunder, Julie A. DI Paolo, Neelufar Mozaffarian, Sean Hsueh, Jiyun Kim, Wendy Jiang, Lin Liu, John Sundry, Mark C. Genovese

LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL,

Helena Marzo-Ortega, Joachim Sieper, Alan Kivitz, Ricardo Blanco, Martin Cohen, Karel Pavelka, Eumorphia Maria Delicha, Anna Stefanska, Hanno Richards, Susanne Rohrer

LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CSDMARDS: RESULTS AT 60 WEEKS FROM THE SELECT-NEXT STUDY,

Gerd Rüdiger Burmester, Filip van den Bosch, Louis Bessette, Alan Kivitz, LI Yihan, Alan Friedman, Aileen Pangan, Heidi Camp, Joel Kremer

SAFETY AND EFFICACY OF LY3337641, A BRUTON'S TYROSINE KINASE INHIBITOR IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART PHASE 2 STUDY,

Mark C. Genovese, Alberto Spindler, Akira Sagawa, Won Park, Anna Dudek, Alan Kivitz, Jeannie Chao Lai Shan (Melanie) Chan, William Barchuk, Ajay Nirula

SECUKINUMAB IMPROVES GRAPPA-OMERACT CORE DOMAINS OF PSORIATIC ARTHRITIS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR,

Ana-Maria Orbai, M Elaine Husni, Dafna D. Gladman, Ying Ying Leung, Stefan Siebert, William Tillett, Marijn Vis, Olivier Chambenoit, Xiangyi Meng, Philip J. Mease

SECUKINUMAB PROVIDES RAPID AND SIGNIFICANT IMPROVEMENT IN THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS: PRIMARY (16-WEEK) RESULTS FROM A PHASE 3 CHINA-CENTRIC STUDY, MEASURE 5,

Feng Huang, Fei Sun, Weiguo Wan, Lijun Wu, Lingli Dong, Xiao Zhang, Tae-Hwan Kim, Raj Sengupta, Ladislav Šenolt, Yi Wang, Haomin Qiu, Brian Porter, Sibylle Haemmerle

SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN'S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL,

Benjamin Fisher, Antónia Szántó, Wan Fai Ng, Michele Bombardieri, Maximilian Posch, Athena Papas, Arwa Farag, Thomas Daikeler, Bettina Bannert, Alan Kivitz, Steven Carsons, David Isenberg, Francesca Barone, Simon J. Bowman, Pascal Espie, Grazyna Wiecek, Pierre Moulin, David Floch, Cyrielle Dupuy, Amanda Nguyen, Andrew Wright, Michael Rotte, James Rush, Peter Gergely

UNITED STATES RHEUMATOLOGY PRACTICE-BASED REAL-WORLD EVIDENCE OF METHOTREXATE UTILIZATION AND RESPONSE TO THERAPY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB,

Aaron Broadwell, Vance Bray, Douglas Conaway, Joy Schechtman, Alan Kivitz, Dennis Parenti, Shawn Black, Stephen Xu, Wayne Langholff, Shelly Kafka

[Kivitz AJ](#)¹, [Nash P](#)², [Tahir H](#)³, [Everding A](#)⁴, [Mann H](#)⁵, [Kaszuba A](#)⁶, [Pellet P](#)⁷, [Widmer A](#)⁷, [Pricop L](#)⁸, [Abrams K](#)⁸. Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. *Rheumatology and Therapy* (PubMed link: <https://www.ncbi.nlm.nih.gov/pubmed/31228101>)

Roy Fleischmann, Mark C. Genovese, Yong Lin, Gregory St. John, Desiree van der Heijde, Sheldon Wang, Juan Jose Gomez-Reino, Jose Antonio Maldonado-Cocco, Marina Stanislav, Alan J. Kivitz, and Gerd R. Burmester. "Long-Term safety of sarilumab in Rheumatoid Arthritis: an integrated analysis with up to 7 years' follow-up" Published July 18, 2019. <https://academic.oup.com/rheumatology>

[Hans-Peter Tony](#), [Klaus Krüger](#), [Stanley B. Cohen](#), [Hendrik Schulze-Koops](#), [Alan J. Kivitz](#), [Sławomir Jeka](#), [Edit Vereckei](#), [Liyi Cen](#), [Laura Kring](#), [Dmitrij Kollins](#). "Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch From Reference Rituximab in Patients With Active Rheumatoid Arthritis" *Journal: Arthritis Care & Research* 2019

Alan J. Kivitz, Philip G. Conaghan, Amy Cinar, Joelle Lufkin, Scott D. Kelley. "Rescue Analgesic Medication Use by Patients Treated with Triamcinolone Acetonide Extended-Release for Knee Osteoarthritis Pain: Pooled Analysis of Three Phase 2/3 Randomized Clinical Trials" *Pain and Therapy*, December 2019, Volume 8, [Issue 2](#), pp 271–280

- [2019 ACR/ARP Annual Meeting](#)
[Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies](#)
Alan [Kivitz](#)¹, Joel Kremer², Clarence Legerton³, Jacqueline Palmer⁴, Xiangyi Meng⁴, Luminita Pricop⁴ and Atul Singhal^{5, 1}Altoona Center for Clinical Research, Duncansville, PA, ²Albany Medical College, Albany, NY, ³Low Country Rheumatology/Articularis Healthcare, North Charleston, SC, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Southwest Rheumatology, Dallas, TX
- [ABSTRACT NUMBER: 1329](#) • [2019 ACR/ARP Annual Meeting](#)

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

Kevin Winthrop¹, Mark Genovese², Bernard Combe³, Yoshiya Tanaka⁴, Alan Kivitz⁵, Franziska Matzkies⁶, Beatrix Bartok⁶, Lei Ye⁶, Ying Guo⁶, Chantal Tasset⁷, John Sundy⁶, Edward Keystone⁸, Rene Westhovens⁹, William F.C. Rigby¹⁰ and Gerd Burmester¹¹, ¹Oregon Health and Science University, Portland, OR, ²Stanford University, Stanford, CA, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, ⁸Mount Sinai Hospital and University of Toronto, Toronto, Canada, ⁹University Hospitals, Leuven, Belgium, ¹⁰Dartmouth College, Lebanon, NH, ¹¹Charité—University Medicine Berlin, Berlin, Germany

[ABSTRACT NUMBER: 1332](#) • [2019 ACR/ARP Annual Meeting](#)

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization

Sergio Schwartzman¹, Aaron Broadwell², Alan Kivitz³, Shawn Black⁴, Stephen Xu⁵ and Shelly Kafka⁶, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, RI, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA

[ABSTRACT NUMBER: 1217](#) • [2019 ACR/ARP Annual Meeting](#)

Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development

Rehan Azeem¹, Alan Kivitz², Horacio Plotkin¹, Lloyd Johnston¹, Takashi K. Kishimoto¹, Justin Park¹, Stephen Smolinski¹ and Wesley DeHaan¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA

[ABSTRACT NUMBER: 1218](#) • [2019 ACR/ARP Annual Meeting](#)

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients

Rehan Azeem¹, Justin Park¹, Horacio Plotkin¹, Alan Kivitz², Lloyd Johnston¹, Takashi K. Kishimoto¹, Stephen Smolinski¹ and Wesley DeHaan¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA

[ABSTRACT NUMBER: 1235](#) • [2019 ACR/ARP Annual Meeting](#)

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients

Wesley DeHaan¹, Alan Kivitz², Rehan Azeem¹, Horacio Plotkin¹, Lloyd Johnston¹, Takashi K. Kishimoto¹, Justin Park¹, Stephen Smolinski¹ and Sheldon Leung¹, ¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA

[ABSTRACT NUMBER: 1309](#) • [2019 ACR/ARP Annual Meeting](#)

Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis

Philip G Conaghan¹, Edgar Ross², Alan Kivitz³, Dennis Turk⁴, Andrew Spitzer⁵, Deryk Jones⁶, Ryan Lanier⁷, Amy Cinar⁸, Joelle Lufkin⁸ and Scott Kelley⁸, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Brigham and Women's Hospital, Boston, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University of Washington, Seattle, ⁵Cedars-Sinai Medical Center, Los Angeles, ⁶Ochsner Sports Medicine Institute, Harahan, GA, ⁷Analgesic Solutions, Natick, ⁸Flexion Therapeutics, Burlington

- [ABSTRACT NUMBER: 824](#) • [2019 ACR/ARP Annual Meeting](#)
Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients
 Jeffrey Curtis¹, S Louis Bridges², Stacey S Cofield², John Bassler¹, Theresa Ford³, Stephen Lindsey⁴, Alan Kivitz⁵, Ilhem Messaoudi⁶, Kaleb Michaud⁷, Joseph Huffstutter⁸, Ted Mikuls⁹, David Ridley¹⁰, William Shergy¹¹, Sarah Siegel¹² and Kevin Winthrop¹³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶University of California Irvine, Irvine, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Arthritis Associates, Hixon, TN, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Rheumatology Associates of North Alabama, Huntsville, AL, ¹²Oregon Health Science University, Portland, OR, ¹³Oregon Health and Science University, Portland, OR
- [ABSTRACT NUMBER: 930](#) • [2019 ACR/ARP Annual Meeting](#)
Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
 Norman Gaylis¹, David Sikes², Alan Kivitz³, Diane Horowitz⁴, Charles Peterfy⁵, Yaakov Levine⁶, David Chernoff⁶ and Mark Genovese⁷, ¹Arthritis and Rheumatic Disease Specialties, Aventura, FL, ²Florida Medical Clinic, Land O Lakes, FL, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Northwell Health, Manhasset, NY, ⁵Spire Sciences Inc, Boca Raton, ⁶SetPoint Medical, Valencia, CA, ⁷Stanford University, Stanford, CA

Markman JD, Bolash RB², McAlindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, Li DJ, Viktrup L, B. “Subcutaneous Tanezumab Versus Placebo or Tramadol in Patients with Chronic Low Back Pain: 16-Week Efficacy and Safety Results from a Phase 3 Study”. Presented at the American Academy of Neurology (AAN) in Canada. April 2020

Alan Kivitz, Yoshiya Tanaka, Susan J Lee, Lei Ye, Hao Hu, Robin Besuyen, Bernard Combe **“Filgotinib provided rapid and sustained improvements in functional status, pain, health-related quality of life, and fatigue in patients with rheumatoid arthritis and inadequate response to methotrexate: Results from the FINCH 1 study”**

EULAR 2020 ABSTRACTS

ADVERSE EVENTS IN PATIENTS WITH OSTEOARTHRITIS TREATED WITH SUBCUTANEOUS TANEZUMAB: A POOLED ANALYSIS OF THE OVERALL POPULATION AND SELECTED SUBGROUPS FROM 3 RANDOMISED PLACEBO-CONTROLLED TRIALS.

F. Berenbaum, A. Kivitz, T. Schnitzer, M. Brown, S. Donevan, A. Hickman, L. Viktrup, C. West, T. Yamabe

EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY.

D. Van der Heijde, L. S. Gensler, A. Deodhar, X. Baraliakos, D. Poddubnyy, A. Kivitz, M. K. Farmer, D. Baeten, N. Goldammer, J. Coarse, M. Oortgiesen, M. Dougados

EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS.

B. Combe, A. Kivitz, Y. Tanaka, D. Van der Heijde, J. A. Simon-Campos, H. S. B. Baraf, U. Kumar, F. Matzkies, B. Bartok, L. Ye, Y. Guo, C. Tasset, J. Sundy, A. Jahreis, N. Mozaffarian, R. B. M. Landewé, S. C. Bae, E. Keystone, P. Nash

FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE FINCH 1 STUDY.

A. Kivitz, Y. Tanaka, S. Lee, L. Ye, H. Hu, R. Besuyen, B. Combe

GENERAL SAFETY AND TOLERABILITY OF SUBCUTANEOUS TANEZUMAB FOR THE TREATMENT OF OSTEOARTHRITIS: A POOLED ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED TRIALS.

F. Berenbaum, T. Schnitzer, A. Kivitz, L. Viktrup, A. Hickman, G. Pixton, M. Brown, I. Davignon, C. West

INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS.

M. C. Genovese, K. Winthrop, Y. Tanaka, T. Takeuchi, A. Kivitz, F. Matzkies, L. Ye, D. Jiang, Y. Guo, B. Bartok, R. Besuyen, G. R. Burmester, J. E. Gottenberg

NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS FROM THE MEASURE 2, 3 AND 4 PHASE 3 TRIALS.

M. Dougados, U. Kiltz, A. Kivitz, K. Pavelka, S. Rohrer, S. McCreddin, E. Quebe-Fehling, B. Porter, Z. Talloczy

SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, IMMUNOGENICITY, AND PRELIMINARY EFFICACY OF ROZIBAFUSP ALFA IN SUBJECTS WITH RHEUMATOID ARTHRITIS: INTERIM ANALYSIS OF A PHASE 1B RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE CLINICAL TRIAL.

L. Abuqayyas, L. Cheng, D. Mitragotri, S. Smith, M. Teixeira Dos Santos, Y. Zhou, V. Chindalore, S. Cohen, A. Kivitz, M. Posch, B. Sullivan, J. Parnes

SARILUMAB AS MONOTHERAPY OR IN COMBINATION WITH CONVENTIONAL SYNTHETIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: 12-WEEK TREATMENT RESULTS FROM A MULTICENTER, OPEN-LABEL, PROSPECTIVE, SINGLE-ARM OBSERVATIONAL STUDY.

A. Kivitz, J. E. Gottenberg, M. Bergman, M. Iglesias-Rodriguez, G. St John, C. Qiu, H. Van Hoogstraten, L. Bessette

SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY.

J. Braun, R. Blanco, E. Dokoupilova, L. S. Gensler, A. Kivitz, S. Hall, H. Kameda, D. Poddubnyy, M. Van de Sande, D. Van der Heijde, A. Wiksten, B. Porter, H. Richards, S. Haemmerle, A. Deodhar

TOFACITINIB AS MONOTHERAPY FOLLOWING METHOTREXATE WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS PREVIOUSLY TREATED WITH OPEN-LABEL TOFACITINIB + METHOTREXATE: A RANDOMISED, PLACEBO-CONTROLLED SUBSTUDY OF OPAL BALANCE.

P. Nash, L. C. Coates, P. J. Mease, A. Kivitz, D. D. Gladman, F. Behrens, J. C. C. Wei, D. Fleishaker, J. Wu, C. Wang, A. B. Romero, L. Fallon, M. A. Hsu, K. Kanik

UNITED STATES RHEUMATOLOGY PRACTICE-BASED REAL-WORLD EVIDENCE OF INFUSION REACTIONS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB OR INFlixIMAB: IMPACT OF PRIOR BIOLOGIC EXPOSURE AND METHOTREXATE UTILIZATION.

S. Schwartzman, A. Broadwell, A. Kivitz, S. Black, S. Xu, W. Langhoff, S. Kafka

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Authors: [Peter Nash](#), [Laura C. Coates](#), [Alan J. Kivitz](#), [Philip J. Mease](#), [Dafna D. Gladman](#), [José A. Covarrubias-Cobos](#), [Oliver FitzGerald](#), [Dona Fleishaker](#), [Cunshan Wang](#), [Joseph Wu](#), [Ming-Ann Hsu](#), [Sujatha Menon](#), [Lara Fallon](#), [Ana Belén Romero](#) & [Keith S. Kanik](#)

Springer Link *Rheumatology and Therapy* June 2020

5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the Phase 3 MEASURE 2 trial. Authors: Helena Marzo-Ortega, Joachim Sieper, Alan J Kivitz, Ricardo Blanco, Martin Cohen, Karel Pavelka, Eumorphia M Delicha, Anna Stefanska, Hanno B Richards, Susanne Rohrer
The Lancet Vol. 2 June 2020

A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Authors: Cynthia Aranow, John Cush, Marcy Bolster, Christopher Striebich, Maria Dall'era, Meggan Mackay, Ewa Olech, Tracy Frech, Jane Box, Richard Keating, Mary Chester Wasko, William St. Clair, Alan Kivitz, Weiquang Huang, PetaGay Ricketts, Beverly Welch, Sherrie Callahan, Meagan Spsychala, Karen Boyle, Kate York, Lynette Keyes-Elstein, Ellen Goldmuntz, Betty Diamond, Anne Davidson

Rheumatology, Volume 59, Issue 7, July 2020, Pages 1504-1513 18 October 2019

Clinical Utility and Cost Savings in Predicting Inadequate Response to Anti-TNF Therapies in Rheumatoid Arthritis. Authors: [Martin J. Bergman](#), [Alan J. Kivitz](#), [Dimitrios A. Pappas](#), [Joel M. Kremer](#), [Lixia Zhang](#), [Anna Jeter](#) & [Johanna B. Withers](#)
Rheumatology and Therapy (2020)

Michael R. Robinson, Nemanja Damjanov, Bojana Stamenkovic, Goran Radunovic, Alan Kivitz, Lori Cox, Zorayr Manukyan, Michael Saunders, Deepa Chandra, Michael S. Vincent, Jessica Mancuso, Elena Peeva, Jean S. Beebe. "Efficacy and Safety of PF- 06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate- to- Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate"

Arthritis & Rheumatology, Vol. 72, No. 10, October 2020, pp 1621-1631

Christopher Ritchlin, Alan J Kivitz, Peter Nash, Renato Calheiros, Xiangyi Meng, Corine Gaillez, Bruce Kirkham, Iain B McInnes. "Efficacy of Secukinumab Treatment in Patients With Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies"

Presented at the Winter Clinical Dermatology Conference (WCDC) 2021 January 16-24, 2021

Atul Deodhar, Ricardo Blanco, Eva Dokoupilova, Stephen Hall, Hideto Kameda, Alan J. Kivitz, Denis Poddubnyy, Marleen van de Sande, Anna S. Wiksten, Brian O. Porter, Hanno B. Richards, Sibylle Jaemmerle, and Jurgen Braun. "Improvement of Signs and Symptoms of Non radiographic Axial Spondyloarthritis in Patients Treated with Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.

Arthritis & Rheumatology, Vol. 73. No 1. Jan 2021. Pp 110-120

ABSTRACT NUMBER: 0208 • ACR Convergence 2020

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: 52-Week Results

Bernard Combe¹, Alan Kivitz², Yoshiya Tanaka³, Désirée van der Heijde⁴, J-Abraham Simon-Campos⁵, Herbert S. Baraf⁶, Uma Kumar⁷, Franziska Matzkies⁸, Beatrix Bartok⁸, Lei Ye⁸, Ying Guo⁹, Chantal Tasset¹⁰, John S. Sundry⁸, Angelika Jahreis⁸, Neelufar Mozaffarian¹¹, Robert Landewé¹², Sang-Cheol Bae¹³, Edward C Keystone¹⁴ and Peter Nash¹⁵, ¹University of Montpellier, Montpellier, France, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Köhler & Milstein Research, Mérida, Mexico, ⁶The Ctr for Rheumatology and Bone Research, Wheaton, MD, ⁷All India Institute of Medical Sciences, New Delhi, India, ⁸Gilead Sciences, Inc., Foster City, CA, ⁹Gilead Sciences, Inc., Foster City, ¹⁰Galapagos NV, Mechelen, Belgium, ¹¹Ichnos Sciences, Paramus, ¹²Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ¹³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁴Mount Sinai Hospital, Toronto, ON, Canada, ¹⁵School of Medicine Griffith University, Brisbane, Queensland, Australia

ABSTRACT NUMBER: 0229 • ACR Convergence 2020

Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years

Kevin Winthrop¹, Yoshiya Tanaka², Tsutomu Takeuchi³, Alan Kivitz⁴, Franziska Matzkies⁵, Mark Genovese⁵, Deyuan Jiang⁵, Kun Chen⁵, Beatrix Bartok⁵, Angelika Jahreis⁵, Robin Besuyen⁶, Gerd Burmester⁷ and Jacques-Eric Gottenberg⁸, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁴Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos BV, Leiden, Netherlands, ⁷Charité University Hospital Berlin, Berlin, Germany, ⁸Strasbourg University Hospital, Strasbourg, France

ABSTRACT NUMBER: 0235 • ACR Convergence 2020

Safety and Biological Activity of Rozibafusp Alfa in Subjects with Rheumatoid Arthritis: Final Results of a Phase 1b Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study

Lubna Abuqayyas¹, Laurence Cheng¹, Kyong Park¹, Marcia Teixeira dos Santos¹, Barbara Sullivan¹, Hui Wang¹, Yanchen Zhou¹, Vishala Chindalore², Stanley Cohen³, Alan Kivitz⁴, Maximilian Posch⁵ and Jane Parnes¹, ¹Amgen Inc., Thousand Oaks, CA, ²Pinnacle Research Group, Anniston, AL, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁵Charité Research Organisation, Berlin, Germany

ABSTRACT NUMBER: 0889 • ACR Convergence 2020

Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies

Christopher Ritchlin¹, Alan Kivitz², Peter Nash³, Renato Calheiros⁴, Xiangyi Meng⁵, Corine Gaillez⁶, Bruce Kirkham⁷ and Iain McInnes⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom

ABSTRACT NUMBER: 1218 • ACR Convergence 2020

Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate

Alan Kivitz¹, Yoshiya Tanaka², Susan Lee³, Lei Ye³, Hao Hu³, Robin Besuyen⁴ and Bernard Combe⁵, ¹Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵University of Montpellier, Montpellier, France

ABSTRACT NUMBER: 1340 • ACR Convergence 2020

Secukinumab Improves Pain, Morning Stiffness, Fatigue and Physical Function in Tumor Necrosis Factor Inhibitor-Naïve Patients with Non-Radiographic Axial Spondyloarthritis: Results from a Randomized Controlled Phase III Study

Helena Marzo-Ortega¹, Atul Deodhar², Ricardo Blanco³, Hideto Kameda⁴, Alan Kivitz⁵, Denis Poddubnyy⁶, Marina Magrey⁷, Jianyuan Wang⁸, Sibylle Haemmerle⁸, Abhijit Shete⁸ and Juergen Braun⁹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²Oregon Health & Science University, Portland, OR, ³Hospital University Marqués de Valdecilla, Santander, Spain, ⁴Toho University, Tokyo, Japan, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁶Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁷Case Western Reserve University School of Medicine, Cleveland, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Rheumazentrum Ruhrgebiet and Ruhr-University, 44649 Herne, Germany

ABSTRACT NUMBER: 1352 • ACR Convergence 2020

Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension

Joseph Merola¹, Frank Behrens², Alan Kivitz³, Philip Mease⁴, Iain McInnes⁵, Barbara Ink⁶, Deepak Assudani⁷, Paulatsya Joshi⁷, Jason Coarse⁸ and Christopher Ritchlin⁹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ³Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UCB Pharma, Slough, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Raleigh, NC, ⁹Department of Medicine, University of Rochester Medical Center, Rochester, NY

ABSTRACT NUMBER: 1544 • ACR Convergence 2020

Tc99m Tilmanocept Imaging Is an Early Predictor of Clinical Response in Rheumatoid Arthritis Patients Beginning New Anti-TNF α Therapy

Mara Leach¹, David Ralph¹, Beth Potter¹, Bonnie Abbruzzese¹, Rachael Hershey¹, Jessica Fitzpatrick¹, Katherine Repp¹, Haya Shakhtra¹, Madison Palmer¹, Nicole Korczak¹, Audrey Villarosa¹, Michael Blue¹, Martin Jacobs², Yelliann Ruis³, Debbie Foley⁴, Alan Kivitz⁵ and Michael Rosol¹, ¹Navidea Biopharmaceuticals, Dublin, ²Kettering Medical Center, Kettering, ³Innovation Medical Research Center, Palmetto Bay, ⁴Premier Rheumatology of Oklahoma, Tulsa, ⁵Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA

ABSTRACT NUMBER: 1996 • ACR Convergence 2020

Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study

Kevin Winthrop¹, Juan Vargas², Edit Drescher³, Conrado Garcia⁴, Alan Friedman⁵, Jeffrey Enejosa⁵, Nasser Khan⁵, Yihan Li⁵, Justin Klaff⁵ and Alan Kivitz⁶. ¹Oregon Health & Science University, Portland, OR, ²Quantum Research, Puerto Varas, Chile, ³Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary, ⁴Hospital General de México "Dr. Eduardo Liceaga", Mexico, Mexico, ⁵AbbVie Inc., North Chicago, IL, ⁶Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA

ABSTRACT NUMBER: L14 • 2019 ACR/ARP Annual Meeting

Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance

Peter Nash¹, Laura Coates², Philip J. Mease³, Alan Kivitz⁴, Dafna Gladman⁵, Frank Behrens⁶, James C Wei⁷, Dona Fleishaker⁸, Joseph Wu⁸, Cunshan Wang⁸, Ana Romero⁹, Lara Fallon¹⁰, Ming-Ann Hsu⁸ and Keith Kanik⁸. ¹Griffith University, Brisbane, Queensland, Australia, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, Washington, ⁴Altoona Center for Clinical Research, Duncansville, ⁵University of Toronto, Toronto, Canada, ⁶CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁷Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁸Pfizer Inc, Groton, Connecticut, ⁹Pfizer Inc, Barcelona, Spain, ¹⁰Pfizer Inc, Montreal, Canada

ABSTRACT NUMBER: 2877 • 2019 ACR/ARP Annual Meeting

Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis

Kim Papp¹, Melinda Gooderham², Akimichi Morita³, Alan Kivitz⁴, Ranjeeta Sinval⁵, Andrew Topp⁵, Graham Heap⁵, Ann Eldred⁵ and Philip Mease⁶. ¹K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, Waterloo, ON, Canada, ²School of Medicine, Queen's University, Kingston, ON and Skin Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada, ³Dept of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵AbbVie Inc., North Chicago, ⁶Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA

ABSTRACT NUMBER: 1497 • 2019 ACR/ARP Annual Meeting

Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies

Alan Kivitz¹, Joel Kremer², Clarence Legerton³, Jacqueline Palmer⁴, Xiangyi Meng⁴, Luminita Pricop⁴ and Atul Singhal⁵. ¹Altoona Center for Clinical Research, Duncansville, PA, ²Albany Medical College, Albany, NY, ³Low Country Rheumatology/Arthritis Healthcare, North Charleston, SC, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Southwest Rheumatology, Dallas, TX

ABSTRACT NUMBER: 1329 • 2019 ACR/ARP Annual Meeting

Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis

Kevin Winthrop¹, Mark Genovese², Bernard Combe³, Yoshiya Tanaka⁴, Alan Kivitz⁵, Franziska Matzkies⁶, Beatrix Bartok⁶, Lei Ye⁶, Ying Guo⁶, Chantal Tasset⁷, John Sundy⁶, Edward Keystone⁸, Rene Westhovens⁹, William F.C. Rigby¹⁰ and Gerd Burmester¹¹. ¹Oregon Health and Science University, Portland, OR, ²Stanford University, Stanford, CA, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Galapagos NV, Mechelen, Belgium, ⁸Mount Sinai Hospital and University of Toronto, Toronto, Canada, ⁹University Hospitals, Leuven, Belgium, ¹⁰Dartmouth College, Lebanon, NH, ¹¹Charité—University Medicine Berlin, Berlin, Germany

ABSTRACT NUMBER: 1332 • 2019 ACR/ARP Annual Meeting

United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization

Sergio Schwartzman¹, Aaron Broadwell², Alan Kivitz³, Shawn Black⁴, Stephen Xu⁵ and Shelly Kafka⁶.¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, RI, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA

ABSTRACT NUMBER: 1217 • 2019 ACR/ARP Annual Meeting

Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development

Rehan Azeem¹, Alan Kivitz², Horacio Plotkin¹, Lloyd Johnston¹, Takashi K. Kishimoto¹, Justin Park¹, Stephen Smolinski¹ and Wesley DeHaan¹.¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA

ABSTRACT NUMBER: 1218 • 2019 ACR/ARP Annual Meeting

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients

Rehan Azeem¹, Justin Park¹, Horacio Plotkin¹, Alan Kivitz², Lloyd Johnston¹, Takashi K. Kishimoto¹, Stephen Smolinski¹ and Wesley DeHaan¹.¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA

ABSTRACT NUMBER: 1235 • 2019 ACR/ARP Annual Meeting

Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients

Wesley DeHaan¹, Alan Kivitz², Rehan Azeem¹, Horacio Plotkin¹, Lloyd Johnston¹, Takashi K. Kishimoto¹, Justin Park¹, Stephen Smolinski¹ and Sheldon Leung¹.¹Selecta Biosciences, Watertown, MA, ²Altoona Center for Clinical Research, Duncansville, PA

ABSTRACT NUMBER: 1309 • 2019 ACR/ARP Annual Meeting

Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis

Philip G Conaghan¹, Edgar Ross², Alan Kivitz³, Dennis Turk⁴, Andrew Spitzer⁵, Deryk Jones⁶, Ryan Lanier⁷, Amy Cinar⁸, Joelle Lufkin⁸ and Scott Kelley⁸.¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Brigham and Women's Hospital, Boston, MA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴University of Washington, Seattle, ⁵Cedars-Sinai Medical Center, Los Angeles, ⁶Ochsner Sports Medicine Institute, Harahan, GA, ⁷Analgesic Solutions, Natick, ⁸Flexion Therapeutics, Burlington

ABSTRACT NUMBER: 824 • 2019 ACR/ARP Annual Meeting

Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients

Jeffrey Curtis¹, S Louis Bridges², Stacey S Cofield², John Bassler¹, Theresa Ford³, Stephen Lindsey⁴, Alan Kivitz⁵, Ilhem Messaoudi⁶, Kaleb Michaud⁷, Joseph Huffstutter⁸, Ted Mikuls⁹, David Ridley¹⁰, William Shergy¹¹, Sarah Siegel¹² and Kevin Winthrop¹³.¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³North Georgia Rheumatology Group, PC, Lawrenceville, GA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶University of California Irvine, Irvine, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Arthritis Associates, Hixon, TN, ⁹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹Rheumatology Associates of North Alabama, Huntsville, AL, ¹²Oregon Health Science University, Portland, OR, ¹³Oregon Health and Science University, Portland, OR

ABSTRACT NUMBER: 930 • 2019 ACR/ARP Annual Meeting

Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator

Norman Gaylis¹, David Sikes², Alan Kivitz³, Diane Horowitz⁴, Charles Peterfy⁵, Yaakov Levine⁶, David Chernoff⁶ and Mark Genovese⁷, ¹Arthritis and Rheumatic Disease Specialties, Aventura, FL, ²Florida Medical Clinic, Land O Lakes, FL, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Northwell Health, Manhasset, NY, ⁵Spire Sciences Inc, Boca Raton, ⁶SetPoint Medical, Valencia, CA, ⁷Stanford University, Stanford, CA

ABSTRACT NUMBER: 937 • 2019 ACR/ARP Annual Meeting

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

Désirée van der Heijde¹, Lianne Gensler², Atul Deodhar³, Xenofon Baraliakos⁴, Denis Poddubnyy⁵, Alan Kivitz⁶, Marga Oortgiesen⁷, Dominique Baeten⁸, Nadine Goldammer⁹, Jason Coarse⁷, MK Farmer⁷ and Maxime Dougados¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁸UCB Pharma, Brussels, Belgium, Brussels, ⁹UCB Pharma, Monheim, Germany, Monheim, Germany, ¹⁰Cochin Hospital, Paris, France

ABSTRACT NUMBER: 506 • 2019 ACR/ARP Annual Meeting

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results

Bernard Combe¹, Alan Kivitz², Yoshiya Tanaka³, Désirée van der Heijde⁴, Franziska Matzkies⁵, Beatrix Bartok⁵, Lei Ye⁵, Ying Guo⁵, Chantal Tasset⁶, John Sundry⁵, Neelufar Mozaffarian⁵, Robert B.M. Landewé⁷, Sang-Cheol Bae⁸, Edward Keystone⁹ and Peter Nash¹⁰, ¹CHU Montpellier, Montpellier University, Montpellier, France, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰University of Queensland, Brisbane, Queensland, Australia

ABSTRACT NUMBER: 538 • 2019 ACR/ARP Annual Meeting

Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks

Gerd Burmester¹, Filip Van den Bosch², Louis Bessette³, Alan Kivitz⁴, Yihan Li⁵, Alan Friedman⁶, Aileen Pangan⁶, Heidi Camp⁵ and Joel Kremer⁷, ¹Charité—University Medicine Berlin, Berlin, Germany, ²Ghent University Hospital, Ghent, Belgium, ³Laval University, Quebec City, QC, Canada, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, ⁷Albany Medical College, Albany, NY

ABSTRACT NUMBER: 535 • 2016 ACR/ARHP Annual Meeting

Examination of Diurnal and Daily Variation of the Multi-Biomarker Disease Activity (MBDA) Score in RA to Establish the Minimally Important Difference

David Chernoff¹, Rebecca J. Bolce¹, Ching Chang Hwang², Xingbin Wang¹, Alan Kivitz³ and Jeffrey R. Curtis⁴, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL

ABSTRACT NUMBER: 616 • 2016 ACR/ARHP Annual Meeting

ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study

Stanley Cohen¹, Jose L. Pablos², Nan Zhang³, Warren Rizzo⁴, Gerhard Muller⁵, Devi Padmanaban⁶, Alan Kivitz⁷, Alan K. Matsumoto⁸ and Primal Kaur⁹. ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ³Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁴Advanced Arthritis Care & Research, Scottsdale, AZ, ⁵Dept of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, NIEDERSACHSEN, Germany, ⁶Biosimilars, Amgen, Thousand Oaks, CA, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Rheumatology, Arthritis & Rheumatism Associate, Wheaton, MD, ⁹Amgen, Thousand Oaks, CA

ABSTRACT NUMBER: 687 • 2016 ACR/ARHP Annual Meeting

Safety and Efficacy of Certolizumab Pegol over 204 Weeks in Patients with Axial Spondyloarthritis,

Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

Atul A. Deodhar¹, Maxime Dougados², Robert Landewé³, Joachim Sieper⁴, Walter Maksymowych⁵, Martin Rudwaleit⁶, Filip van Den Bosch⁷, Jürgen Braun⁸, Philip J Mease⁹, Alan Kivitz¹⁰, Jessica Walsh¹¹, Owen Davies¹², Bengt Hoepken¹³, Luke Peterson¹⁴ and Désirée van der Heijde¹⁵. ¹Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Academic Medical Center, Amsterdam and Zuyderland Medical Center, Heerlen, Netherlands, ⁴Rheumatology Department, Charité – University Medicine Berlin, Berlin, Germany, ⁵Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁶Klinikum Bielefeld and Charité – University Medicine Berlin, Berlin, Germany, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ⁹Swedish Medical Center and University of Washington, Seattle, WA, ¹⁰Altoona Center for Clinical Research, Duncansville, PA, ¹¹Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Monheim, Germany, ¹⁴UCB Pharma, Raleigh, NC, ¹⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

ABSTRACT NUMBER: 1595 • 2016 ACR/ARHP Annual Meeting

Magnitude and Duration of Early Response with Tofacitinib: Post-Hoc Analysis of Two Phase 3, Placebo-Controlled Studies

Daniel Aletaha¹, Alan Kivitz², Guillermo Valenzuela³, John Tesser⁴, Steven Hays⁵, Huihua Li⁵, Carol A Connell⁶, Eustratios Bananis⁵, Arif Soonasra⁵ and Josef Smolen⁷. ¹Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria, ²Altoona Center for Clinical Research, Duncansville, PA, ³Integral Rheumatology & Immunology Specialists, Fort Lauderdale, FL, ⁴Arizona Arthritis & Rheumatology Associates, Glendale, AZ, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT, ⁷Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria

ABSTRACT NUMBER: 295 • 2016 ACR/ARHP Annual Meeting

Efficacy and Safety of Fasinumab for Osteoarthritic Pain in Patients with Moderate to Severe Osteoarthritis of the Knees or Hips

Jennifer Maloney¹, Alan Kivitz², Thomas J. Schnitzer³, Paula Dakin¹, Catherine Stehman-Breen¹ and Greg Geba¹. ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Northwestern University, Chicago, IL

ABSTRACT NUMBER: 2469 • 2014 ACR/ARHP Annual Meeting

The Efficacy and Safety of Tocilizumab Subcutaneous Q2W and Following Escalation from Q2W to QW Therapy in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis at 96 Weeks

Alan Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, S. C. Radominski⁶, Joan T. Merrill⁷, Jinglan Pei⁸, Lucy Rowell⁹, Clare Nasmyth-Miller⁹, Sunethra Wimalasundera⁹ and Janet E. Pope¹⁰. ¹Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ²Internal Medicine, Division of Rheumatology, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigación en Enfermedades Reumáticas, Mexicali, Mexico, ⁵Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ⁶Universidade Federal do Paraná,

Curitiba, Brazil, ⁷Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Genentech, South San Francisco, CA, ⁹Roche, Welwyn Garden City, United Kingdom, ¹⁰St Joseph Health Care, London, ON, Canada

ABSTRACT NUMBER: 2240 • 2014 ACR/ARHP Annual Meeting

An Exploratory 4-Week Study of a P2X3 Antagonist AF-219 in the Treatment of Patients with Osteoarthritis (OA) of the Knee

Vibeke Strand¹, Michael Kitt², Alan Kivitz³, Anthony Ford², Peter Butera² and Bruce McCarthy², ¹Stanford University, Portola Valley, CA, ²Afferent Pharmaceuticals, Inc., San Mateo, CA, ³Altoona Center for Clinical Research, Duncansville, PA

ABSTRACT NUMBER: 1844 • 2014 ACR/ARHP Annual Meeting

Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data

Jeffrey R. Curtis¹, Melvin Churchill², Alan Kivitz³, Laura Gauer⁴, Christopher Herrem⁴, David Carter⁵, Jeffrey Melin⁴ and Yusuf Yazici⁶, ¹The University of Alabama at Birmingham, Birmingham, AL, ²Arthritis Center of Nebraska, Lincoln, NE, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Brussels, Belgium, ⁶New York University Hospital for Joint Diseases, New York, NY

ABSTRACT NUMBER: 1572 • 2014 ACR/ARHP Annual Meeting

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial

Christopher J. Edwards¹, Jacob A. Aelion², Adewale O. Adebajo³, Alan Kivitz⁴, Paul Bird⁵, ChiaChi Hu⁶, Randall M. Stevens⁶ and Alvin Wells⁷, ¹University Hospital Southampton, Southampton, United Kingdom, ²West Tennessee Research Institute, Jackson, TN, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷Rheumatology & Immunotherapy Center, Franklin, WI

ABSTRACT NUMBER: 1543 • 2014 ACR/ARHP Annual Meeting

Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial

Alvin Wells¹, Adewale O. Adebajo², Jacob A. Aelion³, Paul Bird⁴, Alan Kivitz⁵, Frédéric Lioté⁶, Piercarlo Sarzi-Puttini⁷, ChiaChi Hu⁸, Randall M. Stevens⁸ and Christopher J. Edwards⁹, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University of Sheffield, Sheffield, United Kingdom, ³West Tennessee Research Institute, Jackson, TN, ⁴Combined Rheumatology Practice, Kogarah, Australia, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁷Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁸Celgene Corporation, Warren, NJ, ⁹University Hospital Southampton, Southampton, United Kingdom

ABSTRACT NUMBER: 1487 • 2014 ACR/ARHP Annual Meeting

A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy

Craig Wiesenhutter^{1,2}, Rakesh Patel³, John Lavery⁴, Nighat Tahir^{5,6}, Lydie Hazan⁷, Alan Kivitz⁸, Elizabeth Bretton⁹ and Jeffrey Kaine¹⁰, ¹University of Washington School of Medicine, Seattle, WA, ²Coeur d'Alene Arthritis Clinic, Coeur d'Alene, ID, ³PMG Research of Salisbury, Salisbury, NC, ⁴Allen Arthritis and Allergy, Allen, TX, ⁵Community Hospital of Anderson and Madison County, Inc., Anderson, IN, ⁶Community Rheumatology of Anderson, Anderson, IN, ⁷Axis Clinical Trials, Los Angeles, CA, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹Albuquerque Clinical Trials, Albuquerque, NM, ¹⁰Sarasota Arthritis Center, Sarasota, FL

ABSTRACT NUMBER: 602 • 2014 ACR/ARHP Annual Meeting

A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-Week) Improvements in Physical Function

Alvin Wells¹, Jacob A. Aelion², Adewale O. Adebajo³, Alan Kivitz⁴, Paul Bird⁵, ChiaChi Hu⁶, Randall M. Stevens⁶ and Christopher J. Edwards⁷, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²West Tennessee Research Institute, Jackson, TN, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Kogarah, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷University Hospital Southampton, Southampton, United Kingdom

ABSTRACT NUMBER: 249 • 2014 ACR/ARHP Annual Meeting

A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes

Vibeke Strand¹, Allan Gibofsky², Marc Hochberg³, Roy Altman⁴, Byron Cryer⁵, Alan Kivitz⁶, Olaolu Imasogie⁷ and Clarence Young⁸, ¹Stanford University, Palo Alto, CA, ²Medicine and Public Health, Hospital for Special Surgery, New York, NY, ³University of Maryland School of Medicine, College Park, MD, ⁴University of California–Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Iroko Pharmaceuticals LLC, Philadelphia, PA, ⁸150 Rouse Boulevard, Iroko Pharmaceuticals, LLC, Phila, PA

ABSTRACT NUMBER: 2765 • 2013 ACR/ARHP Annual Meeting

A Double-Blind Randomized Placebo-Controlled Trial Of Lovastatin in Patients with Rheumatoid Arthritis

Cynthia Aranow¹, John J. Cush², Marcy B. Bolster³, Christopher C. Striebich⁴, Maria Dall'era⁵, Meggan Mackay⁶, Ewa Olech⁷, Tracy M. Frech⁸, J. Box⁹, Richard M. Keating¹⁰, Mary Chester M. Wasko¹¹, E. William St Clair¹², Alan Kivitz¹³, Betty Diamond¹⁴, Anne Davidson¹⁵, Meagan Spychala¹⁶, Ellen A. Goldmuntz¹⁷ and Autoimmunity Centers of Excellence¹⁸, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴University of Colorado Denver, Aurora, CO, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁹Carolina Bone and Joint, Charlotte, NC, ¹⁰Rheumatology Section, The University of Chicago, Chicago, IL, ¹¹West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ¹²Medicine, Duke University Medical Center, Durham, NC, ¹³Altoona Center for Clinical Research, Duncansville, PA, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Rho, Inc., Chapel Hill, NC, ¹⁷DAIT, NIAID/NIH, Bethesda, MD, ¹⁸NIAID, National Institutes of Health, Bethesda, MD

ABSTRACT NUMBER: 1743 • 2013 ACR/ARHP Annual Meeting

Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study

Barbara Sullivan¹, Wayne H. Tsuji², Vishala L. Chindalore³, Thomas D. Geppert⁴, Alla Rudinskaya⁵, Patricia Pardo⁶, Alan Kivitz⁷, C. Michael Neuwelt⁸, Meggan Mackay⁹, R. John Looney¹⁰, J. Carter Thorne¹¹, Marilee Andrew¹², Greg Arnold¹³, Michael Boedigheimer¹, Kit Chiu¹, Cherie Green¹, Arunan Kaliyaperumal¹, Christine Wang¹⁴, Andrew Welcher¹ and James Chung¹, ¹Amgen, Thousand Oaks, CA, ²Clinical Research/Inflammation, Amgen, Seattle, WA, ³Anniston Medical Clinic PC, Anniston, AL, ⁴Metroplex Clinical Research Center, LLC, Dallas, TX, ⁵Danbury Hospital, Danbury, CT, ⁶MRA Clinical Research, Miami, FL, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸East Bay Rheumatology Research Institute, San Leandro, CA, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Amgen, Seattle, WA, ¹³Medical Sciences, Amgen, Thousand Oaks, CA, ¹⁴Biostatistics, Amgen, Thousand Oaks, CA

- ABSTRACT NUMBER: 1609 • 2013 ACR/ARHP Annual Meeting**
AMG 811 (anti-IFN-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL10 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies
David A. Martin¹, Andrew Welcher², Michael Boedigheimer², Zahir Amoura³, Alan Kivitz⁴, Jill P. Buyon⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Alla Rudinskaya⁸, Kevin M. Latinis⁹, S Cohen¹⁰, Cynthia Aranow¹¹, Mike Damore², Winnie Sohn², Kit Chiu², Christine Wang¹², Naren Chirmule², Barbara Sullivan² and James Chung², ¹Medical Sciences, Amgen, Seattle, WA, ²Amgen, Thousand Oaks, CA, ³Department of Internal Medicine 2, Referral center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Danbury Hospital, Danbury, CT, ⁹Latinis Rheumatology, Leawood, KS, ¹⁰Metroplex Clinical Research Center, Dallas, TX, ¹¹The Feinstein Institute, Manhasset, NY, ¹²Biostatistics, Amgen, Thousand Oaks, CA
 - ABSTRACT NUMBER: 1428 • 2013 ACR/ARHP Annual Meeting**
The Safety and Efficacy Of Tocilizumab Subcutaneous In Combination With Traditional Dmards In Patients With Moderate To Severe Rheumatoid Arthritis Up To 48 Weeks (BREVACTA)
Alan Kivitz¹, Ewa Olech², Michael A. Borofsky³, Beatriz M. Zazueta⁴, Federico Navarro-Sarabia⁵, Sebastião C. Radominski⁶, Joan T. Merrill⁷, Chris Wells⁸, Sunethra Wimalasundera⁸, Wendy Douglass⁸ and Janet E. Pope⁹, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, ³Clinical Research Center of Reading, Reading, PA, ⁴Reumatologia, Centro de Investigación en Enfermedades Reumáticas, Mexicali, Mexico, ⁵Rheumatology, Hospital Virgen Macarena, Serv. de Reumatología, Sevilla, Spain, ⁶Universidade Federal do Paraná, Curitiba, Brazil, ⁷Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, St Joseph Health Centre, London, ON, Canada
 - ABSTRACT NUMBER: 1358 • 2013 ACR/ARHP Annual Meeting**
No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial
Roy Fleischmann¹, Alan Kivitz², Ronald F van Vollenhoven³, James W. Shaw⁴, Stefan Florentinus⁵, Piyalal M. Karunaratne⁴, Hartmut Kupper⁶, Maxime Dougados⁷ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Altoona Center for Clinical Research, Duncansville, PA, ³ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷Hopital Cochin, René Descartes University, Paris, France, ⁸Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
- ABSTRACT NUMBER: 1354 • 2013 ACR/ARHP Annual Meeting**
Successful Self-Administration Of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector Pen
Jaime Pachon¹, Alan Kivitz², Kay-Uwe Heuer³ and Uwe Pichlmeier³, ¹Arthritis and Rheumatic Care Center, Miami Research Associates, South Miami, FL, ²Altoona Center for Clinical Research, Duncansville, PA, ³medac GmbH, Wedel, Germany
- ABSTRACT NUMBER: 1177 • 2013 ACR/ARHP Annual Meeting**
Efficacy and Safety Of Canakinumab Pre-Filled Syringe Versus Triamcinolone Acetonide In Acute Gouty Arthritis Patients
Prashanth Sunkureddi¹, Edith Toth², Jacques P. Brown³, Rüdiger Möricke⁴, Jan Michael Nebesky⁵, Gerhard Krammer⁵, Aiyang Tao⁶, Markus John⁵ and Alan Kivitz⁷, ¹Rheumatology, Clear Lake Rheumatology, Nassau Bay, TX, ²Flór Francis Hospital Rheumatology Department, Kistarcsa, Hungary, ³CHU de Québec Research Centre and Laval University, Quebec City, QC, Canada, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Altoona Center for Clinical Research, Duncansville, PA

Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients. [Alvin F Wells](#), [Christopher J Edwards](#), [Alan J Kivitz](#), [Paul Bird](#), [Benoit Guerette](#), [Nikolay Delev](#), [Maria Paris](#), [Lichen Teng](#), [Jacob A Aelion](#)

Rheumatology, keab449, <https://doi.org/10.1093/rheumatology/keab449>

Published: Oxford Academic 08 June 2021 <https://academic.oup.com/rheumatology/advance-article-abstract/doi/10.1093/rheumatology/keab449/6294945>

A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis

Alan Kivitz, Purvi Mehra, Peter Hanson, Louis Kwong, Amy Cinar, Joelle Lufkin, Scott Kelley
Rheumatology and Therapy (2022)

ALAN J. KIVITZ, MD, CPI
CLINICAL TRIAL EXPERIENCE

Altoona Center for Clinical Research
175 Meadowbrook Lane, Duncansville, PA 16635
(814) 693-0300 Office; (814) 693-0400 FAX
WEB SITE: www.altoonaresearch.com

| Sponsor | Indication | Drug | Year | Actual Enrollment |
|----------------------|-------------------------|--------------------------|-------------|--------------------------|
| Boehringer Ingelheim | Abdominal Cramping/Pain | Hyoscine Butylbromide | 2005 | 2 |

| | | | | |
|---------------------------|-------------------------------------|--|------|----|
| Novartis CVAK694A2201 | Allergy / Seasonal Rhinitis | VAK694 | 2009 | 1 |
| Luitpold 1VIT09030 | Anemia | FERRIC CARBOXYMALTOSE | 2010 | 7 |
| GSK 205270 | Anemia | Novel Prolyl Hydroxylase Inhibitor Daprodustat | 2020 | 1 |
| Noven | Ankle Sprain Pain | Ketoprofen Patch | 2000 | 15 |
| Pharmacia 193 | Ankylosing Spondylitis | Celecoxib | 2001 | 21 |
| Immunex 016.0037 | Ankylosing Spondylitis | Etanercept | 2001 | 16 |
| Abbott M03-607 | Ankylosing Spondylitis | Adalimumab | 2003 | 16 |
| Centocor C0524T09 | Ankylosing Spondylitis | Golimumab | 2005 | 24 |
| Abbott M10-791 | Axial Spondyloarthritis | Humira | 2010 | 1 |
| NOVARTIS CAIN457A2209 | ANKYLOSING SPONDYLITIS | AIN457 | 2010 | 4 |
| SANOFI AVENTIS DRI11073 | Ankylosing Spondylitis | SAR153191 | 2009 | 5 |
| ABBOTT M10-883 | Peripheral Spondyloarthritis | Humira | 2010 | 1 |
| UCB SCHWARZ AS001 | Ankylosing Spondylitis | Certolizumab Pegol | 2010 | 9 |
| Roche WA22908 | Ankylosing Spondylitis | Tocilizumab | 2011 | 4 |
| Roche NA22823 | Ankylosing Spondylitis | Tocilizumab | 2011 | 6 |
| Novartis CAIN457F2305 | Ankylosing Spondylitis | Secukinumab | 2012 | 7 |
| Abbott F12-117 | Axial Spondyloarthritis – Back Pain | Questionnaire | 2012 | 25 |
| Novartis CAIN457F2310 | Ankylosing Spondylitis | Secukinumab | 2012 | 2 |
| Celgene T-CC-10004-AS001 | Ankylosing Spondylitis | Apremilast | 2011 | 8 |
| Merck P07642 (MK8259-006) | Axial Spondylitis | Simponi | 2013 | 5 |
| Merck 0663-108 | Ankylosing Spondylitis | MK-0663 | 2014 | 7 |
| Pfizer A3921119 | Ankylosing Spondylitis | Tofacitinib | 2014 | 2 |
| JANSSEN CNTO148AKS3001 | Ankylosing Spondylitis | GOLIMUMAB | 2015 | 7 |
| NOVARTIS CAIN457F2320 | Ankylosing Spondylitis | SECUKINUMAB | 2015 | 4 |
| AbbVie M13-375 | Ankylosing Spondylitis | Adalimumab | 2015 | 15 |
| Janssen CNTO1275AKS3001 | Ankylosing Spondylitis | Ustekinumab | 2016 | 0 |
| UCB AS0005 | axSpA Axial Spondyloarthritis | Certolizumab Pegol | 2017 | 1 |
| Janssen CNTO1275AKS3002 | Axial Spondyloarthritis | Ustekinumab | 2017 | 0 |
| UCB AS0008 | Ankylosing Spondylitis | Bimekizumab | 2017 | 3 |
| Lilly IIF-MC-RHBX | Ankylosing Spondylitis | Ixekizumab (LY2439821) | 2017 | 0 |
| Lilly IIF-MC-RHBW | Ankylosing Spondylitis | Ixekizumab | 2017 | 1 |
| Novartis CAIN457H2315 | Ankylosing Spondylitis | Secukinumab | 2018 | 6 |
| Novartis CAIN457K2340 | Ankylosing Spondylitis | Secukinumab | 2019 | 3 |
| Novartis CAIN457FUS06 | Ankylosing Spondylitis | Secukinumab | 2020 | 20 |
| UCB AS0011 | Ankylosing Spondylitis | Bimekizumab | 2021 | 2 |
| Novartis CAIN457P12301 | Ankylosing Spondylitis & NR Axial | Secukinumab | 2021 | 5 |

| | | | | |
|-------------------------------------|----------------------------------|---------------------|------|---------------------------------|
| | SpondyloArthritis | | | |
| AbbVie M19-944 | Axial Spondyloarthritis | Upadacitinib | 2021 | 5 |
| UCB AS0010 | NR Axial Spondyloarthritis | Bimekizumab | 2021 | 4 |
| Novartis CAIN457P12301 | NR Axial Spondyloarthritis or AS | Secukinumab | 2021 | 6 |
| | | | | |
| Schwarz | Anxiety or Panic Disorder | Niravam | 2005 | 5 |
| | | | | |
| Targeted Genetics I3G01 (Phase 1) | Arthritis (Inflammatory) | TNFR-Fc Fusion Gene | 2006 | 14 |
| | | | | |
| Byk Gulden/Altana | Asthma | Roflumilast | 2002 | 0 |
| | | | | |
| Pfizer Esperion 642-006 | Atherosclerosis | ETC-642 | 2005 | 9 |
| | | | | |
| Medimmune D6080C00001 Phase 1 | Autoimmune Diseases | MEDI7734 | 2017 | 8 |
| | | | | |
| Ortho-McNeil | Back Pain | Ultram | 1998 | 18 |
| Pfizer | Back Pain | CJ13,974 | 1999 | 1 |
| Ortho-McNeil | Back Pain | Tramadol | 1999 | 12 |
| Merck | Back Pain | Cox II | 1999 | 14 |
| Biovail | Back Pain | Tramadol | 2000 | 20 |
| Pharmacia 244 | Back Pain | Celecoxib | 2002 | 21 |
| Pharmacia 269 | Back Pain | Celecoxib | 2003 | 8 |
| Purdue BUP3015 | Back Pain | BTDS | 2004 | 13 |
| Endo EN3261-001 | Back Pain | Lidocaine Patch | 2004 | 7 |
| Dov Pharm. 020 & 022 | Back Pain | Bicifadine | 2004 | 11 |
| Hisamitsu HKT400US04 | Back Pain | Ketaprofen Patch | 2005 | 0 |
| Pfizer A3191165 | Back Pain | Celecoxib | 2006 | 3 |
| Abbott M05-790 | Back Pain | Vicodin | 2006 | 3 (Closed Early) |
| Purdue BUP3024 | Back Pain | BTDS | 2007 | 11 |
| Neuromed NMT 1077-301 | Back Pain | NMED-1077 | 2008 | 2 |
| Johnson and Johnson 42160443PAI2003 | Back Pain | JNJ 42160443 | 2009 | 7 |
| Regeneron R475-PN-0908 | Sciatica | REGN475 | 2009 | 8 |
| Pfizer A4091012 | Back Pain | Tanezumab | 2010 | 18 |
| Purdue ONU3701 | Back Pain | Oxycodone/Naloxone | 2012 | 14 |
| Pfizer B4531002 | Back Pain | ALO-02 | 2012 | 6 |
| Endo EN3409-308 | Back Pain | Buprenorphine | 2012 | 1 |
| Endo EN3409-307 | Back Pain | Buprenorphine | 2012 | Open Label=10 Double-Blind=4 |
| Zalicus Z160-LSR-201 | Lumbar Radiculopathy | Z160 | 2012 | 3 |
| TEVA C33237/3103 | Back Pain | CEP-33237 | 2013 | 5 |
| BIOGEN 103NS201 | Sciatica | BG00010 | 2013 | 8 |

| | | | | |
|--|-------------------------------|--|------|----------------------------|
| PFIZER B7431006 | Back Pain | PF-06372865 | 2015 | 4 |
| Nektar 14-181-08 | Chronic LBP or Noncancer Pain | NKTR-181 | 2016 | 2 |
| Egalet OC-EG-302 | Chronic Low Back Pain | EGALET-002 | 2016 | 2 |
| Nektar 14-181-07 | Chronic LBP | NKTR-181 | 2016 | 1 Completed 21 Screened |
| Regeneron R475-PN-1524 | Chronic LBP | Fasinumab | 2016 | 3 |
| Pfizer A4091059 | Chronic LBP | Tanezumab | 2017 | 10 |
| | | | | |
| Pharmacia 201 | Bursitis –Tendinitis Shoulder | Celecoxib | 2001 | 39 |
| | | | | |
| Regeneron 0505 | CIASI | IL-1 Trap | 2005 | 3 |
| | | | | |
| Bayer 12198 | Cardiovascular Events | Aspirin | 2007 | 1 |
| CIRT (National Heart Lung & Blood Institute) | Cardiovascular Events | MTX | 2018 | 14 |
| | | | | |
| Endo EN3272-301 | Carpal Tunnel Syndrome | Lidocaine Patch | 2005 | 3 |
| | | | | |
| Abbott M02-403 | Crohn’s Disease | Adalimumab | 2003 | 1 |
| Abbott M02-404 | Crohn’s Disease | Adalimumab | 2003 | 1 |
| Abbott M06-808 | Crohn’s Disease | Adalimumab | 2006 | 4 |
| Pfizer A3921043 | Crohn’s Disease | CP-690,550 | 2007 | 3 |
| | | | | |
| Ortho-McNeil | Chronic Pain | Ultram | 1997 | 25 |
| Ortho-McNeil | Chronic Pain | Tramadol | 1998 | 91 |
| Parke-Davis | Chronic Pain | Pregabalin | 1998 | 15 |
| Purdue | Chronic Pain | Tramadol - OL | 1998 | 73 |
| Purdue | Chronic Pain | Tramadol | 1998 | 18 |
| Parke-Davis | Chronic Pain | Pregabalin | 1999 | 32 |
| Endo | Pain | Oxycodone | 1999 | 24 |
| Endo | Chronic Pain | Numorphan | 2000 | 6 |
| Purdue Pharma | Chronic Pain | Hydromorphone Hydrochloride ER | 2000 | 17 |
| Biovail | Chronic Pain | Tramadol | 2000 | 67 |
| Endo Pharmaceuticals | Chronic Pain | Oxymorphone | 2001 | 26 |
| Shire 308 | Chronic Pain | Propiram Fumarate | 2001 | 10 |
| Sanofi-Synthlebo | Chronic Painful Shoulder | Hyalgan | 2002 | 16 |
| Alza/Johnson and Johnson | Opioid Tolerant Patients | D-Trans® fentanyl | 2002 | 11 |
| Endo EN3202.028 | Chronic Pain | Oxymorphone | 2003 | 5 |
| Purdue HMP4005 | Non-Malignant Pain | Hydromorphone® HCl ER and Duragesic | 2003 | 42 |
| Harris Interactive | Avinza Pain Questionnaire | Avinza | 2004 | 8 |
| Abbott M03-666 | Chronic Pain | Vicodin | 2005 | 12 |
| Purdue HMP3011 | Persistent Pain | Hydromorphone | 2005 | 0 |

| | | | | |
|--------------------------------------|---|-----------------------------------|------|----|
| | | Hydrochloride ER | | |
| Hisamitsu HKT400US03 | Shoulder Pain | Ketapofen Patch | 2005 | 9 |
| Sagedmed | Chronic Pain | Questionnaire | 2006 | 17 |
| Johnson & Johnson R331333-PAI-3007 | Chronic Pain | CG5503 PR | 2006 | 28 |
| Cephalon C25608/3054/BP/US | Chronic Pain | Fentanyl Buccal | 2006 | 10 |
| Cephalon C25608/3055/BP/MN | Chronic Pain | Fentanyl Buccal | 2008 | 4 |
| Wyeth 3200A3-1113-US | Pain | MOA-728 | 2008 | 5 |
| KING ALPHARMA CONVERT | PAIN | EMBEDA | 2010 | 6 |
| Egalet OC-EG-303 | Chronic Non Cancer Pain | Egalet-002 ADER Oxycodone | 2016 | 8 |
| | | | | |
| Johnson and Johnson R331333-PAI-3024 | Opioid Induced Constipation | Questionnaire | 2008 | 2 |
| Johnson and Johnson R331333PAI3020 | Opioid Induced Constipation | Tapentadol IR and Oxycodone IR | 2008 | 9 |
| THERAVANCE TD-1211 | Opioid Induced Constipation | TD-1211 | 2011 | 0 |
| | | | | |
| IOMED | DeQuervain's Disease | Iontophoresis | 2000 | 12 |
| | | | | |
| Centocor CNTO C0999D02 | Device Trial for Autoinjector | AUTOINJECTOR | 2007 | 38 |
| Abbott | Rheumatoid Arthritis | AUTOINJECTOR Humira | | |
| Janssen CNTO1959NAP0001 | AutoInjector | AUTOINJECTOR | 2013 | 31 |
| BMS IM133-060 | AutoInjector | AUTOINJECTOR | 2014 | 28 |
| Medac MC-MTX.15/HF | Rheumatoid Arthritis | MTX AUTOINJECTOR | 2012 | 28 |
| BMS 101-366 | Rheumatoid Arthritis | ABATACEPT INJECTOR | 2014 | 28 |
| ANTARES | Rheumatoid Arthritis | MTX AUTOINJECTOR | 2010 | 36 |
| Antares MTX-11-002 | Rheumatoid Arthritis | MTX AUTOINJECTOR | 2012 | 25 |
| Antares MTX-11-003 | Rheumatoid Arthritis | MTX AUTOINJECTOR | 2012 | 31 |
| Amgen 200990176 | RA and Psoriasis | Enbrel AutoInjector | 2013 | 16 |
| AMGEN 20110107 | RA or PSA | Enbrel Autoinjector | 2013 | 16 |
| Genentech BrevactaWA29917 | Rheumatoid Arthritis | Tocilizumab | 2015 | 8 |
| Coherus CHS-1420-04 | Autoinjector Device for Rheumatoid Arthritis | CHS-1420 | 2016 | 8 |
| Baxalta 911502 | RA Injector | M923 | 2015 | 12 |
| | | | | |
| Pfizer | Diabetic Foot Ulcer | Antibiotic | 1998 | 19 |
| | | | | |
| Bristol-Myers Squibb | Diabetes | Metformin | 2000 | 1 |
| Novartis 2302 | Diabetes & Cardio outcomes in Impaired Glucose Intolerance | Nateglinide & Valsartan | 2002 | 2 |
| | | | | |
| Abbott | Diabetic Neuropathy | ABT594 | 2000 | 7 |
| Sanwa | Diabetic Neuropathy | SNK-860 | 2001 | 2 |
| Pfizer A0081060 | Diabetic Neuropathy | Pregabalin | 2004 | 5 |
| Astellas 05-0-223 | Diabetic Neuropathy | FK1706 | 2006 | 3 |

| | | | | |
|------------------------------------|--|-------------------------|------|-----|
| Takeda 01-06-TL-583-006 | Diabetic Neuropathy | TAK-583 | 2007 | 6 |
| Johnson & Johnson R331333-PAI-3015 | Diabetic Neuropathy | CG5503 | 2007 | 11 |
| Adolor 33CL231 | Diabetic Neuropathy | ADL5859 | 2007 | 4 |
| Forest RG8-MD-02 | Diabetic Neuropathy | RGH-896 | 2008 | 6 |
| Sangamo SB-509-0107 | Diabetic Neuropathy (Mod/Severe) | SB-509 | 2007 | 2 |
| Sangamo SB-509-0601 | Diabetic Neuropathy | SB-509 | 2007 | 0 |
| AEGERA AEG33773-201 | Diabetic Neuropathy | AEG33773 | 2009 | 15 |
| JOHNSON & JOHNSON R331333-PAI-3027 | Diabetic Neuropathy | TAPENTADOL | 2010 | 11 |
| Daiichi Sankyo DS5565-AU201 | Diabetic Neuropathy | DS-5565 | 2012 | 2 |
| Pfizer A0081268 | Diabetic Neuropathy | PREGABALIN | 2011 | 3 |
| Pfizer A0081269 | Diabetic Neuropathy | PREGABALIN | 2012 | 2 |
| AstraZeneca D3031C00001 | Diabetic Neuropathy | AZD5213 | 2014 | 1 |
| Aptinyx NYX-2925-2008 | Diabetic Neuropathy | NYX-2925 | 2021 | 2 |
| | | | | |
| IOMED | Epicondylitis | Iontophoresis | 2000 | 2 |
| Hisamitsu HKT400US05 | Epicondylitis | Ketaprofen Patch | 2005 | 1 |
| | | | | |
| Ortho-McNeil | Fibromyalgia | Tramadol | 1999 | 12 |
| Parke-Davis | Fibromyalgia | Pregabalin | 1999 | 33 |
| Parke-Davis/Pfizer | Fibromyalgia, Post Herpetic Neuralgia, Diabetic Neuropathy | Pregabalin | 2001 | 3 |
| Cypress Bioscience | Fibromyalgia Questionnaire | None | 2002 | 193 |
| Pfizer A2571003 | Fibromyalgia | CP-424,391 | 2003 | 22 |
| Pfizer A0081056 | Fibromyalgia | Pregabalin | 2004 | 7 |
| Cypress Bioscience | Fibromyalgia | Milnacipran | 2004 | 13 |
| Orphan | Fibromyalgia | Xyrem | 2004 | 13 |
| Forest MLN-MD-02 | Fibromyalgia | Milnacipran | 2004 | 8 |
| Pfizer A6061034 | Fibromyalgia | Reboxetine | 2006 | 7 |
| Wyeth 3151A4-327-US | Fibromyalgia | DVS SR | 2006 | 19 |
| Allergan 203818-503 | Fibromyalgia | AGN 203818 | 2006 | 6 |
| Pfizer A6061043 | Fibromyalgia | Reboxetine | 2007 | 11 |
| Pfizer A6061046 | Fibromyalgia | Reboxetine | 2007 | 8 |
| Boehringer Ingelheim 248.637 | Fibromyalgia | Pramipexole | 2008 | 8 |
| Wyeth 3151A4-2003-US | Fibromyalgia | DVS SR | 2008 | 7 |
| Lilly F1J-MC-B020 | Fibromyalgia | Questionnaire | 2008 | 150 |
| Pfizer FMS BOI | Fibromyalgia | Questionnaire | 2008 | 25 |
| Jazz 06-009 and 06-010 | Fibromyalgia | Xyrem | 2008 | 14 |
| Jazz FMS Interview | Fibromyalgia | Interview/Questionnaire | 2009 | 5 |
| Pfizer A0081165 | Fibromyalgia with Insomnia | Pregabalin | 2009 | 1 |
| Jazz 06-010 | Fibromyalgia | Xyrem | 2010 | 14 |
| Bioenergy Ribocor BIOE02C010 | Fibromyalgia | D-Ribose | 2012 | 27 |
| OMC Research SLS2009001 | Fibromyalgia | Pregabalin | 2012 | 130 |

| | | | | |
|---------------------------------|------------------------------------|----------------------------------|------|-------------|
| Theravance TD9855 Protocol 0092 | Fibromyalgia | TD-9855 | 2013 | 10 |
| Lilly FIJ-MC-HMGW | Fibromyalgia adolescents | Duloxetine | 2014 | 5 |
| DAIICHI DS5565-A-E311 | Fibromyalgia | DS-5565 | 2016 | 5 |
| Teva TV48125-PN-20028 | Fibromyalgia | Fremanezumab | 2021 | 3 |
| Aptinyx NYX-2925-2005 | Fibromyalgia | NYX-2925 | 2022 | 8 |
| | | | | |
| Genomics | Genotype | DNA | 2000 | 2,316 |
| CORRONA | Data Collection on OA, RA, OP, PSA | None | 2002 | In Progress |
| Seracare | Healthy, Psoriasis, Lupus, RA, MS | Genetic Blood Collection | 2004 | 300+ |
| Asterand | Healthy, Lupus | Genetic Blood collection | 2006 | 1000+ |
| | | | | |
| Reliant | GERD | Nizatidine ER | 2001 | 4 |
| AstraZeneca 0003 | GI Symptoms (relief) | Esomeprazole | 2002 | 8 |
| AstraZeneca 0004 | GI Symptoms (rollover) | Esomeprazole | 2002 | 4 |
| Takeda 01-01-TL-370-001 | Regurgitation | TAK-370 | 2002 | 4 |
| Tap PACE-M02-420 | Regurgitation | Lansoprazole verses Esomeprazole | 2002 | 1 |
| AstraZeneca 325 | Healed EE | Nexium | 2003 | 4 |
| AstraZeneca 322 | Moderate/Severe EE | Nexium | 2003 | 4 |
| AstraZeneca | Heartburn & Sleep disturbances | Esomeprazole | 2003 | 6 |
| AstraZeneca D9770C00011 | GERD w/o Erosive Esophagitis | AZD0865 | 2004 | 3 |
| AstraZeneca D9770C00012 | GERD Esophagitis | AZD0865 | 2004 | 3 |
| AstraZeneca D9612100062 | Erosive Esophagitis | Nexium® | 2004 | 1 |
| AstraZeneca D9612L00084 | Esophageal Mucosal Pathology | Prilosec OTC | 2005 | 1 |
| Altana BY1023/M3-340 | GERD | Pantoprazole | 2005 | 25 |
| Tap T-GD04-082 | GERD (non-erosive) | TAK-390MR | 2005 | 19 |
| Tap T-EE04-084 | Healing Erosive Esophagitis | TAK-390MR | 2005 | 24 |
| TAP T-GD05-137 | Non-Erosive GERD | TAK-390 MR | 2006 | 17 |
| TAP Z-EE05-123 | Erosive Esophagitis | Ilaprazole | 2007 | 13 |
| AstraZeneca D9120C00027 | GERD | AZD3355 | 2008 | 2 |
| Eisai E3810-G000-302 | GERD | Rabeprazole | 2008 | 1 |
| Eisai E3810-G000-303 | GERD | Rabeprazole | 2008 | 9 |
| Tap aka Takeda T-GD07-170 | Nocturnal GERD | TAK-390MR | 2008 | 4 |
| | | | | |
| Adolor Corp. | GI Dysfunction (Opioid-Induced) | Opioid Therapy | 2001 | 6 |
| Adolor | GI Symptoms from Opioids | Data Collection Study | 2009 | 1 |
| | | | | |
| Merck | Gout | Etoricoxib & Indomethacin | 2000 | 3 |
| Bio-Technology General | Gout | None | 2001 | 4 |
| Tap C02-010 | Gout | TMX-67 | 2002 | 2 |
| Tap | Gout | Febuxostat | 2003 | 1 |

| | | | | |
|------------------------------|-----------------------|-----------------------|------|----|
| Savient C0406 | Gout | Peg-Uricase | 2006 | 4 |
| Regeneron IL1T-A1-0608 | Gout | Riloncept | 2006 | 4 |
| Tap F-GT06-153 | Gout | Febuxostat | 2006 | 9 |
| AR Scientific MPC-004-06-001 | Gout | Colchicine | 2007 | 13 |
| Regeneron IL1T-GA-0619 | Gout | IL-1 Trap | 2007 | 4 |
| Pfizer A3191219 | Gouty Arthritis | Celebrex | 2008 | 1 |
| Novartis CACZ885H2255 | Gout | Canakinumab (ACZ885) | 2008 | 4 |
| Enzymerx ENZ-101 | Gout | Uricase PEG 20 | 2009 | 10 |
| Regeneron IL1T-GA-0810 | Gout | Riloncept | 2009 | 2 |
| Biocryst BCX4208-201 | Gout | BCX4208 | 2010 | 1 |
| Enzymerx ENZ-102 PHASE 1 | Gout | URICASE-PEG 20 | 2009 | 12 |
| Novartis CACZ885H2357 | Gout | ACZ885 | 2010 | 2 |
| Biocryst BCX4208-202 | Gout | BCX4208 | 2010 | 3 |
| Regeneron IL1T-GA-0815 | Gout | Riloncept | 2010 | 10 |
| NUON A3007GT | GOUT | TRANILAST | 2010 | 4 |
| Biocryst BCX4208-203 | Gout | BCX4208 | 2010 | 5 |
| Takeda TMX_67-204 | Gout | Febuxostat | 2011 | 1 |
| Metabolix M102-21122 | Gout | MBX 102 | 2011 | 1 |
| ARDEA ALLO-401 | GOUT | ALLOPURINOL | 2011 | 7 |
| NOVARTIS CACZ885H2361 | Gout | ACZ885 | 2011 | 1 |
| REGENERON IL1T-GA-1103 | Gout | Colchicine (Colcrys®) | 2011 | 0 |
| Ardea RDEA594-304 | Gout | Lesinurad | 2011 | 1 |
| Ardea RDEA594-301 | Gout | Lesinurad | 2011 | 3 |
| Ardea RDEA3170-207 | Gout | Febuxostat | 2016 | |
| SELECTA SEL-037 | HIGH URIC ACID LEVELS | SEL-037 | 2015 | 5 |
| Takeda FEB-XR_301 | Gout | Febuxostat | 2015 | 7 |
| Takeda TMX-67_301 | Gout | Febuxostat | 2016 | 31 |
| Takeda FEB-XR_201 | Gout | Febuxostat | 2015 | 1 |
| Selecta SEL-212/101 PHASE 1 | Gout | SEL-212 | 2016 | 3 |
| Selecta SEL-212/201 | Gout | SEL-212 | 2018 | 1 |
| Recipe – Dr. Saag | Gout | KRYSTEXXA | 2019 | 7 |
| SELECTA SEL-212/202 | Gout | Krystexxa | 2020 | 2 |
| Ampel AMP-001 | Gout | Pegloticase | 2020 | 15 |
| LG CHEM LG-GDCL002 | Gout | LC350189 | 2020 | 3 |
| Horizon HZNP-KRY-202 | Gout | Krystexxa/Pegloticase | 2020 | 5 |
| | | | | |
| Centocor | Giant Cell Arteritis | Infliximab | 2004 | 4 |
| | | | | |
| Merck 205 | Normal Subjects | Alendronate Sodium | 2001 | 17 |
| Pfizer A3471019 | Healthy Elderly | Bextra® | 2002 | 32 |
| Pharmacia 258 | Healthy Subjects | Celecoxib | 2002 | 30 |

| | | | | |
|---|---|---|------|-----|
| Pfizer A9451141 | Healthy | Gabapentin | 2004 | 108 |
| Pfizer A3191171 | Healthy | Celebrex | 2004 | 40 |
| ARRAY ARRAY-797-101 PHASE 1 | Healthy | ARRY-371797 | 2006 | 36 |
| PLX Pharma | Healthy – on Aspirin | Aspirin-PC (ASA-PC) | 2009 | 23 |
| Regeneron R375-PN-0817 PHASE 1 | Healthy | REGN 475 | 2009 | 19 |
| Primus PIV-01 with Influenza Shot | Healthy | Botanical Source | 2013 | 44 |
| Primus BCPS-01 | Healthy | Botanical Source | 2013 | 27 |
| AggreGuide VAL0085 | Healthy | ADP Assay for Antiplatelet Drugs | 2018 | 49 |
| Navidea NAV3-35 | Healthy | Tc 99m Tilmanocept | 2021 | 39 |
| | | | | |
| Berlex | Hot Flushes | HRT | 1998 | 2 |
| | | | | |
| Pharmacia | Hypercholesterolemia | SD-5613 | 2001 | 11 |
| AstraZeneca 4522US/0003 | Hypercholesterolemia | Rosuvastatin, Atorvastatin, Simvastatin | 2002 | 2 |
| AstraZeneca 4522US/0011 | Cardiovascular Events in Low to Normal Level of LDL-C & CRP | Crestor® | 2004 | 0 |
| Abbott M05-749 | Hyperlipidemia | Fenofibric Acid | 2006 | 4 |
| Abbott – KOS Life Sciences 019-05-06-CR | Hyperlipidemia | Niacin ER & Zocor | 2006 | 12 |
| Abbott M10-229 | Hyperlipidemia | Niaspan | 2008 | 4 |
| Abbott M10-275 | Dyslipidemia | ABT-335 | 2008 | 2 |
| Abbott M10-667 | Hypercholesterolemia | ABT-143 | 2008 | 13 |
| ABBOTT M10-313 | DYSLIPIDEMIA | ABT-335 | 2010 | 4 |
| Amgen 20101154 | Hyperlipidemia | AMG 145 | 2011 | 11 |
| Pfizer B1481005 | Hyperlipidemia | PF-04950615 | 2011 | 3 |
| Pfizer B1481012 | Hyperlipidemia | PF-04950615 | 2011 | 0 |
| Pfizer B1481015 | Hyperlipidemia | PF-04950615 | 2012 | 11 |
| Amgen 20110109 | Hyperlipidemia | AMG 145 | 2012 | 9 |
| Amgen 20110114 | Hyperlipidemia | AMG 145 | 2012 | 8 |
| Sanofi LTS11717 | Hyperlipidemia | REGN727/SAR23655 3 | 2011 | 1 |
| Amgen 20110115 | Hyperlipidemia | AMG145 | 2013 | 9 |
| Amgen 20120348 | Hyperlipidemia | AMG145 | 2013 | 5 |
| Amgen 20120356 | Hyperlipidemia | AMG 145 | 2013 | 4 |
| Regeneron R727-CL-1532 | Hyperlipidemia | Praluent | 2018 | 1 |
| Pfizer B1481020 | Hyperlipidemia | PF-04950615 | 2013 | 4 |
| | Hyperlipidemia | | | |
| | | | | |
| Berlex | Hyperplasia | HRT | 1998 | 4 |
| | | | | |
| Bristol Myers Squibb | Hypertension | Omapatrilat or Enalapril | 2000 | 4 |
| Pharmacia 145 | Hypertension | Celecoxib vs Rofecoxib | 2001 | 11 |

| | | | | |
|---------------------------------------|------------------------------------|------------------------|------|-------------------------|
| Alteon | Hypertension | ALT-711 | 2002 | 3 |
| NicOx HCT3012-X-104 | Hypertension with ABP | HCT 3012 | 2006 | Sponsor Cancelled |
| Novartis CVAH631BUS06 | Obese HTN | HCTZ | 2006 | 1 |
| | | | | |
| Sepracor | Adult Insomnia | Zopiclone | 2001 | 8 |
| Sepracor | Geriatric Insomnia | Zopiclone | 2001 | 5 |
| Neurocrine Biosciences | Insomnia | NBI-34060 | 2002 | 6 |
| Neurocrine Biosciences | Primary Insomnia | NBI-34060 | 2002 | 5 |
| GlaxoSmithKline MAD103894 | Insomnia | GW679769 | 2006 | 0 |
| Sepracor 190-904 | Insomnia | Eszopiclone | 2007 | 4 |
| Merck 009-00 | Insomnia | MK-0822 | 2010 | 6 |
| | | | | |
| Lilly/Boehringer Ingelheim | Female Stress Urinary Incontinence | Duloxetine HCl | 2003 | 10 |
| | | | | |
| Glaxo-Wellcome | Irritable Bowel Syndrome | Alosetron | 1999 | 3 |
| Forest | Irritable Bowel Syndrome | Dexloxyglumide | 2002 | 3 |
| GlaxoSmithKline | IBS in Females | Alosetron | 2003 | 2 |
| | | | | |
| Orthobiotech | Chronic Kidney Disease | Epoetin Alfa | 2006 | 5 |
| Amgen 20110226 | Chronic Kidney Disease | Darbepoetin | 2012 | 0 |
| | | | | |
| LaJolla – LJP | Lupus | LJP - 394 | 2000 | 3 |
| Genelabs | Lupus | Prestara™ | 2003 | 2 |
| LaJolla LJP394-90-14 | Lupus | LJP394 | 2004 | 2 |
| LaJolla LJP394-90-16 | Lupus | ABETIMUS SODIUM | 2004 | Sponsor Closed Study |
| Genentech U2971g | Lupus | Rituximab | 2005 | 0 |
| MEDIMMUNE MI-CP126 | Lupus | MEDI-545 | 2006 | 1 |
| Schering Plough P03722 PHASE 1 | Lupus | IL-10 | 2006 | 13 |
| Human Genome Sciences | Lupus | Belimumab | 2007 | 6 |
| Amgen 20060203 PHASE 1 | Lupus | AMG 811 | 2007 | 6 |
| Genentech IFN3958g | Lupus | rhuMAb IFNalpha | 2007 | 0 |
| MedImmune MI-CP179 | Lupus | MEDI-545 | 2008 | 1 |
| Wyeth 3227K2-1002-NA | Lupus | SIB-087 | 2010 | 10 |
| AMGEN 20060132 | Lupus | AMG 557 | 2010 | 21 |
| AMGEN 20070283 | Lupus | AMG 811 | 2008 | 7 |
| Cephalon C33457/2047 | Lupus | CEP-33457 | 2011 | 1 |
| Argos Novo Nordisk AGS-009-001 | Lupus | NNC0152-0000-0001 | 2011 | 7 |
| AMGEN 20060169 | Lupus | AMG 557 | 2011 | 6 |
| CENTOCOR CNTO136LUN2001 | Lupus | CNTO 136 | 2011 | 0 |
| Lilly H9B-MC-BCDT | Lupus | LY2127399 | 2013 | 5 |

| | | | | |
|---------------------------|---|---------------------------------|------|----|
| HGS 1006-C1115 BLISS | LUPUS | BELIMUMAB | 2013 | 0 |
| UCB SL0009 | LUPUS | EPRATUZUMAB | 2014 | 3 |
| LILLY H9B-MC-BCEI | LUPUS | LY2127399 | 2014 | 5 |
| Janssen NOCOMPOUNDLUP0001 | LUPUS Rash | No Drug | 2014 | 1 |
| HGS 1006-C1117 | Lupus | Belimumab Vaccine | 2014 | 1 |
| GSK 200339 | LUPUS | BELIMUMAB | 2014 | 2 |
| RESOLVE PHASE 1B 132-02 | LUPUS | RSLV-132 | 2014 | 4 |
| INVION PHASE 1 | LUPUS | INV103/Ala-chaperonin 10 | 2013 | 4 |
| BIOGEN 230LE101 | LUPUS | BIIB059 | 2016 | 1 |
| CELGENE CC-220-SLE-001 | LUPUS | CC-220 | 2017 | 1 |
| HGS1006-C1113 | LUPUS | BELIMUMAB | 2017 | 11 |
| XENCOR XmAb5871-04 | LUPUS | XmAb5871 | 2017 | 1 |
| Mallinckrodt | LUPUS | MNK14304067 | 2019 | 1 |
| AstraZeneca D3461R00001 | LUPUS OBSERVATIONAL | OBSERVATIONAL | 2019 | 5 |
| Nektar 17-358-02 | LUPUS | NKTR-358 | 2019 | 2 |
| HGS1006-C1124 | LUPUS | BENLYSTA | 2020 | 26 |
| Amgen 20170103 | LUPUS | AMG 592 | 2020 | 5 |
| Idorsia ID-064A202 | LUPUS | Cenerimod | 2021 | 1 |
| Amgen 20170103 | LUPUS | AMG592 | 2021 | 5 |
| | | | | |
| Abbott M03-598 | Metabolic Syndrome | Tarka® & Hyzaar® | 2004 | 2 |
| | | | | |
| Biogen (Phase 1) 101MS101 | Multiple Sclerosis | Natalizumab | 2006 | 4 |
| | | | | |
| Searle | NSAID-Induced GI (MUCOSA) | NSAID | 1991 | 78 |
| AstraZeneca 286 | NSAID associated Gastric Ulcers when Daily NSAID is continued | NEXIUM | 2001 | 2 |
| AstraZeneca 288 | NSAID associated Gastric Ulcers when daily NSAID is D/C | NEXIUM | 2001 | 3 |
| AstraZeneca 289 | Prevention of Gastric Ulcers with daily NSAID use | NEXIUM | 2001 | 59 |
| Pozen PN200-301 | Patients at Risk for Developing NSAID associated Ulcers | PN200 | 2006 | 38 |
| Horizon HZ-CA-303 | For Patients Requiring NSAIDs | HZT-501 | 2006 | 97 |
| Pozen PN400-302 | NSAID Induced Ulcers | PN400 | 2007 | 36 |
| Pozen PN400-304 | NSAID Induced Ulcers | PN400 | 2007 | 24 |
| Pozen PN400-303 | NSAID Induced Ulcers | PN400 | 2007 | 1 |
| Pozen PN400-301 | NSAID Induced Ulcers | PN400 | 2007 | 2 |
| Sucampo SPI/8811SU-0621 | Prevention of Ulcers | PI-8811 | 2008 | 44 |
| Horizon HZ-CA-401 | NSAID | HZT-501 | 2009 | 36 |
| Logical LT-NS001-003 | Gastric Ulcers | LT-NS001 | 2010 | 25 |
| Pozen PA32540-302 | Gastric Ulcers | PA32540 | 2011 | 9 |
| | | | | |

| | | | | |
|--------------------------|--|-------------------------|------|----|
| Pfizer 1008-160 | Disturbed Sleep from Neuropathic Pain | Pregabalin | 2000 | 2 |
| Pfizer 1008-174 | Open Label Disturbed Sleep from Neuropathic Pain | Pregabalin | 2000 | 1 |
| GlaxoSmithKline A1A20004 | Peripheral Neuropathic Pain | GW493838 | 2002 | 1 |
| NeurogesX | Neuropathic Pain | NGX 4010 | 2004 | 4 |
| | | | | |
| Sanofi-Synthelabo | Obese Patients with Dyslipidemia | SR141716 | 2001 | 10 |
| Merck 006 | Obesity | L-000899055 | 2004 | 15 |
| Merck 015 | Obesity | L-000899055 | 2005 | 26 |
| Merck 012 | Obesity | MK-0364 | 2006 | 24 |
| Orexigen NB-CVOT | Obesity | Naltrexone/Bupropion SR | 2012 | 53 |
| EISAI APD356-G000-401 | Weight Loss | BELVIQ | 2014 | 6 |
| | | | | |
| SmithKline Beecham | Osteoarthritis | NSAID | 1991 | 14 |
| Chiesi | Osteoarthritis | NSAID | 1995 | 34 |
| Searle | Osteoarthritis | Cox II | 1996 | 20 |
| Searle | OA Knee | NSAID | 1992 | 16 |
| Searle | Osteoarthritis 021 | Cox II | 1996 | 50 |
| Merck | Osteoarthritis 029 | Cox II | 1996 | 37 |
| Searle | Osteoarthritis 033 | Arthrotec | 1997 | 62 |
| Searle | Osteoarthritis of the Hip | Cox II | 1996 | 20 |
| Merck 029 | OA Knee/Hip | Cox II | 1996 | 28 |
| Merck 029 | OA Knee or Hip | Cox II | 1996 | 17 |
| Hyal | OA Knee | Gel | 1997 | 23 |
| Searle | OA Knee | Cox II | 1997 | 40 |
| Searle 087 | OA Knee | Cox II | 1998 | 22 |
| Merck | OA of the Knee/Hip | Cox II | 1997 | 22 |
| Boehringer Ingelheim | OA Knee/Hip | Meloxicam/Diclofenac | 1997 | 18 |
| Parke-Davis | Osteoarthritis | Gabapentin | 1998 | 5 |
| Parke-Davis | Osteoarthritis | Gabapentin | 1998 | 14 |
| Merck | Osteoarthritis 083 | Cox II | 1998 | 29 |
| Merck | OA Knee | Cox II | 1998 | 28 |
| Merck | OA Knee | Cox II | 1998 | 23 |
| RW Johnson | OA Knee | RWJ57504 | 1998 | 12 |
| Roche | Osteoarthritis | Trocade | 1998 | 7 |
| Parke-Davis | Osteoarthritis | Pregabalin | 1998 | 22 |
| Searle | Osteoarthritis | Oxaprozin Potassium | 1998 | 20 |
| Chiesi | Osteoarthritis | Piroxicam | 1998 | 28 |
| Searle | Osteoarthritis 031 | Cox II | 1998 | 75 |
| MacroChem | OA Knee | Topical Ibuprofen Gel | 1998 | 27 |
| Merck | OA Knee | Cox II | 1999 | 20 |
| Merck 452 | OA Knee | Cox II | 1998 | 30 |

| | | | | |
|---------------------|--------------------------|--------------------------------|------|----|
| Parke-Davis | Osteoarthritis | Darbufelone | 1999 | 32 |
| Parke-Davis | Osteoarthritis Extension | Darbufelone | 1999 | 18 |
| Searle | Osteoarthritis GI 048 | Valdecoxib | 1999 | 30 |
| Searle | Osteoarthritis GI 049 | Valdecoxib | 1999 | 13 |
| Searle | Osteoarthritis GI 053 | Valdecoxib | 1999 | 45 |
| Zeneca | OA Hip or Knee | ZD6416 | 1999 | 12 |
| Abbott | OA Knee | ABT594 | 1999 | 21 |
| Merck | OAKnee | Cox II | 1999 | 19 |
| Roberts | OA Hip or Knee | Propiram/Tramadol | 1999 | 89 |
| Merck | Osteoarthritis GI 029 | Cox II | 1999 | 42 |
| Searle 149 | Osteoarthritis HTN | Cox II | 1999 | 15 |
| Parke-Davis | OA Knee | Gabapentin | 1999 | 54 |
| Parke-Davis | OA Knee - Open Label | Gabapentin | 1999 | 33 |
| Purdue | OA Hip or Knee | Buprenorphine | 1999 | 6 |
| Merck 116 | OA Hip or Knee | Cox II | 1999 | 22 |
| Roxanne | Osteoarthritis | Oxycodone | 2000 | 18 |
| Searle | Hypertension with OA | Celecoxib vs Rofecoxib | 2000 | 34 |
| Noven | Osteoarthritis | Ketoprofen Patch | 2000 | 15 |
| United Therapeutics | OA Knee | Ketotop | 2000 | 21 |
| Biovail | OA Knee | Tramadol | 2000 | 32 |
| Merck 136 | OA with Ulcers | MK-0966 | 2000 | 79 |
| Pharmacia/Pfizer | OA Knee | Compare Celecoxib to Rofecoxib | 2001 | 18 |
| Endo EN3231-M030 | OA with Chronic Pain | DEXTROMETHORPHAN | 2001 | 76 |
| Pharmacia/Pfizer | OA with HTN and DM | Celecoxib, Rofecoxib | 2001 | 16 |
| Pfizer TINE | Osteoarthritis | CP-544,439 | 2001 | 16 |
| Merck 150 | OA Knee | Rofecoxib | 2001 | 28 |
| Dimethaid | OA Knee | PENNSAID | 2001 | 17 |
| Forest Laboratories | OA Knee | ML3000 | 2001 | 35 |
| Novartis 0109 | OA Knee | COX189 | 2001 | 35 |
| Searle 158 | OA Knee | Celecoxib | 2001 | 58 |
| Pharmacia 010 | OA Hip or Knee | Celecoxib | 2001 | 17 |
| Pharmacia | OA Knee | Valdecoxib/Celecoxib | 2001 | 21 |
| Novartis 0117 | Osteoarthritis | COX189 | 2001 | 23 |
| Forest 03 | OA of Knee or Hip | ML3000 | 2001 | 32 |
| Pfizer 1045-0008 | OA Hip or Knee | CI-1045 | 2001 | 14 |
| Forest 02 | OA Knee or Hip | ML3000 | 2002 | 23 |
| Shire | OA Knee or Hip | Dirame™ | 2002 | 6 |
| Novartis 2332 | Osteoarthritis | COX189 | 2002 | 35 |
| AstraZeneca 0010 | OA Knee | AR-P900758XX | 2002 | 45 |
| Pharmacia 142 | OA Knee | Valdecoxib | 2002 | 35 |
| Pharmacia 249 | OA Knee or Hip | Celecoxib | 2002 | 20 |

| | | | | |
|-----------------------------|-----------------------------------|---|------|----|
| McNeil 00-103 | OA Knee or Hip | Acetaminophen | 2002 | 16 |
| Merck 061-00 | Osteoarthritis | Etoricoxib vs Diclofenac | 2002 | 16 |
| Merckle ML3-MD-01 | OA Knee | ML3000 | 2002 | 15 |
| Grunenthal KF5503/09 | OA Hip or Knee | CG5503 or Oxycodone | 2002 | 16 |
| McNeil 98-055 | OA Hip or Knee | Acetaminophen and Naproxen | 2002 | 4 |
| Merck 065 | Cardiac Biomarkers in Pts with OA | Etoricoxib vs. Celecoxib, Ibuprofen | 2002 | 22 |
| Biovail B02.CT3.023.TRA P02 | OA Hip and/or Knee | Tramadol HCI ER | 2002 | 40 |
| Pharmacia 008 | OA Knee | SD-6010 | 2003 | 27 |
| Purdue OXY4003 | OA Hip or Knee | OxyContin® | 2003 | 16 |
| Merck 071 | Osteoarthritis | Etoricoxib | 2003 | 35 |
| Purdue BUP3012 | OA Hip or Knee | BTDS | 2003 | 19 |
| Alticor | OA Knee | Magna Bloc™ | 2002 | 9 |
| Labopharm | OA Knee | Tramadol HCI | 2003 | 17 |
| Tap LAN-0003-0041 | OA | Celebrex - Naproxen | 2003 | 97 |
| Sanofi L8445 | OA with Insomnia | Zolpidem | 2003 | 8 |
| Pfizer A4141004 | OA Knee | CI-1027 | 2003 | 29 |
| Novartis 2360 | OA Knee | Lumiracoxib | 2003 | 12 |
| Pfizer A3191082 | OA Knee | Celebrex | 2003 | 6 |
| Purdue 3011 | Osteoarthritis Pain | Buprenorphine | 2003 | 4 |
| McNeil 00-104 | OA Hip or Knee | Acetaminophen ER | 2004 | 7 |
| Pfizer A6171009 | OA Knee | SD-6010 | 2004 | 20 |
| Amgen 20040100 | OA Knee | Anakinra | 2004 | 9 |
| Pfizer A3191152 | OA Knee | Celebrex & Naproxen | 2004 | 16 |
| J & J R3313333-PA1-2001 | OA Knee | CG5503 | 2004 | 8 |
| Endo EN3220-012 | OA Knee | Lidocaine Patch | 2004 | 20 |
| Wyeth TD-04-02 | OA Knee | TDS-943 | 2004 | 13 |
| Pfizer A5231011 | OA Knee | CJ-023,423 | 2004 | 18 |
| Labopharm MDT3-005 | Osteoarthritis | Tramadol | 2004 | 11 |
| Genzyme SYVN-004-02 | OA Hip | Synvisc® | 2004 | 9 |
| Novartis COX189A2367 | OA Hip | Lumiracoxib | 2004 | 13 |
| Sanofi L-9385 | OA Knee | Hyalgan | 2004 | 13 |
| Novartis VOSG-PN-304 | OA Knee | Diclofenac Gel | 2004 | 2 |
| GlaxoSmithKline CXA30007 | OA Knee | GW406381 | 2005 | 7 |
| McNeil 17-007 | OA Knee | IDEA-033/23 (Ketoprofen in Transfersome®) | 2005 | 13 |
| Endo EN3260-001 | OA Knee | Lidocaine 5% | 2005 | 16 |
| Pfizer A3191173 | OA Knee | Celecoxib | 2005 | 12 |
| Pfizer A5231001 | OA Knee | CJ-023,423 | 2005 | 27 |
| Purdue BUP3019 | Osteoarthritis (Severe) | BTDS and OxyIR® | 2005 | 0 |
| Regeneron 0425 | OA Knee | IL-1 Trap | 2005 | 18 |

| | | | | |
|---|------------------------------------|---------------------------------|------|---------------------------------|
| NicOx | OA Knee | HCT3012 | 2005 | 29 |
| Abbott M04-697 | Osteoarthritis | Vicodin | 2005 | 18 |
| Primus | OA Knee | Limbrel | 2006 | 39 |
| Seikagaku SI-6606/01 PHASE 1 | OA Knee | Synvisc or GEL-200 | 2006 | 18 Double Blind 7 Open Label |
| BIONICARE | OA Knee | Knee Device | 2006 | 10+ |
| Astellas 04-0-211 | OA Knee | FK555 | 2006 | 35 |
| FLEXX FPI-EUFLX-2005-01D PHASE 1 | OA Knee | EUFLEXXA | 2006 | 11 |
| Wyeth 3175A1-202-WW | OA Knee | PLA-695 | 2006 | 20 |
| Johnson & Johnson R331333-PAI-3002 | Pts. Waiting for Joint Replacement | CG5503 | 2006 | 4 |
| Pfizer A6341008 | OA Knee | CE-224,535 | 2006 | 16 |
| Rinat RN624-CL006 | OA Knee | RN624 | 2006 | 4 |
| Wyeth 3189A1-104-US PHASE 1 | OA | AGG-523 | 2006 | 10 |
| Alpharma ALO-KNT-301 | OA Hip or Knee | Kadian NT | 2006 | 9 |
| Alpharma ALO-KNT-202 | OA Hip or Knee | Kadian NT | 2006 | 13 |
| Amgen 20060145 PHASE 1 | OA Knee | AMG 403 | 2007 | 4 |
| NicOx HCT3012-X-302 | OA Knee | Naproxcinod | 2007 | 11 |
| Merck 057-00 | OA | Ibuprofen | 2007 | 17 |
| Zars ZMK-301 | OA Knee | ThermoProfen | 2007 | 24 |
| Endo EN3260-003 | OA Knee | Lidocaine | 2007 | 11 |
| Johnson and Johnson R331333-PAI-3008 | OA Knee | CG5503 | 2007 | 6 |
| Wyeth TD-07-14A | OA Knee | TDS-943 | 2007 | 21 |
| Pfizer A6171016 | OA Knee | SD-6010 | 2007 | 12 |
| Combinatorx CRx-102-006 | OA Knee | CRx-102 | 2007 | 3 |
| Neuromed NMT 1077-302 | OA | NMED-1077 | 2007 | 9 |
| Nicox HCT3012-X-303 | OA Hip | Naproxcinod | 2008 | 5 |
| Hisamitsu HKT-500-US12 | OA Knee | HKT-500 | 2007 | 24 |
| Nicox HCT3012-X-111 | OA with HTN | Naproxcinod | 2008 | 5 |
| Pozen PN400-307 | OA Knee | PN 400 | 2008 | 8 |
| IDEA CL-033-III-06 | OA Knee | Ketoprofen | 2008 | 10 |
| Merck 105-00 | OA Knee | Naproxen and Ultracet | 2008 | 16 |
| Anika 0702 | OA Knee | Monovisc | 2008 | 19 |
| Purdue BUP3025 | OA Knee | BTDS | 2008 | 9 |
| Pfizer A4091011 | OA Knee | Tanezumab | 2008 | 18 |
| Pfizer A4091014 | OA Hip | Tanezumab | 2008 | 9 |
| Johnson and Johnson R331333-PAI-2020 | OA (End Stage Joint Disease) | Tapentadol IR & Oxycodone IR | 2008 | 8 |
| Regeneron R475-PN-0901 | OA | REGN 475 | 2009 | 19 |
| Pfizer GI Reasons A3191331 | OA | Celebrex | 2007 | 23 |
| Johnson and Johnson 42160443PAI2004 | OA Knee or Hip | JNJ 42160443 | 2009 | 8 |
| Pfizer A4091015 | OA Knee | Tanezumab | 2009 | 16 |
| Adolor 44CL240 | OA Knee | ADL5859 & ADL5747 | 2010 | 22 |

| | | | | |
|-----------------------------|----------------|-------------------------------|------|----|
| Pfizer A4091026 | OA | Tanezumab | 2010 | 13 |
| Pfizer A4091030 | OA Knee or Hip | Tanezumab | 2010 | 13 |
| Pfizer A4091027 | OA Knee | Tanezumab | 2010 | 5 |
| Bayer 15256 | OA Knee | UC-11 | 2010 | 7 |
| LILLY F1J-US-HMGL | OA KNEE | Duloxetine | 2010 | 8 |
| STRYKER 09-OA-002 | OA KNEE | BMP-7 | 2010 | 19 |
| LILLY TREADMILL H7L-MC-TRED | OA Knee | NAPROSYN | 2010 | 24 |
| NOVARTIS CACZ885C2201 | OA Knee | CANAKINUMAB | 2010 | 46 |
| ABBOTT M10-889 | OA KNEE | ABT 652 | 2010 | 18 |
| J & J 42160443PAI2006 | OA KNEE | JNJ-42160443 | 2010 | 2 |
| Iroko DIC3-08-05 | OA KNEE | Diclofenac Nanoformulation | 2011 | 25 |
| ABBOTT M13-237 | OA KNEE | ABT 652 | 2011 | 11 |
| ARRAY 797-223 | OA KNEE | ARRY-371797 | 2011 | 5 |
| IROKO DIC3-08-05 | OA KNEE OR HIP | DICLOFENAC NANOFORMULATION | 2011 | 25 |
| IROKO DIC3-08-06 | OA KNEE | DICLOFENAC | 2011 | 21 |
| NOVUM DCL-269 | OA KNEE | DICLOFENAC SODIUM | 2011 | 2 |
| Fidia R29-09-02 | OA KNEE | Hymovis | 2012 | 14 |
| FLEXION FX-006-2011-001 | OA KNEE | FX006 TO KENALOG | 2011 | 2 |
| Purdue VND2001 | OA Knee | V116517 | 2012 | 22 |
| Nektar 12-181-04 | OA Knee | NKTR-181 | 2012 | 13 |
| Iroko MEL33-12-03 | OA Knee or Hip | Meloxicam | 2013 | 7 |
| Ampio AMP-003-A | OA Knee | Ampion | 2013 | 15 |
| Iroko MEL3-12-02 | OA Hip or Knee | Meloxicam | 2013 | 1 |
| Q-MED Dusk 35GA1203 | OA Knee | Durolane | 2013 | 4 |
| XOMA X052162 | OA HAND | GEVOKIZUMAB | 2013 | 4 |
| XOMA X052160 | OA HAND | GEVOKIZUMAB | 2012 | 6 |
| Afferent AF219-004-OA | OA Knee | AF 219 | 2013 | 7 |
| Forest GRT-MD-101 | OA KNEE | GRT6005 | 2013 | 13 |
| Flexion FX006-2013-005 | OA Knee | FX006 | 2013 | 26 |
| Ampio AP-004-A | OA Knee | Ampion | 2014 | 15 |
| Charleston CLCT-006 | OA KNEE OR HIP | CCX168 | 2014 | 9 |
| GENZYME SYN04910/EFC12791 | OA HIP | SYNVISC | 2014 | 9 |
| Samumed | OA | SM04690 | 2014 | 4 |
| Flexion FX006-2014-006 | OA Knee | FX006 | 2015 | 13 |
| TECHFIELDS TF-X0002-21 | OA KNEE | X0002 | 2013 | 5 |
| SEIKAGAKU GEL/1133 | OA KNEE | GEL ONE | 2014 | 8 |
| AbbVie M13-741 | OA KNEE | ABT-981 | 2015 | 2 |
| GLAXOSMITHKLINE RHO2448 | OA | PARACETAMOL | 2015 | 3 |
| CARA CR845-CLIN2001-PO | OA HIP OR KNEE | CR845 | 2015 | 24 |
| Regeneron R475-PN-1227 | OA HIP OR KNEE | FASINUMAB | 2015 | 7 |

| | | | | |
|--|---|------------------------------------|------|----|
| Flexion FX006-2014-008 | OA KNEE | FX006 | 2015 | 8 |
| AbbVie M14-171 | OA Hand | ABT-981 | 2016 | 6 |
| CYTORI ACT-OA | OA KNEE | Adipose Derived Regenerative Cells | 2016 | 6 |
| SAMUMED SM04690-OA-02 | OA KNEE | SM04690 | 2016 | 5 |
| CENTREXION 4975-OA-502 | OA KNEE | CNTX-4975 | 2016 | 2 |
| FLEXION FX006-2015-009 | OA KNEE | FX006 | 2016 | 13 |
| Vertex VX15-150-101 | OA Knee | VX-150 | 2016 | 17 |
| Cara Therapeutics | OA Hip or Knee | CR845 | 2017 | 15 |
| GSK 204851 | OA Hands | GSK3196165 | 2017 | 1 |
| Pfizer A4091058 | OA Hip or Knee | Tanezumab | 2017 | 3 |
| Samumed SM04690-OA-04 | OA Knee | SMO4690 | 2017 | 5 |
| 3V Medical | OA Knee | 3vM1001 Cream | 2017 | 50 |
| Flexion FX006-2017-012 | OA Knee | FX006 | 2018 | 10 |
| Seikagaku Corp. 613/1121 | OA Knee | SI-613 | 2018 | 5 |
| Flexion FX006-2017-013 | OA Shoulder or Hip | FX006 | 2018 | 7 |
| Regeneron R475-PN-1612 | LBP and OA Hip or Knee | Fasinumab | 2018 | 1 |
| Unity UBX0101-OAR-101 | OA KNEE | UBX0101 | 2019 | 14 |
| Galapagos CL2-201086-002/GLPG1972-CL-201 | OA Knee | S201086/GLPG1972 | 2019 | 9 |
| Regeneron R475-PN-1523 | OA Knee or Hip | Fasinumab | 2019 | 3 |
| Regeneron R475-OA-1611 | OA Knee or Hip | Fasinumab | 2019 | 5 |
| Primus POAC-01 | OA Hip or Knee | PC-010 | 2019 | 30 |
| Flexion FX006-2017-014 | OA Knee | FX006 | 2019 | 24 |
| Ampio AP-013 | OA Knee | Ampion | 2020 | 74 |
| Flexion FX006-2018-016 | Glenohumeral OA or Shoulder Adhesive Capsulitis | FX006 | 2020 | |
| Unity UBX0101-MUS-201 | OA KNEE | UBX0101 | 2020 | 11 |
| Calibr CBR-KA34-3001 | OA Knee | KA34 | 2020 | 12 |
| TAIWAN LIPOSOME TLC 599A3005 | OA KNEE | TLC599 | 2020 | 3 |
| SAMUMED SM04690-OA-11 | OA KNEE | SM04690 | 2020 | 1 |
| SAMUMED SM04690-OA-15 | OA KNEE – | RADIOGRAPHIC SCREENING STUDY | 2020 | 17 |
| SAMUMED SM04690-OA-10 | OA KNEE | SM04690 | 2020 | 1 |
| Novartis CLNA043X2202 | OA KNEE | LNA043 | 2021 | 0 |
| Samumed SM04690-OA-10 | Osteoarthritis | SM04690-OA-10 | 2021 | 1 |
| | | | | |
| Searle | OA or RA | Cox II | 1997 | 53 |
| Searle 062 | OA or RA | Cox II | 1997 | 36 |
| Searle 035 - CLASS | OA or RA | Cox II | 1998 | 50 |
| Searle | OA or RA | Cox II | 1999 | 50 |
| Merck 141 | Biomarkers of Inflammation in RA/OA | No Drug | 2001 | 94 |
| Merck 066 | OA or RA | Etoricoxib | 2002 | 99 |

| | | | | |
|-----------------------------|----------------------------------|-----------------------------|------|----|
| Merck 003 | OA or RA | L-001069957 | 2004 | 26 |
| Pfizer (Precision) A3191172 | OA or RA | Celecoxib | 2006 | 65 |
| | | | | |
| Procter & Gamble | Osteoporosis | Risedronate | 1994 | 63 |
| Parke-Davis | Osteoporosis Prevention | HRT | 1998 | 5 |
| Pfizer | Osteoporosis | Droloxifene | 1998 | 7 |
| Aventis (HMR) | Osteoporosis | Risedronate | 1999 | 26 |
| NPS/Allelix | Osteoporosis | PTH | 2000 | 20 |
| Merck 005 | Osteoporosis | L-845704 | 2000 | 22 |
| Merck | Glucocorticoid-Induced Bone Loss | Alendronate | 2001 | 9 |
| Wyeth Ayerst 300 | Osteoporosis Prevention | TSE-424 | 2001 | 16 |
| P & G and Aventis | Osteoporosis | Risedronate | 2001 | 17 |
| Pfizer-Bones | Osteopenia | Atorvastatin | 2001 | 13 |
| Pharmacia 200 | Osteopenia | Celecoxib | 2001 | 3 |
| Wyeth Ayerst 301 | Osteoporosis | Bazedoxifene Acetate | 2001 | 3 |
| Organon | Osteoporosis | Tibolone | 2002 | 5 |
| Novartis 2301 | Osteoporosis | Zoledronic Acid | 2002 | 4 |
| Lilly B3D-MC-GHCD | Osteoporosis | Teriparatide and Raloxifene | 2002 | 12 |
| Amgen 20010223 | Low Bone Mineral Density | AMG 162 | 2002 | 12 |
| Merck 211 (FACT) | Osteoporosis | Alendronate Risedronate | 2002 | 17 |
| Merck 227 | Osteoporosis | Alendronate | 2003 | 15 |
| Roche MA17843 | Osteoporosis | Ibandronate | 2004 | 21 |
| Aventis HMR4003B/4034 | Osteoporosis | Teriparatide | 2004 | 1 |
| Lilly B3D-US-GHCQ | Osteoporosis | Arzoxifene | 2004 | 9 |
| Amgen 20040132 | Osteopenia | AMG162 | 2004 | 1 |
| Amgen 20030216 | Osteoporosis | AMG162 | 2004 | 0 |
| Lilly | OP Observational | Forteo® | 2004 | 20 |
| GlaxoSmithKline BON103593 | Osteoporosis | Ibandronate | 2005 | 15 |
| Merck 230 | Osteoporosis | MK-217A | 2005 | 1 |
| Amgen 20050141 | Osteoporosis | Denosumab | 2006 | 9 |
| Roche MA19547 (Balto III) | Osteoporosis | Boniva vs Actonel | 2006 | 22 |
| Amgen 20050241 (Phase 1) | Osteoporosis | Denosumab | 2006 | 18 |
| GlaxoSmithKline BON05960 | Osteoporosis for men | Boniva | 2006 | 13 |
| Deltanoid 2MD-3H-2B | Osteoporosis | DP001 | 2006 | 12 |
| GlaxoSmithKline CR9108963 | Osteoporosis | SB-751689 | 2007 | 9 |
| Primus FOS-01 PHASE 1 | Osteopenia | Fosteum | 2007 | 20 |
| Amgen 20060221 | Osteopenia Men | AMG 785 | 2007 | 15 |
| Amgen 20060223 PHASE 1 | Osteopenia | AMG 785 | 2008 | 28 |
| Roche BA20341 | Osteoporosis / Renal Involvement | Ibandronate | 2008 | 4 |
| Merck 042.00 | Osteoporosis | MK-0822 | 2009 | 3 |

| | | | | |
|---|--------------------------------|------------------------------|------|-------------------|
| Unigene/Tarsa UGL-OR0801 | Osteoporosis | Calcitonin Nasal Spray | 2008 | 11 |
| Amgen 20080098 | Osteoporosis for Men | DENOSUMAB | 2009 | 13 |
| Merck 012-00 | Osteoporosis | MK-5442 | 2010 | 0 |
| Amgen 20080389 | Osteoporosis | AMG 167 | 2010 | 27 |
| Amgen 20080562 | Osteoporosis | AMG 162 Denosumab | 2009 | 5 |
| AMGEN 2010218 | Osteoporosis | PROLIA | 2010 | 20 |
| MERCK 053 | OP FOR MEN | ODANACATIB | 2010 | 7 |
| Novartis CBPS804A2203 PHASE 1 | Osteoporosis | BPS804 | 2012 | 4 |
| Amgen 20120187 | Osteoporosis | Denosumab | 2014 | 1 |
| Amgen 20070337 | Osteoporosis | AMG785 | 2013 | 1 |
| LILLY B3D-EW-GHDW | Osteoporosis | Teriparatide and Risedronate | 2014 | 5 |
| MERCK 076-01 | Osteoporosis | MK-0822 | 2014 | 2 |
| Amgen 20101217 | Osteoporosis | RISEDRONATE | 2015 | 4 |
| Pfenex PF708-301 | Osteoporosis | PF708 | 2017 | 11 |
| Dr. Saag – EDGE study- NIH | Osteoporosis | Bisphosphonates | 2016 | 2 |
| Amgen 201707501 | Osteoporosis | Romozosumab | 2018 | 3 |
| National Bone Health Alliance: Dr. Silverman. Biochemical Markers of Bone Turnover from Drug Holiday from Bisphosphonates | Osteoporosis | Bisphosphonates | 2018 | 2 |
| Amgen 20150120 | Osteoporosis | Romozosumab | 2018 | 2 |
| UC DAVIS LLP2A-001 | Osteoporosis | LLP2A-Alendronate | 2019 | 42 |
| Oscotec OSCOP2201 | Osteoporosis | SKI-O-703 | 2020 | 2 |
| Radius BA058-05-019 | Osteoporosis – Men | Abaloparatide – SC | 2020 | 4 |
| Sandoz CGP24112301 | Osteoporosis | GP2411 (biosimilar) | 2020 | 1 |
| Teva TVB009-IMB-30085 | Osteoporosis | TVP-009P | 2021 | 2 |
| | | | | |
| Yamanouchi | Overactive Bladder | Vesicare® | 2004 | 12 |
| Targacept TC-5214-23-CRD-003 | Overactive Bladder | Dexmecamylamine | 2013 | 2 |
| | | | | |
| Regeneron 0423 | Polymyalgia Rheumatica | IL-1 Trap | 2005 | 0 |
| | | | | |
| Trubon (PHASE 1) | Polymyositis & Dermatomyositis | TRU-015 | 2004 | 0 |
| MedImmune MI-CP151 (Phase 1) | Polymyositis & Dermatomyositis | MEDI-545 | 2008 | 2 |
| Horizon HZNP-PRE-IIS02 | Polymyalgia Rheumatica | Prednisone | 2016 | 3 |
| Kezar KZR-616-003 | Polymyositis & Dermatomyositis | KZR-616 | 2021 | 2 |
| | | | | |
| Pfizer A6061001 | Post Herpetic Neuralgia | S,S-Reboxetine | 2004 | 4 |
| Neurogesx C116 | Post Herpetic Neuroalgia | NGXZ-4010 | 2005 | 5 |
| Pfizer A6061026 | Post Herpetic Neuralgia | Reboxetine | 2006 | 2 |
| King K862-06-2001 | Post Herpetic Neuralgia | T-62 | 2007 | Sponsor Cancelled |

| | | | | |
|---|---|---------------------------------------|------|----|
| Pfizer A4091005 | Post Herpetic Neuralgia | RN624 | 2007 | 3 |
| | | | | |
| Searle | Post-Operative Pain 080 | Cox II | 1998 | 1 |
| Searle | Post-Operative Pain 086 | Cox II | 1998 | 33 |
| | | | | |
| Alexion | Psoriasis | H5F1.1-mAb | 2000 | 8 |
| Abgenix | Psoriasis | ABX-IL8 | 2000 | 22 |
| Serono | Psoriasis & Psoriatic Arthritis | Onercept | 2002 | 2 |
| Genentech | Psoriasis | Efalizumab | 2002 | 7 |
| Amgen 20030190 | Psoriasis | Enbrel® | 2004 | 13 |
| Biogen (Atlas) | Psoriasis (Safety Study) | Amevive® | 2003 | 0 |
| Genentech ACD3101g | Psoriasis Questionnaire | Raptiva | 2005 | 24 |
| Amgen 20040210 | Psoriasis (Post-Marketing Study) | Enbrel | 2006 | 10 |
| Novartis CAIN457B2102 PHASE 1 | Psoriasis | AIN457 | 2006 | 6 |
| Schering Plough PO4581 PHASE 1 | Psoriasis | SCH 900875 | 2007 | 4 |
| Wyeth 3199K2-1105 | Psoriasis | ILV-094 | 2007 | 6 |
| Novartis CAIN457A2204 | Psoriasis | AIN457 | 2008 | 2 |
| Genentech ACD3101g | Psoriasis Registry | Raptiva | 2008 | 29 |
| Schering Plough P05382 | Psoriasis | SCH 9000222 | 2010 | 4 |
| NOVARTIS CAIN457A2302 | Psoriasis | SECUKINUMAB | 2011 | 2 |
| Novartis CAIN457A2309 | Psoriasis | SECUKINUMAB | 2012 | 4 |
| Amgen 20090176 | Psoriasis Injector | Etanercept | 2013 | 15 |
| Merck MK-3222-010 | Psoriasis | SCH900222/MK-3222 | 2013 | 7 |
| Novartis CAIN457A2302 | Psoriasis | SECUKINUMAB | 2013 | 2 |
| Novartis CAIN457A2309 | Psoriasis | SECUKINUMAB | 2013 | 4 |
| Novartis CAIN457A2313 | Psoriasis | SECUKINUMAB | 2014 | 1 |
| Novartis CAIN457A2317 | Psoriasis | USTEKINUMAB | 2014 | 0 |
| KADMON KD025-206 | Psoriasis | PF-04965842 | 2015 | 5 |
| COHERUS CHS-0214-04 | Psoriasis | CHS0214 | 2014 | 1 |
| Kadmon KD025-206 | Psoriasis | KD025 | 2016 | 6 |
| Janssen CNTO1959PSO1003 | Psoriasis | CNTO 1959 | 2016 | 1 |
| Boehringer Ingelheim 1311.28 | Psoriasis | RISANKIZUMAB VERSUS USTEKINUMAB | 2015 | 2 |
| Boehringer Ingelheim 1311.12 | Psoriasis | BI 695501 | 2016 | 5 |
| Lilly I7P-MC-DSAB | Psoriasis, Palmoplantar Pustulosis, Hidradenitis Suppura | LY3041658 | 2018 | 7 |
| CELEGENE CC-9006-CP-002 Phase 1 | Psoriasis | CC-9006-CP-002 | 2018 | 2 |
| Prothena Phase 1 | Psoriasis | PRX003 | 2016 | 2 |
| Arcutis ARQ-151-301 | Psoriasis | ARQ-151 | 2020 | 10 |
| | | | | |
| Immunex | Psoriatic Arthritis | Enbrel | 2000 | 23 |

| | | | | |
|------------------------------------|---------------------|--------------------------------|------|----|
| Pharmacia 202 | Psoriatic Arthritis | Celecoxib | 2001 | 7 |
| XOMA | Psoriatic Arthritis | Efalizumab | 2003 | 17 |
| Abbott M02-570 | Psoriatic Arthritis | Humira® | 2003 | 12 |
| Centocor C0524T08 | Psoriatic Arthritis | Golimumab | 2005 | 13 |
| Bristol Myers IM101-158 | Psoriatic Arthritis | Abatacept | 2007 | 12 |
| CENTOCOR CNTO1275PSA3001 | Psoriatic Arthritis | USTEKINUMAB | 2009 | 9 |
| UCB SCHWARZ PSA001 | Psoriatic Arthritis | CERTOLIZUMAB PEGOL | 2010 | 3 |
| ROCHE PP22713/A | Psoriatic Arthritis | RO5310074 | 2010 | 2 |
| Centocor CNTO1275PSA3002 | Psoriatic Arthritis | Ustekinumab | 2011 | 8 |
| Amgen 20101227 | Psoriatic Arthritis | AMG827 | 2012 | 9 |
| Amgen 20110107 | Psoriatic Arthritis | Enbrel | 2013 | 14 |
| Celgene CC-10004-PSA-005 | Psoriatic Arthritis | Apremilast | 2012 | 6 |
| Celgene CC-10004-PSA-002 | Psoriatic Arthritis | Apremilast | 2013 | 12 |
| Bristol Myers Squibb IM133-004-006 | Psoriatic Arthritis | BMS-945429 | 2012 | 0 |
| Novartis CAIN457A2306 | Psoriatic Arthritis | SECUKINUMAB | 2011 | 6 |
| Novartis CAIN457F2312 | Psoriatic Arthritis | SECUKINUMAB | 2013 | 8 |
| LILLY IIF-MC-RHAP | Psoriatic Arthritis | LY2439821 | 2014 | 1 |
| Celgene CC-10004-PSA-006 | Psoriatic Arthritis | Apremilast | 2014 | 3 |
| Pfizer A3921091 | Psoriatic Arthritis | Tofacitinib | 2014 | 1 |
| Novartis CAIN457F2318 | Psoriatic Arthritis | Secukinumab | 2014 | 2 |
| Amgen 20090406 | Psoriatic Arthritis | Brodalumab | 2015 | 1 |
| NOVARTIS CAIN457F2336 | Psoriatic Arthritis | SECUKINUMAB | 2015 | 2 |
| PFIZER A3921125 | Psoriatic Arthritis | Tofacitinib | 2015 | 5 |
| JANSSEN CNTO148PSA3001 | Psoriatic Arthritis | Golimumab | 2016 | 2 |
| LILLY IIF-MC-RHBE | Psoriatic Arthritis | LY2439821 | 2016 | 5 |
| Novartis CAIN457F2342 | Psoriatic Arthritis | Secukinumab | 2016 | 1 |
| AbbVie 1311.5 | Psoriatic Arthritis | BI655066/ABBV-066/Risankizumab | 2016 | 5 |
| Amgen 20130207 | Psoriatic Arthritis | Etanercept | 2017 | 20 |
| UCB PA0008 | Psoriatic Arthritis | Bimekizumab | 2017 | 2 |
| Novartis CAIN457FUS01 | Psoriatic Arthritis | Secukinumab | 2017 | 5 |
| NOVARTIS CAIN457F2366 | Psoriatic Arthritis | SECUKINUMAB | 2018 | 3 |
| AbbVie M15-554 | Psoriatic Arthritis | UPADACITINIB (ABT-494) | 2019 | 20 |
| AbbVie M14-496 | Psoriatic Arthritis | ADALIMUMAB | 2019 | 5 |
| AbbVie M15-572 | Psoriatic Arthritis | UPADACITINIB | 2019 | 4 |
| BMS IM011084 | Psoriatic Arthritis | BMS-986165 | 2020 | 3 |
| AbbVie M15-998 | Psoriatic Arthritis | RISANKIZUMAB | 2020 | 5 |
| Gilead GS-US-431-4566 | Psoriatic Arthritis | FILGOTINIB | 2020 | 1 |
| Gilead GS-US-431-4567 | Psoriatic Arthritis | FILGOTINIB | 2020 | 6 |
| UCB PA0010 | Psoriatic Arthritis | BIMEKIZUMAB | 2021 | 14 |
| UCB PA0011 | Psoriatic Arthritis | BIMEKIZUMAB | 2021 | 8 |

| | | | | |
|-------------------------------|------------------------------|---|------|--------------------------|
| Novartis CAIN457P12302 | Psoriatic Arthritis | SECUKINUMAB | 2021 | 11 |
| | | | | |
| Sanofi L8890 | (Prostate) BPH | Registry and Survey | 2004 | 33 |
| | | | | |
| Actelion (Uncover) | PAH | Questionnaire | 2003 | 20 |
| Actelion CHRC 015 | PAH | Questionnaire | 2005 | 12 |
| | | | | |
| Otsuka | Raynaud's Phenomenon | OPC-28326 | 2001 | 9 |
| Ostuka 21-01-335 | Raynaud's in Juveniles | Pletal (Cilostazol) | 2002 | 1 |
| PFIZER A7331010 | Raynaud's | Phosphodiesterase 5 Inhibitor (PF-00489791) | 2010 | 5 |
| Covis VAS-014-001 | Raynaud's | Nitroglycerine, Vascana | 2016 | 17 |
| Primus PVR-02 | Raynaud's | Diosmiplex (Vasculera) | 2016 | 22 |
| | | | | |
| Amgen 20040245 PHASE 1 | Renal Insufficiency | AMG162 | 2008 | 1 |
| Astellas 3606-CL-3010 | Renal Impairment | Regadenoson | 2008 | 32 |
| | | | | |
| Aventis Treat | Respiratory Tract Infections | Ketek® | 2001 | 12 |
| | | | | |
| GlaxoSmithKline | Restless Legs Syndrome | Ropinirole | 2006 | 1 (Sponsor Closed Study) |
| GSK – Xenoport RXP114025 | Restless Legs Syndrome | GSK1838262 | 2012 | 7 |
| | | | | |
| Greenwich | Rheumatoid Arthritis | NSAID | 1992 | 8 |
| Pfizer | Anti-Rheumatic Therapy | Anti-Rheumatic | 1994 | 12 |
| Pfizer | Rheumatic Extension | Anti-Rheumatic | 1996 | 2 |
| Boston Life | Rheumatoid Arthritis | NSAID | 1996 | 8 |
| Pfizer | Rheumatoid Arthritis | BMD Drug | 1996 | 35 |
| Millennium | Rheumatoid Arthritis | Genetic | 1996 | 40 |
| Searle 022 | Rheumatoid Arthritis | Cox II | 1996 | 60 |
| Searle 023 | Rheumatoid Arthritis | Cox II | 1996 | 40 |
| Boston Life | Rheumatoid Arthritis | NSAID | 1997 | 5 |
| Schering Plough | Rheumatoid Arthritis | Interleukin | 1997 | 11 |
| Pfizer | Rheumatoid Arthritis | CP195,543 | 1997 | 19 |
| Boehringer Ingelheim | Rheumatoid Arthritis | Meloxicam | 1997 | 12 |
| Immunex | Rheumatoid Arthritis | Anti-TNF | 1997 | 14 |
| Searle 016 | Rheumatoid Arthritis | Cox II | 1997 | 40 |
| Merck 068 | Rheumatoid Arthritis | Cox II | 1997 | 12 |
| Schering-Plough | Rheumatoid Arthritis | Interleukin | 1998 | 11 |
| Merck | Rheumatoid Arthritis | Cox II | 1998 | 16 |
| Schering Plough | Rheumatoid Arthritis | Interleukin | 1998 | 11 |
| Parke-Davis | Rheumatoid Arthritis | NSAID | 1998 | 6 |
| Parke-Davis | Rheumatoid Arthritis | NSAID | 1998 | 18 |

| | | | | |
|--------------------------|----------------------------|----------------------|------|---------------------|
| Immune Response | Rheumatoid Arthritis | Vaccine | 1998 | 28 |
| AutoImmune | Rheumatoid Arthritis | Colloral | 1998 | 7 |
| RW Johnson | Rheumatoid Arthritis | RW57504 | 1998 | 24 |
| Eli Lilly | Rheumatoid Arthritis | IND55091 | 1998 | 26 |
| Roche | Rheumatoid Arthritis | Trocade | 1998 | 23 |
| Immunex | Rheumatoid Arthritis | TNF | 1999 | 19 |
| Inflammatics | Rheumatoid Arthritis | LeukoVAX | 1999 | 21 |
| Schering-Plough | Rheumatoid Arthritis | Tenovil | 1999 | 20 |
| Corixa/Anergen | Rheumatoid Arthritis | AG4263 | 1999 | 6 |
| Merck 088-VIGOR | Rheumatoid Arthritis | Cox II | 1998 | 50 |
| Amgen | Rheumatoid Arthritis | PEGTNF | 1999 | 17 |
| Fujisawa 049 & 051 | Rheumatoid Arthritis | Prograf | 1999 | 049 = 6 051 = 24 |
| Merck | JRA | Cox II | 1999 | 4 |
| Amgen (145) | Rheumatoid Arthritis | Anakinra | 1999 | 9 |
| Centocor PROMPT | Rheumatoid Arthritis | Remicade | 1999 | 9 |
| Amgen | Rheumatoid Arthritis | Anakinra | 1999 | 18 |
| Knoll | Rheumatoid Arthritis | AntiTNF | 1999 | 16 |
| Alexion | Rheumatoid Arthritis | 5G1.1 | 1999 | 14 |
| Roche | Rheumatoid Arthritis | Trocade | 1999 | 31 |
| Searle 060 | Rheumatoid Arthritis | Cox II | 1999 | 27 |
| Searle 061 | Rheumatoid Arthritis | Valdecoxib | 1999 | 4 |
| Searle 067 | Rheumatoid Arthritis | Cox II | 1999 | 18 |
| Merck | JRA | Cox II | 1999 | 1 |
| Immunex | Rheumatoid Arthritis | Enbrel | 2000 | 49 |
| Merck 026 | Rheumatoid Arthritis GI | Cox II | 2000 | 38 |
| Searle 076 | Rheumatoid Arthritis | Valdecoxib | 2000 | 8 |
| IDEC | Rheumatoid Arthritis | Clenoliximab | 2000 | 16 |
| Alexion E99 | Rheumatoid Arthritis | h5G1.1-mAb | 2000 | 6 |
| Centocor | Early Rheumatoid Arthritis | Remicade | 2000 | 20 |
| Novartis (A2312) | Rheumatoid Arthritis | COX189 | 2000 | 24 |
| Knoll (S.O.N.O.R.A) | Rheumatoid Arthritis | Observational for RA | 2000 | 14 |
| Abgenix | Rheumatoid Arthritis | ABX-IL8 | 2000 | 19 |
| Knoll | Rheumatoid Arthritis | Anti-TNF | 2000 | 26 |
| Novartis 114 | Rheumatoid Arthritis | Celecoxib | 2000 | 30 |
| Vertex | Rheumatoid Arthritis | VX-745 | 2000 | 6 |
| Serono | Rheumatoid Arthritis | IFN-beta-1a | 2001 | 5 |
| Serono 22766 | Rheumatoid Arthritis | Onercept r-hTBP-1 | 2001 | 7 |
| Bristol Myers Squibb 101 | Rheumatoid Arthritis | BMS-188667 | 2001 | 2 |
| Novartis 0110 | Rheumatoid Arthritis | COX189 | 2001 | 25 |
| AstraZeneca | Rheumatoid Arthritis | ZD2315 | 2001 | 8 |
| Amgen 143 | Rheumatoid Arthritis | Kineret | 2001 | 16 |

| | | | | |
|---------------------------|-------------------------------|--|------|----|
| Boehringer Ingelheim | Juvenile Rheumatoid Arthritis | Meloxicam | 2001 | 17 |
| Bristol Myers Squibb 100 | Rheumatoid Arthritis | BMS-188667 | 2001 | 7 |
| MedImmune | Rheumatoid Arthritis | MEDI-522 | 2001 | 5 |
| Immunex 52.0003 | Rheumatoid Arthritis | IL-1R _{II} | 2001 | 9 |
| Regeneron Pharmaceuticals | Rheumatoid Arthritis | IL-1 Trap | 2001 | 6 |
| MedImmune CP083 | Rheumatoid Arthritis | MEDI-522 | 2001 | 2 |
| Immunex Radius I | RA Questionnaire Study | None | 2001 | 53 |
| Angiotech | Rheumatoid Arthritis | Paxeed™ | 2002 | 8 |
| Immunex 36 | Rheumatoid Arthritis | Enbrel | 2002 | 15 |
| Alexion C01-004 | Rheumatoid Arthritis | h5G1.1-mAb | 2002 | 12 |
| Amgen 238 | Rheumatoid Arthritis | AMG 719 | 2002 | 4 |
| Amgen 198 | Rheumatoid Arthritis | PEG sTNF-RI | 2002 | 2 |
| Immunex 052.0005 | Rheumatoid Arthritis | IL-1RI | 2002 | 5 |
| Xoma | Rheumatoid Arthritis | Efalizumab | 2002 | 18 |
| Regeneron IL1T-RA-0111 | Rheumatoid Arthritis | IL1 Trap | 2002 | 2 |
| Scios | Rheumatoid Arthritis | SCIO-469 | 2002 | 13 |
| GenMab 004 | Rheumatoid Arthritis | HuMax-CD4 | 2002 | 2 |
| GenMab 002 | Rheumatoid Arthritis | HuMax-CD4 | 2002 | 8 |
| Elan | Rheumatoid Arthritis | Antegren™ (Natalizumab 300 mg) | 2004 | 11 |
| Boehringer Ingelheim | Rheumatoid Arthritis | Meloxicam | 2002 | 26 |
| ISIS | Rheumatoid Arthritis | TNF-alpha Antisense Oligonucleotide | 2002 | 15 |
| Pharmacia | RA in Juveniles and Adults | Celecoxib | 2002 | 40 |
| Amgen 20020101 | Rheumatoid Arthritis | Anakinra | 2002 | 10 |
| Wyeth 3066A3-125-US | Rheumatoid Arthritis | CC1-779 | 2002 | 4 |
| Immunex Radius 2 | Rheumatoid Arthritis | Enbrel | 2002 | 8 |
| Genentech | Rheumatoid Arthritis | MabThera® | 2003 | 3 |
| Genmab | Rheumatoid Arthritis | Humax IL15 | 2003 | 5 |
| Bristol Myers Squibb 102 | Rheumatoid Arthritis | BMS-188667 | 2002 | 5 |
| Abbott M02-498 | Rheumatoid Arthritis | D2E7 | 2002 | 17 |
| Lilly | Biomarkers in RA | None | 2002 | 24 |
| Regeneron IL1T-RA-0102 | Rheumatoid Arthritis | IL-1 Trap | 2002 | 9 |
| Bristol Myers Squibb 029 | Rheumatoid Arthritis | BMS-188667 | 2002 | 1 |
| Pharmacia 014 | Rheumatoid Arthritis | CDP-870 | 2002 | 4 |
| Phytomedics | Rheumatoid Arthritis | Tripterygium wilfordii Hook F | 2003 | 12 |
| Novartis 2335 | Rheumatoid Arthritis | COX 189 | 2003 | 10 |
| Aventis HMR3480A/2003 | Rheumatoid Arthritis | HMR3480 | 2003 | 18 |
| IDEC | Rheumatoid Arthritis | Rituximab | 2003 | 3 |
| Pfizer A3471018 | Rheumatoid Arthritis | Bextra® | 2003 | 23 |
| NARAC | Trio Families with RA | Blood Collection | 2002 | 10 |
| Merck 072 | Rheumatoid Arthritis | Etoricoxib | 2003 | 20 |

| | | | | |
|-------------------------------------|----------------------|---------------------------|------|----|
| Neurogen PHASE 1 | Rheumatoid Arthritis | NGD 2000-1 Dibesylate | 2003 | 12 |
| Pharmacia 011 | Rheumatoid Arthritis | CDP-870 | 2003 | 4 |
| GlaxoSmithKline CXA20006 | Rheumatoid Arthritis | GW406381X | 2003 | 19 |
| Bristol Myers Squibb 031 | Rheumatoid Arthritis | BMS-188667 | 2003 | 10 |
| Fresenius Hemocare | Rheumatoid Arthritis | PROSORBA® | 2003 | 1 |
| Abbott M03-600 | Rheumatoid Arthritis | Adalimumab | 2003 | 32 |
| Wyeth 3066A3-206-WW | Rheumatoid Arthritis | CCI-779 | 2004 | 8 |
| Wyeth 3140A1-103-US | Rheumatoid Arthritis | TMI-005 | 2004 | 4 |
| Abbott (HERO) M04-684 | Rheumatoid Arthritis | Humira® | 2004 | 22 |
| Amgen 20030236 | Rheumatoid Arthritis | Etanercept | 2004 | 11 |
| NIH | Rheumatoid Arthritis | danJ peptide (dnaJp1) | 2004 | 8 |
| Roche RB17861 | Rheumatoid Arthritis | Observational | 2004 | 23 |
| Ortho Biotech | RA with Anemia | Procrit® | 2004 | 0 |
| University of Alabama at Birmingham | Rheumatoid Arthritis | Etanercept | 2004 | 37 |
| University of Massachusetts | Rheumatoid Arthritis | Marine and Botanical Oils | 2004 | 11 |
| Wyeth 3140A1-200-WW | Rheumatoid Arthritis | TMI-005 | 2004 | 4 |
| Genentech ACT2847g | Rheumatoid Arthritis | rhuMAb 2H7 | 2004 | 4 |
| Scios B0007 | Rheumatoid Arthritis | SCIO-469 | 2004 | 15 |
| Takeda 01-03-TI-715-005 | Rheumatoid Arthritis | TAK-715 | 2004 | 3 |
| Bristol Myers 033 | JRA | BMS-188667 | 2004 | 3 |
| Trubuo (Phase 1) | Rheumatoid Arthritis | TRU-015 | 2004 | 9 |
| Amgen 20040201 | Rheumatoid Arthritis | Enbrel | 2004 | 5 |
| Fresenius Hemocare | Rheumatoid Arthritis | Prosorba | 2004 | 4 |
| Pfizer A3921019 | Rheumatoid Arthritis | CP-690,550 | 2004 | 1 |
| Regeneron IL1T-RA-0408 | Rheumatoid Arthritis | IL-1 Trap | 2004 | 8 |
| Celltech CDP870-027 | Rheumatoid Arthritis | CDP-870 | 2005 | 0 |
| Merrimack MM-093-01-200 | Rheumatoid Arthritis | MM-093 | 2005 | 5 |
| Genmab HX-CD20-403 | Rheumatoid Arthritis | HuMax CD20 | 2005 | 6 |
| GlaxoSmithKline CXA30009 | Rheumatoid Arthritis | GW406381 | 2005 | 15 |
| Incyte (Phase I) | Rheumatoid Arthritis | INCB003284 | 2005 | 11 |
| Amgen 20040275 | Rheumatoid Arthritis | Enbrel | 2005 | 2 |
| Genentech BRT3321g | Rheumatoid Arthritis | PRO97796 (BR3-Fc) | 2005 | 4 |
| Roche WA17824 | Rheumatoid Arthritis | MRA | 2005 | 9 |
| Roche WA17823 | Rheumatoid Arthritis | MRA | 2004 | 9 |
| Roche WA18062 | Rheumatoid Arthritis | MRA | 2005 | 3 |
| Wyeth 3142A1-202 | Rheumatoid Arthritis | ERB-041 | 2005 | 2 |
| CombinatorX | Rheumatoid Arthritis | CRX-119N | 2005 | 1 |
| Wyeth TD-04-02 | Rheumatoid Arthritis | ERB-041 | 2005 | 13 |
| Targeted Genetics PHASE 1 | Rheumatoid Arthritis | TNFR-Fc Fusion Gene | 2005 | 11 |

| | | | | |
|---------------------------------------|---|---------------------------|------|-------------------------|
| Bristol Myers 023 | Rheumatoid Arthritis | Abatacept | 2005 | 2 |
| Rigel C-935788-004 PHASE 1 | Rheumatoid Arthritis | R935788 | 2005 | 8 |
| Centocor C0524T06 | Rheumatoid Arthritis | Golimumab | 2005 | 5 |
| Centocor C0524T05 | Rheumatoid Arthritis | Golimumab | 2005 | 8 |
| Centocor C0524T11 | Rheumatoid Arthritis | Golimumab | 2005 | 8 |
| Roche WP18663 | Rheumatoid Arthritis | MRA | 2005 | 16 |
| Genentech U3384g | Rheumatoid Arthritis | Rituximab | 2005 | 0 |
| Genentech U3374g | Rheumatoid Arthritis | Rituximab | 2005 | 5 |
| Genentech U3373g | Rheumatoid Arthritis | Rituximab | 2005 | 6 |
| Merck 086 | Rheumatoid Arthritis | Etoricoxib | 2005 | 7 |
| Abbott M05-770 | Rheumatoid Arthritis | Humira | 2006 | 7 |
| Amgen 20050168 | Rheumatoid Arthritis | AMG 108 | 2006 | 5 |
| Regeneron 0404 | Rheumatoid Arthritis | IL1 Trap | 2005 | 0 |
| PDL BioPharma | Rheumatoid Arthritis | Fontolizumab | 2006 | 9 |
| Biogen-Idec 102-RA-201 | Rheumatoid Arthritis | Rituxin | 2006 | 2 |
| University of PA | Rheumatoid Arthritis | Questionnaire for MTX | 2006 | 150 |
| Centocor C0524T12 | Rheumatoid Arthritis | Golimumab | 2006 | 7 |
| Rigel C-935788-006 | Rheumatoid Arthritis | R935788 | 2006 | 11 |
| Genentech BRT3766g PHASE 1 | Rheumatoid Arthritis (Phase 1) | PRO97769 | 2006 | 3 |
| Novartis CAIN457A2101 PHASE 1 | Rheumatoid Arthritis (Phase 1) | AIN457 | 2006 | 9 |
| Alza / J & J C-2006-009-01 | Rheumatoid Arthritis | RJW – 445380 | 2006 | 5 |
| Proctor and Gamble 2005012 | Rheumatoid Arthritis | PG-760564 | 2006 | 2 |
| ARRAY ARRY-162-0603 PHASE 1 | Rheumatoid Arthritis (Phase 1) | ARRAY-438162 | 2006 | 21 |
| Abbott M06-810 | Rheumatoid Arthritis | Humira | 2006 | 16 |
| Genentech WA20494/ACT3985 | Rheumatoid Arthritis | Ocrelizumab | 2006 | 1 |
| Genentech U3839g (Sunstone) | Rheumatoid Arthritis | Rituxin | 2006 | 0 |
| Genentech WA20497/ACT3984g | Rheumatoid Arthritis | Ocrelizumab | 2006 | 2 |
| Pfizer A4001056 | Rheumatoid Arthritis | Maraviroc | 2006 | 17 |
| Merrimack MM-093-01-201 | Rheumatoid Arthritis | MM-093 | 2007 | 8 |
| Pfizer A6341006 PHASE 1 | Rheumatoid Arthritis | CE-224,535 | 2007 | 13 |
| Pfizer A3921035 | Rheumatoid Arthritis | CP-690,550 | 2007 | 4 |
| Pfizer A6261002 PHASE 1 | Rheumatoid Arthritis | PD 0360324 | 2007 | 9 |
| Biogen 104-RA-203 | Rheumatoid Arthritis | BG9924 | 2007 | 0 |
| INCYTE INCB 18424-231 | Rheumatoid Arthritis | INCB018424 Ruxolitinib | 2007 | Sponsor Closed Study |
| Roche WA19923 | Rheumatoid Arthritis | Tocilizumab | 2007 | 3 |
| Adolor 33CL232 | Rheumatoid Arthritis | ADL5859 | 2007 | 10 |
| Serono 27905 | Rheumatoid Arthritis | Atacept | 2007 | 2 |
| Regeneron 6R88-RA-0703 PHASE 1 | Rheumatoid Arthritis | REGN88 (IL6R- mAb) | 2007 | 3 |
| Medarex MDX1342-01 PHASE 1 | Rheumatoid Arthritis | MDX-1342 | 2007 | 1 |
| Combinatorx CRx-102-007 | Rheumatoid Arthritis | CRX-102 | 2007 | 0 |

| | | | | |
|---------------------------------------|---|---------------------------|------|----|
| Bristol Myers IM101-167 | Rheumatoid Arthritis | Abatacept | 2007 | 12 |
| Bristol Myers IM101-173 | Rheumatoid Arthritis | Abatacept | 2007 | 8 |
| Abbott M10-261 | Rheumatoid Arthritis | Humira | 2007 | 16 |
| Centocor C0524T14 PHASE 1 | Rheumatoid Arthritis | Golimumab | 2007 | 6 |
| Incyte INCB 18424-136 PHASE 1 | Rheumatoid Arthritis (Phase 1) | INCB018424 Ruxolitinib | 2008 | 14 |
| Pfizer A6631005 | Rheumatoid Arthritis | PH-797804 | 2008 | 5 |
| Regeneron 6R88-RA-0801 PHASE 1 | Rheumatoid Arthritis (Phase 1) | REGN88 | 2008 | 6 |
| Incyte 28050-103 PHASE 1 | Rheumatoid Arthritis | INCB028050 - Baricitinib | 2008 | 19 |
| Pfizer A6261002 | Rheumatoid Arthritis | 0360324 | 2008 | 10 |
| Regeneron 6R88-RA-0802 | Rheumatoid Arthritis | REGN88 | 2008 | 9 |
| Genentech U3924g (SUNDIAL) | Rheumatoid Arthritis | Rituximab | 2008 | 2 |
| Centocor Restart C0168Z05 | Rheumatoid Arthritis | Golimumab | 2008 | 8 |
| Pfizer A3921045 | Rheumatoid Arthritis | CP-690,550 | 2008 | 13 |
| Biogen TWEEK 211RA101 | Rheumatoid Arthritis | BIIB023 | 2008 | 9 |
| Incyte INCB 28050-103 | Rheumatoid Arthritis | INCB 28050 | 2009 | 28 |
| Nuon A3003RA | Rheumatoid Arthritis | Tranilast | 2009 | 7 |
| Roche ML22533 | Rheumatoid Arthritis | Tocilizumab | 2009 | 6 |
| Genentech CDT4478g | Rheumatoid Arthritis | MTRX1011A | 2008 | 3 |
| Amgen 20070441 | Rheumatoid Arthritis | Observational Study | 2008 | 3 |
| Centocor C1377T04 | Rheumatoid Arthritis | CNTO 136 | 2008 | 2 |
| Incyte INCB 28050-201 | Rheumatoid Arthritis | INCB 2805 | 2009 | 3 |
| UCB/SWARTZ RA0017 | Rheumatoid Arthritis | Certolizumab Pegol | 2010 | 22 |
| LexiconLX3305.201 | Rheumatoid Arthritis | LX3305 | 2010 | 3 |
| Pfizer A9391005 | Rheumatoid Arthritis | PF-04171327 | 2010 | 4 |
| Pfizer B0151002 | Rheumatoid Arthritis | PF-04236921 | 2010 | 5 |
| UCB 87077 | Rheumatoid Arthritis | Certolizumab Pegol | 2010 | 13 |
| Genentech ALT4623g | Rheumatoid Arthritis | MLTA3698A | 2010 | 8 |
| UCB RA0010 | Rheumatoid Arthritis | CDP6038 | 2010 | 5 |
| Wyeth 3199K1-2001-WW | Rheumatoid Arthritis | ILV-094 | 2010 | 14 |
| Bristol Myers Squibb IM101-235 | Rheumatoid Arthritis | Abatacept | 2010 | 7 |
| Amgen 20090061 | Rheumatoid Arthritis | AMG 827 | 2010 | 3 |
| NIH – ACE – ARA05 | Rheumatoid Arthritis | Switch to Anti-TNF | 2010 | 1 |
| REGENERON 000-RA-1008 | Rheumatoid Arthritis | ACTEMRA | 2010 | 3 |
| ROCHE WA19926 | Rheumatoid Arthritis | ACTEMRA | 2009 | 7 |
| ROCHE WA19924 | Rheumatoid Arthritis | ACTEMRA | 2010 | 4 |
| ANTARES | Rheumatoid Arthritis | MTX AUTOINJECTOR | 2010 | 36 |
| VERTEX | Rheumatoid Arthritis | VX-509 | 2010 | 6 |
| PFIZER A3921069 | Rheumatoid Arthritis | CP-690,550 | 2009 | 7 |
| BIOGEN IDEC 99RA002 Batter Up | Rheumatoid Arthritis | Blood Draw | 2010 | 3 |
| SANOFI AVENTIS ACT11575 | Rheumatoid Arthritis | SAR153191 | 2010 | 0 |
| ASTELLAS 2408-CL-0103 | Rheumatoid Arthritis | ORENCIA | 2011 | 8 |

| | | | | |
|--|----------------------|-----------------------|------|--------------------|
| Sanofi Aventis PKM12058 PHASE 1 | Rheumatoid Arthritis | SAR153191 | 2011 | 11 |
| Lilly 14V-MC-JADA | Rheumatoid Arthritis | LY3009104 | 2011 | 3 |
| Celgene CC-10004-RA-002 | Rheumatoid Arthritis | Apremilast | 2011 | 10 |
| UCB (SWITCH) CERT-001 | Rheumatoid Arthritis | Cimzia | 2011 | 2 |
| J & J 38518168ARA1001 PHASE 1 | Rheumatoid Arthritis | NJ-38518168 | 2011 | 7 |
| J & J 39758979ARA1001 PHASE 1 | Rheumatoid Arthritis | JNJ39758979 | 2011 | 2 |
| Roche Visara NA25256 | Rheumatoid Arthritis | Tocilizumab | 2011 | 6 |
| Roche NP 22775 | RA on BCP | Tocilizumab | 2011 | 19 Healthy 2 RA |
| ROCHE MA25522 | Rheumatoid Arthritis | TOCILIZUMAB | 2011 | 1 |
| UCB RA0064 | Rheumatoid Arthritis | Cimzia | 2011 | 26 |
| UCB RA0056 | Rheumatoid Arthritis | CIMZIA | 2010 | 4 |
| PFIZER A3921129 - 1014 | Rheumatoid Arthritis | CP-690,550 | 2011 | 9 |
| Chelsea CH-4051-RA202 | Rheumatoid Arthritis | CH-4051 | 2011 | 1 |
| Celgene CCT-PDA001-RA-001 | Rheumatoid Arthritis | PDA001 | 2011 | 4 |
| Plexxikon PLX115-02 PHASE 1 | Rheumatoid Arthritis | PLX3397 | 2011 | 8 |
| Centocor GoSave CNT0148ART3002 | Rheumatoid Arthritis | Golimumab | 2011 | 5 |
| ZALICUS Z102-008 | Rheumatoid Arthritis | Z102 | 2011 | 5 |
| ABBOTT M12-073 | Rheumatoid Arthritis | HUMIRA | 2010 | 7 |
| ASTRAZENECA D4300C00002 | Rheumatoid Arthritis | FOSTAMATINIB DISODIUM | 2010 | 2 |
| NIH -ACE02 | Rheumatoid Arthritis | LOVASTATIN | 2008 | 1 |
| PORTOLA (PHASE 1) | Rheumatoid Arthritis | PRT062607 | 2011 | 15 |
| AstraZeneca D4300C00003 | Rheumatoid Arthritis | FOSTAMATINIB DISODIUM | 2012 | 1 |
| AstraZeneca D4300C00033 | RA with ABPM | FOSTAMATINIB DISODIUM | 2012 | 1 |
| Bristol Myers Squibb IM126-004 | Rheumatoid Arthritis | BMS817399 | 2012 | 8 |
| Pfizer A3921152 | Rheumatoid Arthritis | CP-690,550 | 2012 | 13 |
| Antares MTX-11-002 | Rheumatoid Arthritis | MTX Injector | 2012 | 25 |
| Antares MTX-11-003 | Rheumatoid Arthritis | MTX Injector | 2012 | 31 |
| Sanofi EFC11072 MOBILITY | Rheumatoid Arthritis | SAR153191 | 2012 | 10 |
| Genentech ML25641 Rate-RA | Rheumatoid Arthritis | Rituximab | 2012 | 3 |
| Astellas 2409-CL-0201 | Rheumatoid Arthritis | ASP2408 | 2012 | 10 |
| Medac MC-MTX.15/HF | Rheumatoid Arthritis | MTX Injector | 2012 | 28 |
| AstraZeneca D4300C00004 | Rheumatoid Arthritis | FOSTAMATINIB DISODIUM | 2010 | 5 |
| Pfizer B3281001 | Rheumatoid Arthritis | PF-05280586 | 2012 | 5 |
| Roche WA25204 Entracte | Rheumatoid Arthritis | Actemra | 2011 | 3 |
| Vertex VX11-509-102 | Rheumatoid Arthritis | VX509 | 2012 | 1 |
| AstraZeneca D4300C00002 | Rheumatoid Arthritis | FOSTAMATINIB DISODIUM | 2010 | 2 |
| UCB RA0055 | Rheumatoid Arthritis | Cimzia | 2011 | 11 |
| Incyte INCB39110-201 | Rheumatoid Arthritis | INCB039110 | 2012 | 5 |
| Astellas 2409-CL-0104 | Rheumatoid Arthritis | ASP2409 | 2012 | 19 |
| UCB RA0077 | Rheumatoid Arthritis | Cimzia | 2011 | 0 |
| Vertex VX12-509-103 | Rheumatoid Arthritis | VX-509 | 2012 | 1 |

| | | | | |
|---|----------------------------------|------------------------|------|----|
| Astellas 015K-CL-RA22 | Rheumatoid Arthritis | ASP015K | 2013 | 10 |
| Astellas 015K-CL-RA21 | Rheumatoid Arthritis | ASP015K | 2013 | 6 |
| AstraZeneca D4300C00004 | Rheumatoid Arthritis | FOSTAMATINIB DISODIUM | 2013 | 5 |
| Amgen 20090176 | Rheumatoid Arthritis Injector | Etanercept | 2013 | 15 |
| Molecular Research (Camcargo) MRC2011-001 | Rheumatoid Arthritis | MRC375 | 2013 | 24 |
| Abbott M12-071 | Rheumatoid Arthritis | HUMIRA | 2013 | 11 |
| Roche NA25220 | Rheumatoid Arthritis | Tocilizumab | 2010 | 7 |
| Protalex PRTX-100-104 Phase 1 | Rheumatoid Arthritis | PRTX-100 | 2014 | 11 |
| AbbVie M14-048 | Rheumatoid Arthritis | ABT 122 | 2014 | 7 |
| Pfizer A9391010 | Rheumatoid Arthritis | PF-04171327 | 2011 | 5 |
| Boehringer Ingelheim | Rheumatoid Arthritis | BI 695500 vs Rituximab | 2014 | 0 |
| Merck 0663-107 | Rheumatoid Arthritis | MK-0663 | 2014 | 23 |
| Morphotek | Rheumatoid Arthritis | MORAB-022 | 2014 | 12 |
| Amplimmune AMP-110-01 | Rheumatoid Arthritis | AMP-110 | 2014 | 13 |
| BMS 101-366 | Rheumatoid Arthritis | ABATACEPT INJECTOR | 2014 | 28 |
| SANOFI EFC13752 | Rheumatoid Arthritis | SARILUMAB | 2014 | 3 |
| JANSSEN CNTO148ART3003 | Rheumatoid Arthritis | REMICADE | 2014 | 0 |
| SANOFI MSC12665 | Rheumatoid Arthritis | SARILUMAB | 2014 | 3 |
| GALAPAGOS GLP0634-CL-203 | Rheumatoid Arthritis | GLPG0634 | 2014 | 0 |
| GALAPAGOS GLP0634-CL-204 | Rheumatoid Arthritis | GLPG0634 | 2014 | 0 |
| AMGEN 20120125 | Rheumatoid Arthritis | ETANERCEPT | 2014 | 1 |
| Horizon HZ-CA-402-01 | JUVENILE IDIOPATHIC ARTHRITIS | DUEXIS® | 2014 | 2 |
| AbbVie M13-550 | Rheumatoid Arthritis | ABT-494 | 2013 | 4 |
| Pfizer A3921133 | Rheumatoid Arthritis | TOFACITNIB | 2013 | 20 |
| Pfizer A3921237 | Rheumatoid Arthritis | TOFACITINIB | 2014 | 8 |
| SANOFI INT12684 | Rheumatoid Arthritis | SARILUMAB | 2015 | 3 |
| ABBVIE M13-537 | Rheumatoid Arthritis | ABT-494 | 2015 | 3 |
| COHERUS CHS-0214-02 | Rheumatoid Arthritis | CHS 0214 | 2014 | 8 |
| AMPLIMMUNE AMP-110-01 PHASE 1 | Rheumatoid Arthritis | RA-AMP-110 | 2013 | 9 |
| Janssen CNTO148ARA3002 | Rheumatoid Arthritis | CNTO136 SIRUKAMAB | 2014 | 20 |
| Janssen CNTO148ARA3004 | Rheumatoid Arthritis | CNTO136 SIRUKAMAB | 2014 | 5 |
| PHARMACYCLICS PCYC-1301-RA PHASE 1 | Rheumatoid Arthritis | PCI-45466 | 2014 | 6 |
| Pfizer A3921187 | Rheumatoid Arthritis | TOFACITNIB | 2015 | 6 |
| Pfizer B5371002 | Rheumatoid Arthritis | OF-06438179 | 2015 | 4 |
| Genentech ML28776 | Rheumatoid Arthritis | Tocilizumab | 2015 | 6 |
| CRESCENDO 083-CL-01 | Rheumatoid Arthritis | VECTRADA | 2015 | 39 |
| ABBVIE M14-197 | Rheumatoid Arthritis | ABT-122 | 2016 | 2 |
| CELGENE CC-292-RA-001 | Rheumatoid Arthritis | CC-292 | 2016 | 7 |
| PFIZER B5381002 | Rheumatoid Arthritis | PF-06410293 | 2016 | 2 |
| FUJIFILM FKB327-002 | Rheumatoid Arthritis | FKB327 | 2016 | 4 |
| Amgen 20101324 PHASE 1 | RA with Low Bone Mineral Density | Denosumab | 2016 | 7 |

| | | | | |
|--------------------------------------|----------------------|--|------|----|
| Sandoz GP13-302 | Rheumatoid Arthritis | GP13-302 | 2016 | 2 |
| Acerta ACE-RA-001 | Rheumatoid Arthritis | ACP-196 | 2016 | 0 |
| Amgen 20110247 | Rheumatoid Arthritis | AMG 357 | 2016 | 4 |
| Novartis CCFZ533X2101 PHASE 1 | Rheumatoid Arthritis | CFZ533 | 2016 | 2 |
| Gilead GS-US-407-1833 | Rheumatoid Arthritis | GS-4059 | 2016 | 9 |
| Astellas 5094-CL-0102 PHASE 1 | Rheumatoid Arthritis | ASP5094 | 2016 | 4 |
| Lilly 18K-MC-JPDA | Rheumatoid Arthritis | LY337641 | 2017 | 10 |
| Merck MS200527-0081 | Rheumatoid Arthritis | M2951 | 2017 | 1 |
| BMS IM101-550 | Rheumatoid Arthritis | Abatacept | 2016 | 4 |
| AbbVie M13-549 | Rheumatoid Arthritis | ABT-494 | 2017 | 5 |
| Gilead GS-US-379-1582 | Rheumatoid Arthritis | GS-9876 | 2017 | 12 |
| GlaxoSmithKline 205180 | Rheumatoid Arthritis | GSK3196165 | 2017 | 5 |
| MedImmune D5100C00002 PHASE 1 | Rheumatoid Arthritis | MED14920 | 2017 | 10 |
| AbbVie M14-465 | Rheumatoid Arthritis | ABT-494 | 2017 | 2 |
| GlaxoSmithKline 205180 | Rheumatoid Arthritis | GSK3196165 | 2017 | 4 |
| ABBVIE M14-500 | Rheumatoid Arthritis | ABT-494 | 2017 | 3 |
| Pfizer A3921192 | Rheumatoid Arthritis | Tofacitinib | 2017 | 18 |
| Amgen 20130108 | Rheumatoid Arthritis | ABP-798 | 2017 | 4 |
| Bristol Myers Squibb IM101-567 | Rheumatoid Arthritis | Abatacept | 2018 | 3 |
| Gilead GS-US-417-0301 | Rheumatoid Arthritis | Filgotinib | 2018 | 2 |
| Gilead GS-US-417-0303 | Rheumatoid Arthritis | Filgotinib | 2018 | 15 |
| Amgen 20110186 | Rheumatoid Arthritis | Etanercept | 2018 | 9 |
| Janssen Aware CNT0148ART4001 | Rheumatoid Arthritis | Simponi Aria vs Remicade | 2018 | 7 |
| Nichi-Iko NI071F2 | Rheumatoid Arthritis | NI-071 & Remicade | 2018 | 7 |
| Roche BP39261 SECARA | Rheumatoid Arthritis | RO7123520 | 2018 | 4 |
| Set Point SPM-008 | Rheumatoid Arthritis | Device/Vagal Stimulator | 2018 | 4 |
| R-PHARM CL04041023 | Rheumatoid Arthritis | Olokizumab | 2019 | 4 |
| AbbVie M15-925 | Rheumatoid Arthritis | ABT-494 | 2019 | 3 |
| Amgen 20150196 | Rheumatoid Arthritis | AMG 570 | 2019 | 7 |
| Crescendo 088-CL-01 | Rheumatoid Arthritis | Vectra DA Outcomes Study | 2019 | 2 |
| Lilly 14V-MC-JAJA | Rheumatoid Arthritis | BARICITINIB | 2019 | 30 |
| Crescendo 133-CL-01 | Rheumatoid Arthritis | Vectra Blood Test | 2020 | 60 |
| Amgen 20170149 | Rheumatoid Arthritis | AMG 592 | 2020 | 1 |
| Sanofi OBS14924 | Rheumatoid Arthritis | Sarilumab | 2020 | 26 |
| Navidea NAV3-31 | Rheumatoid Arthritis | Tilmanocept Uptake Value on Tc99m Tilmanocept Planar Imaging | 2020 | 15 |
| Oscotec OSCO-P2201 | Rheumatoid Arthritis | SKI-O-703 | 2020 | 2 |
| Vielabio VIB4920.P2.S3 | Rheumatoid Arthritis | VIB4920 | 2020 | 1 |
| TARGET Trial | Rheumatoid Arthritis | TREATMENTS AGAINST RA & EFFECT ON PET/CT SCAN | 2020 | 9 |
| ACLARIS | Rheumatoid Arthritis | ATI-450 | 2020 | 6 |
| PFIZER B5381012 | Rheumatoid Arthritis | PF-06410293 | 2020 | 1 |

| | | | | |
|--|---|---|------|-----|
| GlaxoSmithKline 201791 | Rheumatoid Arthritis | GSK3196165 | 2021 | 1 |
| UCB RA0138 | Rheumatoid Arthritis | Electrochemiluminescent Immuno-Assay | 2021 | 11 |
| Dr. Reddy | Rheumatoid Arthritis | DRL_RI | 2021 | 4 |
| Vorso VC2020-7 | Rheumatoid Arthritis | Vorso Protect System - Nerve Stimulator | 2021 | 9 |
| BMS IM014029 | Rheumatoid Arthritis | Abatacept | 2022 | 1 |
| | | | | |
| | | | | |
| Regeneron R1033-SRC-1239 | Sarcopenia | REGN1033 | 2014 | 1 |
| | | | | |
| Actelion MDP-001 | Scleroderma | Questionnaire | 2007 | 8 |
| Actelion DUAL1/AC055C301 | Sclerosis – Digital Ulcers | | 2011 | 1 |
| MedImmune MI-CP200 | Scleroderma | MEDI 551 | 2011 | 1 |
| | | | | |
| TAP | Skin or Skin Structure Infection | Cefditoren | 1998 | 2 |
| | | | | |
| Veldona | Sjogren's Syndrome | Interferon A | 1998 | 18 |
| Snow Brand | Sjogren's Syndrome | Evoxac | 1997 | 17 |
| Snow Brand | Sjogren's Syndrome | Evoxac | 1997 | 19 |
| Veldona | Sjogren's Syndrome | Interferon A | 1999 | 17 |
| Alcon | Dry Eye in CTD Patients | Rimexolone | 2003 | 8 |
| TorreyPines NGX267XSS2001 PHASE 1 | Xerostomia Associated with Sjögren's Syndrome | NGX267 | 2008 | 12 |
| Parion 552-207S | Sjogren's Syndrome | 552-02 | 2008 | 16 |
| Novartis CCFZ533X2203 | Sjogrens Syndrome | CFZ533 | 2016 | 2 |
| F. Hoffmann La Roche BP30037 | Sjogren's Syndrome | RO5459072 | 2016 | 1 |
| BMS IM128-035 | Sjogren's Syndrome | BMS -986142 | 2017 | 1 |
| BMS IM101-603 | Sjogren's Syndrome | Abatacept | 2017 | 2 |
| Lilly 16M-MC-SSAD | Sjogren's Syndrome | LY3090106 | 2018 | 5 |
| Gilead GS-US-445-4189 | Sjogren's Syndrome | Filgotinib | 2018 | 2 |
| Primus PSS-01 | Sjogren's Syndrome | Survey | 2020 | 8 |
| Vielabio VIB4920-PS-S2 | Sjogren's Syndrome | VIB4920 | 2022 | 2 |
| | | | | |
| Philip Morris | Smokers | No Drug | 2002 | 113 |
| Phillip Morris 7435-112 | Smokers | Nicotine | 2004 | 2 |
| | | | | |
| Pharmacia 198 | Ulcerative Colitis | Celecoxib | 2001 | 6 |
| Otsuka 197-02-220 | Ulcerative Colitis | OPC-6535 & Asacol® | 2004 | 0 |
| Cosmo CB-01-02/01 | Ulcerative Colitis | ASACOL | 2008 | 1 |
| | | | | |
| VERVE | Vaccine | Shingles | 2019 | 19 |
| | | | | |

| | | | | |
|------------|--------------------------------|------|------|----|
| Clintrials | Questionnaire for Venous Ulcer | None | 2002 | 10 |
|------------|--------------------------------|------|------|----|